Ipilimumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ipilimumab comprises 1,069 peer-reviewed publications across 15 journals, 76 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Melanoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, and Mesothelioma. Most recent publication: A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)., Future Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX, Finn RS, Edeline J, et al. · Lancet Oncol · 2019
    PubMed: PMID 29875066 · NCT07075120 · Carcinoma, Hepatocellular
  2. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
    Yau T, Kang YK, Kim TY, et al. · JAMA Oncol · 2022
    PubMed: PMID 33001135 · NCT07075120 · Carcinoma, Hepatocellular
  3. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Wang Z, Fan J, Zhou S, et al. · Lancet · 2025
    PubMed: PMID 41125112 · NCT07487662 (ACTION-001)
  4. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY, Burtness B, Mehra R, et al. · Lancet Oncol · 2017
    PubMed: PMID 27247226 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  5. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J, Ribas A, Long GV, et al. · Lancet · 2018
    PubMed: PMID 28822576 · NCT01866319 · Melanoma
  6. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV, Atkinson V, Cebon JS, et al. · Lancet Oncol · 2017
    PubMed: PMID 28729151 · NCT02089685 · Melanoma
  7. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS, Qin S, Ikeda M, et al. · N Engl J Med · 2020
    PubMed: PMID 32402160 · NCT07075120 · Carcinoma, Hepatocellular
  8. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.
    Dawson LA, Winter KA, Knox JJ, et al. · JAMA Oncol · 2025
    PubMed: PMID 39699905 · NCT07075120 · Carcinoma, Hepatocellular

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00324155MelanomaOverall Survival (OS)
Date of randomization to 37 months through 5-year follow-up and up to approximately 76 months
Ipilimumab and Dacarbazine11.17 Months
Placebo and Dacarbazine9.07 Months
NCT00636168—Number of Participants With Recurrence or Death as Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population
Date of randomization to first date of recurrence or death or last available disease assessment with RFS data upto 5 years. Median follow-up was 2.7 years.
Ipilimumab 10mg/kg234 Participants
Placebo294 Participants
NCT00636168—Recurrence-Free Survival (RFS) Rates Per IRC at 1 Year, 2 Years, and 3 Years in the ITT Population
At years 1, 2, and 3
Ipilimumab 10mg/kg46.48 Percentage of participants
Ipilimumab 10mg/kg51.45 Percentage of participants
Ipilimumab 10mg/kg63.50 Percentage of participants
Placebo34.79 Percentage of participants
Placebo43.83 Percentage of participants
Placebo56.13 Percentage of participants
NCT00636168—Recurrence Free Survival (RFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population
Date of randomization to first date of recurrence or death or last available disease assessment with RFS data up to 5 years. Median follow-up was 2.7 years.
Ipilimumab 10mg/kg26.09 months
Placebo17.05 months
NCT00861614Prostatic NeoplasmsOverall Survival (OS)
Date of randomization to date of death
Ipilimumab + Radiotherapy11.04 months
Placebo + Radiotherapy10.02 months
NCT00861614Prostatic NeoplasmsOverall Survival Rate
Date of randomization to date of death
Ipilimumab + Radiotherapy46.5 percentage of participants
Ipilimumab + Radiotherapy7.9 percentage of participants
Ipilimumab + Radiotherapy25.2 percentage of participants
Ipilimumab + Radiotherapy10.1 percentage of participants
Ipilimumab + Radiotherapy15.3 percentage of participants
Placebo + Radiotherapy3.3 percentage of participants
Placebo + Radiotherapy2.7 percentage of participants
Placebo + Radiotherapy40.8 percentage of participants
Placebo + Radiotherapy16.6 percentage of participants
Placebo + Radiotherapy7.9 percentage of participants
NCT01057810Prostatic NeoplasmsOverall Survival (OS) Time
Randomization until death from any cause, up to April 2015, approximately 57 months
Ipilimumab28.65 months
Placebo29.73 months
NCT01274338Melanoma5-year Overall Survival (OS) Rate (Arm A [HIP] vs. Arm B [HDI])
Assessed every 3 months for 2 years, then every 6 months for years 3-5
Arm A (HIP)0.70 proportion of participants
Arm B (HDI)0.65 proportion of participants
NCT01274338Melanoma5-year Overall Survival (OS) Rate (Arm B [HDI] vs. Arm C [LIP])
Assessed every 3 months for 2 years, then every 6 months for years 3-5
Arm B (HDI)0.67 proportion of participants
Arm C (LIP)0.72 proportion of participants
NCT01274338MelanomaRecurrence-free Survival (RFS; Arm A [HIP] vs. Arm B [HDI])
Assessed every 3 months for 2 years, then every 6 months for years 3-5 and then annually up to 8 years
Arm A (HIP)3.9 years
Arm B (HDI)2.4 years
NCT01274338MelanomaRecurrence-free Survival (RFS; Arm B [HDI] vs. Arm C [LIP])
Assessed every 3 months for 2 years, then every 6 months for years 3-5 and then annually up to 8 years
Arm B (HDI)2.5 years
Arm C (LIP)4.5 years
NCT01285609—Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint
Randomization until 518 deaths were observed in randomized participants treated with at least one dose of blinded study therapy and 705 deaths were observed in all randomized participants, up to June 2015 (approximately 48 months post study start)
Ipilimumab With Paclitaxel/Carboplatin13.37 months
Placebo With Paclitaxel/Carboplatin12.42 months
NCT01450761Small Cell Lung CarcinomaOverall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy
Randomization until date of death, up to March 2015, approximately 38 months
Ipilimumab and Platinum/Etoposide10.97 months
Placebo and Platinum/Etoposide10.94 months
NCT01515189MelanomaOverall Survival (OS)
Approximately 48 months (assessed up to February 2016)
Ipilimumab (10 mg/kg)15.70 months
Ipilimumab (3 mg/kg)11.53 months
NCT01844505MelanomaOverall Survival (OS)
From randomization to date of death (Assessed up to September 2016, approximately 39 months)
Ipilimumab19.98 months
Ipilimumab19.94 months
NivolumabNA months
Nivolumab36.93 months
Nivolumab + Ipilimumab71.92 months
Nivolumab + IpilimumabNA months
NCT01844505MelanomaProgression Free Survival (PFS)
From randomization until disease progression or death, whichever occurred first (assessed up to February 2015, approximately 20 months)
Ipilimumab2.86 months
Ipilimumab2.89 months
Nivolumab6.87 months
Nivolumab6.93 months
Nivolumab + Ipilimumab11.50 months
Nivolumab + Ipilimumab11.50 months
NCT01844505MelanomaRate of Overall Survival
24 months
Ipilimumab0.45 Probability of survival at Time T
Ipilimumab0.67 Probability of survival at Time T
Ipilimumab0.82 Probability of survival at Time T
Nivolumab0.85 Probability of survival at Time T
Nivolumab0.74 Probability of survival at Time T
Nivolumab0.59 Probability of survival at Time T
Nivolumab + Ipilimumab0.86 Probability of survival at Time T
Nivolumab + Ipilimumab0.64 Probability of survival at Time T
Nivolumab + Ipilimumab0.73 Probability of survival at Time T
NCT01844505MelanomaRate of Progression-Free Survival
24 months
Ipilimumab0.12 Percentage of participants
Ipilimumab0.28 Percentage of participants
Ipilimumab0.18 Percentage of participants
Nivolumab0.52 Percentage of participants
Nivolumab0.43 Percentage of participants
Nivolumab0.37 Percentage of participants
Nivolumab + Ipilimumab0.50 Percentage of participants
Nivolumab + Ipilimumab0.63 Percentage of participants
Nivolumab + Ipilimumab0.43 Percentage of participants
NCT01866319MelanomaPercentage of Participants With Overall Survival (OS) at 12 Months
Month 12
Ipilimumab58.2 Percentage of participants
Pembrolizumab Q2W74.1 Percentage of participants
Pembrolizumab Q3W68.4 Percentage of participants
NCT01866319MelanomaProgression-free Survival (PFS) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Radiology Plus Oncology Review (IRO)
Up to approximately 12 months (through first pre-specified statistical analysis cut-off date of 03-Sep-2014)
Ipilimumab2.8 Months
Pembrolizumab Q2W5.5 Months
Pembrolizumab Q3W4.1 Months
NCT02017717
CheckMate 143
GlioblastomaOverall Survival (OS) for Cohort 2
Time between the date of randomization and the date of death due to any cause (up to up to 17Jun2019, approximately 5 years)
Cohort 2: Arm B10.05 Months
Cohort 2: Arm N39.77 Months
NCT02017717
CheckMate 143
GlioblastomaPercentage of Participants With Adverse Events (Worst Grade) in Cohorts 1, 1b, 1c and 1d
From first dose to 30 days post last dose (up to approximately 34 months).
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N1+I370.0 Percentage of participants
Cohort 1: Arm N1+I30 Percentage of participants
Cohort 1: Arm N1+I320.0 Percentage of participants
Cohort 1: Arm N1+I30 Percentage of participants
Cohort 1: Arm N310.0 Percentage of participants
Cohort 1: Arm N330.0 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1: Arm N320.0 Percentage of participants
Cohort 1: Arm N340.0 Percentage of participants
Cohort 1b: Arm N3+I125.0 Percentage of participants
Cohort 1b: Arm N3+I120.0 Percentage of participants
Cohort 1b: Arm N3+I10 Percentage of participants
Cohort 1b: Arm N3+I15.0 Percentage of participants
Cohort 1b: Arm N3+I150.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ58.1 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ12.9 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ6.5 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ22.6 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part A Cohort 1d: Arm N3+RT20.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT33.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT26.7 Percentage of participants
Part A Cohort 1d: Arm N3+RT13.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT3.3 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.6 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ50.0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ10.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.6 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ28.6 Percentage of participants
Part B Cohort 1d: Arm N3+RT0 Percentage of participants
Part B Cohort 1d: Arm N3+RT21.4 Percentage of participants
Part B Cohort 1d: Arm N3+RT35.7 Percentage of participants
Part B Cohort 1d: Arm N3+RT17.9 Percentage of participants
Part B Cohort 1d: Arm N3+RT25.0 Percentage of participants
NCT02017717
CheckMate 143
GlioblastomaPercentage of Participants With Drug-Related Adverse Events Leading to Discontinuation by Worst CTC Grade for All Treated Participants in Cohorts 1, 1b, 1c and 1d Who Permanently Discontinued Study Medication Prior to Completing Four Doses
Includes events reported between first dose and 30 days after last dose of study therapy (up to 3 doses, up to approximately 2 months)
Cohort 1: Arm N1+I30 Percentage of participants
Cohort 1: Arm N1+I30 Percentage of participants
Cohort 1: Arm N1+I316.7 Percentage of participants
Cohort 1: Arm N1+I333.3 Percentage of participants
Cohort 1: Arm N1+I30 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1b: Arm N3+I10 Percentage of participants
Cohort 1b: Arm N3+I10 Percentage of participants
Cohort 1b: Arm N3+I10 Percentage of participants
Cohort 1b: Arm N3+I10 Percentage of participants
Cohort 1b: Arm N3+I10 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ66.7 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part A Cohort 1d: Arm N3+RT0 Percentage of participants
Part A Cohort 1d: Arm N3+RT0 Percentage of participants
Part A Cohort 1d: Arm N3+RT0 Percentage of participants
Part A Cohort 1d: Arm N3+RT0 Percentage of participants
Part A Cohort 1d: Arm N3+RT0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part B Cohort 1d: Arm N3+RT0 Percentage of participants
Part B Cohort 1d: Arm N3+RT0 Percentage of participants
Part B Cohort 1d: Arm N3+RT50.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT0 Percentage of participants
Part B Cohort 1d: Arm N3+RT0 Percentage of participants
NCT02017717
CheckMate 143
GlioblastomaPercentage of Participants With Serious Adverse Events (Worst Grade) in Cohorts 1, 1b, 1c and 1d
From first dose to 30 days post last dose (up to approximately 34 months).
Cohort 1: Arm N1+I30 Percentage of participants
Cohort 1: Arm N1+I320.0 Percentage of participants
Cohort 1: Arm N1+I30 Percentage of participants
Cohort 1: Arm N1+I30 Percentage of participants
Cohort 1: Arm N1+I360.0 Percentage of participants
Cohort 1: Arm N340.0 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1: Arm N310.0 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1: Arm N30 Percentage of participants
Cohort 1b: Arm N3+I10 Percentage of participants
Cohort 1b: Arm N3+I10 Percentage of participants
Cohort 1b: Arm N3+I15.0 Percentage of participants
Cohort 1b: Arm N3+I135.0 Percentage of participants
Cohort 1b: Arm N3+I115.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ3.2 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ45.2 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ16.1 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part A Cohort 1d: Arm N3+RT16.7 Percentage of participants
Part A Cohort 1d: Arm N3+RT3.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT16.7 Percentage of participants
Part A Cohort 1d: Arm N3+RT0 Percentage of participants
Part A Cohort 1d: Arm N3+RT16.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ35.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.6 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.6 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.6 Percentage of participants
Part B Cohort 1d: Arm N3+RT10.7 Percentage of participants
Part B Cohort 1d: Arm N3+RT0 Percentage of participants
Part B Cohort 1d: Arm N3+RT32.1 Percentage of participants
Part B Cohort 1d: Arm N3+RT0 Percentage of participants
Part B Cohort 1d: Arm N3+RT14.3 Percentage of participants
NCT02017717
CheckMate 143
GlioblastomaPercentage of Participants With Specific Laboratory Abnormalities in Liver Tests in Cohorts 1, 1b, 1c and 1d
From first dose to 30 days post last dose (up to approximately 34 months).
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N1+I330.0 Percentage of participants
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N1+I320.0 Percentage of participants
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N310.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1b: Arm N3+I15.3 Percentage of participants
Cohort 1b: Arm N3+I10.0 Percentage of participants
Cohort 1b: Arm N3+I115.8 Percentage of participants
Cohort 1b: Arm N3+I15.3 Percentage of participants
Cohort 1b: Arm N3+I110.5 Percentage of participants
Cohort 1b: Arm N3+I10.0 Percentage of participants
Cohort 1b: Arm N3+I10.0 Percentage of participants
Cohort 1b: Arm N3+I10.0 Percentage of participants
Cohort 1b: Arm N3+I10.0 Percentage of participants
Cohort 1b: Arm N3+I10.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ22.6 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ6.5 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ12.9 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ3.2 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT3.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT3.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT3.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT10.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT3.3 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ18.5 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ7.4 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ11.1 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT3.7 Percentage of participants
Part B Cohort 1d: Arm N3+RT3.7 Percentage of participants
Part B Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT14.8 Percentage of participants
Part B Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT3.7 Percentage of participants
Part B Cohort 1d: Arm N3+RT3.7 Percentage of participants
NCT02017717
CheckMate 143
GlioblastomaPercentage of Participants With Specific Laboratory Abnormalities in Thyroid Tests in Cohorts 1, 1b, 1c and 1d
From first dose to 30 days post last dose (up to approximately 34 months).
Cohort 1: Arm N1+I360.0 Percentage of participants
Cohort 1: Arm N1+I30.0 Percentage of participants
Cohort 1: Arm N1+I320.0 Percentage of participants
Cohort 1: Arm N1+I320.0 Percentage of participants
Cohort 1: Arm N1+I320.0 Percentage of participants
Cohort 1: Arm N1+I360.0 Percentage of participants
Cohort 1: Arm N1+I320.0 Percentage of participants
Cohort 1: Arm N1+I330.0 Percentage of participants
Cohort 1: Arm N1+I30.0 Percentage of participants
Cohort 1: Arm N1+I310.0 Percentage of participants
Cohort 1: Arm N350.0 Percentage of participants
Cohort 1: Arm N310.0 Percentage of participants
Cohort 1: Arm N330.0 Percentage of participants
Cohort 1: Arm N330.0 Percentage of participants
Cohort 1: Arm N320.0 Percentage of participants
Cohort 1: Arm N310.0 Percentage of participants
Cohort 1: Arm N310.0 Percentage of participants
Cohort 1: Arm N330.0 Percentage of participants
Cohort 1: Arm N30.0 Percentage of participants
Cohort 1: Arm N330.0 Percentage of participants
Cohort 1b: Arm N3+I15.3 Percentage of participants
Cohort 1b: Arm N3+I110.5 Percentage of participants
Cohort 1b: Arm N3+I110.5 Percentage of participants
Cohort 1b: Arm N3+I131.6 Percentage of participants
Cohort 1b: Arm N3+I115.8 Percentage of participants
Cohort 1b: Arm N3+I10.0 Percentage of participants
Cohort 1b: Arm N3+I110.5 Percentage of participants
Cohort 1b: Arm N3+I10.0 Percentage of participants
Cohort 1b: Arm N3+I131.6 Percentage of participants
Cohort 1b: Arm N3+I110.5 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ3.3 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ10.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ33.3 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ43.3 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ3.3 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ6.7 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ13.3 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ20.0 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ23.3 Percentage of participants
Part A Cohort 1c: Arm N3+RT+TMZ30.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT13.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT13.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT40.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT10.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT40.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT16.7 Percentage of participants
Part A Cohort 1d: Arm N3+RT3.3 Percentage of participants
Part A Cohort 1d: Arm N3+RT16.7 Percentage of participants
Part A Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part A Cohort 1d: Arm N3+RT16.7 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ11.1 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ22.2 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ7.4 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ11.1 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ11.1 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ0.0 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ11.1 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ18.5 Percentage of participants
Part B Cohort 1c: Arm N3+RT+TMZ3.7 Percentage of participants
Part B Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT29.6 Percentage of participants
Part B Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT0.0 Percentage of participants
Part B Cohort 1d: Arm N3+RT33.3 Percentage of participants
Part B Cohort 1d: Arm N3+RT3.7 Percentage of participants
Part B Cohort 1d: Arm N3+RT7.4 Percentage of participants
Part B Cohort 1d: Arm N3+RT18.5 Percentage of participants
Part B Cohort 1d: Arm N3+RT7.4 Percentage of participants
Part B Cohort 1d: Arm N3+RT7.4 Percentage of participants
NCT02224781Melanoma2-year Overall Survival (OS)
assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry
Arm A (Immunotherapy)0.683 Proportion of participants
Arm B (BRAF Inhibitor Therapy)0.541 Proportion of participants
NCT02231749Carcinoma, Renal CellInvestigator-assessed Objective Response Rate(ORR) in Intermediate/Poor Risk Participants Per IRRC Using RECIST v1.1
From first dose until date of documented disease progression or subsequent therapy, whichever occurs first (assessed up to June 2017, approximately 31 months)
Nivolumab + Ipilimumab41.6 percentage of participants
Sunitinib26.5 percentage of participants
NCT02231749Carcinoma, Renal CellOverall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)
From the date of randomization to the date of death (assessed up to June 2017, approximately 31 months)
Nivolumab + IpilimumabNA months
Sunitinib25.95 months
NCT02231749Carcinoma, Renal CellProgression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)
From date of first dose to date of documented disease progression or death due to any cause, whichever occurs first (assessed up to June 2017, approximately 31 months)
Nivolumab + Ipilimumab11.56 months
Sunitinib8.38 months
NCT02279732Carcinoma, Non-Small-Cell LungOverall Survival (OS) of All Randomized Participants Who Received at Least One Dose of Blinded Study Therapy
Approximately 43 months post study start
Ipi + PAC/CARNA months
Placebo + PAC/CARNA months
NCT02388906
CheckMate 238
MelanomaRecurrence-free Survival (RFS)
up to 36 months
Ipilimumab 10 mg/kg24.08 Months
Ipilimumab 10 mg/kg24.15 Months
Nivolumab 3 mg/kg52.37 Months
Nivolumab 3 mg/kg61.14 Months
NCT02477826
CheckMate 227
Carcinoma, Non-Small-Cell LungOverall Survival
From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)
Part 1-Arm A: Nivolumab15.70 months
Part 1-Arm B: Nivo + Ipi17.12 months
Part 1-Arm C: Chemotherapy14.88 months
Part 1-Arm D: Nivo + Ipi17.45 months
Part 1-Arm F: Chemotherapy12.19 months
Part 1-Arm G: Nivo + Chemo15.21 months
Part 2 - Arm H: Nivolumab + Chemotherapy18.27 months
Part 2 - Arm I: Chemotherapy14.72 months
Part 3 - Arm K: Chemotherapy15.11 months
Part 3 -Arm J: Nivolumab + Ipilimumab20.99 months
NCT02477826
CheckMate 227
Carcinoma, Non-Small-Cell LungProgression-Free Survival Per BICR
From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
Part 1-Arm A: Nivolumab4.17 months
Part 1-Arm B: Nivo + Ipi5.06 months
Part 1-Arm C: Chemotherapy5.55 months
Part 1-Arm D: Nivo + Ipi4.90 months
Part 1-Arm F: Chemotherapy4.70 months
Part 1-Arm G: Nivo + Chemo5.55 months
Part 2 - Arm H: Nivolumab + Chemotherapy8.34 months
Part 2 - Arm I: Chemotherapy5.52 months
Part 3 - Arm K: Chemotherapy5.49 months
Part 3 -Arm J: Nivolumab + Ipilimumab5.78 months
NCT02506153MelanomaOverall Survival (OS)
5 years after last randomization
FDA Approved Regimen (SOC)76 percentage of participants
MK-3475 (Pembrolizumab)82 percentage of participants
NCT02538666
CheckMate 451
Lung NeoplasmsOverall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population
From randomization to 400 deaths across the two treatment groups (Nivo+Ipi vs Placebo) (up to approximately 37 months)
Global Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg9.17 Months
Global Placebo9.56 Months
NCT02545075MelanomaTwo-Years Survival Rate
24 months
Dacarbazine (250 mg/m2)34.09 Percentage of Participants
Ipilimumab (3 mg/kg)33.98 Percentage of Participants
NCT02599402
CheckMate 401
MelanomaIncidence of Participants With High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events
From first dose to 30 days after last dose (up to approximately 37 months)
Nivolumab + Ipilimumab Acral1 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral1 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral1 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral1 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Acral0 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Brain Metastasis1 Participants
Nivolumab + Ipilimumab Brain Metastasis5 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Brain Metastasis5 Participants
Nivolumab + Ipilimumab Brain Metastasis1 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Brain Metastasis6 Participants
Nivolumab + Ipilimumab Brain Metastasis0 Participants
Nivolumab + Ipilimumab Cutaneous0 Participants
Nivolumab + Ipilimumab Cutaneous6 Participants
Nivolumab + Ipilimumab Cutaneous8 Participants
Nivolumab + Ipilimumab Cutaneous0 Participants
Nivolumab + Ipilimumab Cutaneous0 Participants
Nivolumab + Ipilimumab Cutaneous20 Participants
Nivolumab + Ipilimumab Cutaneous0 Participants
Nivolumab + Ipilimumab Cutaneous1 Participants
Nivolumab + Ipilimumab Cutaneous57 Participants
Nivolumab + Ipilimumab Cutaneous43 Participants
Nivolumab + Ipilimumab Cutaneous0 Participants
Nivolumab + Ipilimumab Cutaneous0 Participants
Nivolumab + Ipilimumab Cutaneous56 Participants
Nivolumab + Ipilimumab Cutaneous1 Participants
Nivolumab + Ipilimumab ECOG PS0-179 Participants
Nivolumab + Ipilimumab ECOG PS0-17 Participants
Nivolumab + Ipilimumab ECOG PS0-10 Participants
Nivolumab + Ipilimumab ECOG PS0-11 Participants
Nivolumab + Ipilimumab ECOG PS0-131 Participants
Nivolumab + Ipilimumab ECOG PS0-10 Participants
Nivolumab + Ipilimumab ECOG PS0-19 Participants
Nivolumab + Ipilimumab ECOG PS0-11 Participants
Nivolumab + Ipilimumab ECOG PS0-175 Participants
Nivolumab + Ipilimumab ECOG PS0-10 Participants
Nivolumab + Ipilimumab ECOG PS0-158 Participants
Nivolumab + Ipilimumab ECOG PS0-10 Participants
Nivolumab + Ipilimumab ECOG PS0-11 Participants
Nivolumab + Ipilimumab ECOG PS0-10 Participants
Nivolumab + Ipilimumab ECOG PS24 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS21 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS24 Participants
Nivolumab + Ipilimumab ECOG PS27 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab ECOG PS20 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Mucosal3 Participants
Nivolumab + Ipilimumab Mucosal1 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Mucosal2 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Mucosal5 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Mucosal2 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Mucosal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal17 Participants
Nivolumab + Ipilimumab Ocular/Uveal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal0 Participants
Nivolumab + Ipilimumab Ocular/Uveal1 Participants
Nivolumab + Ipilimumab Ocular/Uveal1 Participants
Nivolumab + Ipilimumab Ocular/Uveal6 Participants
Nivolumab + Ipilimumab Ocular/Uveal7 Participants
Nivolumab + Ipilimumab Ocular/Uveal9 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Other6 Participants
Nivolumab + Ipilimumab Other11 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Other4 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Other1 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Other6 Participants
Nivolumab + Ipilimumab Other0 Participants
Nivolumab + Ipilimumab Total83 Participants
Nivolumab + Ipilimumab Total0 Participants
Nivolumab + Ipilimumab Total1 Participants
Nivolumab + Ipilimumab Total0 Participants
Nivolumab + Ipilimumab Total58 Participants
Nivolumab + Ipilimumab Total0 Participants
Nivolumab + Ipilimumab Total82 Participants
Nivolumab + Ipilimumab Total1 Participants
Nivolumab + Ipilimumab Total10 Participants
Nivolumab + Ipilimumab Total0 Participants
Nivolumab + Ipilimumab Total35 Participants
Nivolumab + Ipilimumab Total1 Participants
Nivolumab + Ipilimumab Total7 Participants
Nivolumab + Ipilimumab Total0 Participants
NCT02714218MelanomaThe Percentage of Participants With Drug-Related Grade 3 - 5 Adverse Events (AEs)
From first dose of study treatment up to primary completion date 20-Apr-2017 (up to approximately 12 months)
Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV45.5 Percentage of participants
Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV32.8 Percentage of participants
NCT02741570
CheckMate 651
Head and Neck NeoplasmsOverall Survival (OS) in All Randomized Participants
From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)
EXTREME Regimen13.50 Months
Nivolumab + Ipilimumab13.90 Months
NCT02741570
CheckMate 651
Head and Neck NeoplasmsOverall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20
From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)
EXTREME Regimen14.59 Months
Nivolumab + Ipilimumab17.58 Months
NCT02785952—Overall Survival
From date of registration to maximum of 3 years or death
Arm I (Nivolumab, Ipilimumab)10 months
Arm II (Nivolumab)11 months
NCT02864251
CheckMate722
Carcinoma, Non-Small-Cell LungProgression Free Survival (PFS) by Blinded Independent Centralized Review (BICR)
From randomization to the date of first documented tumor progression or death (approximately 58 months)
Arm A: Nivolumab Plus Platinum-doublet Chemotherapy5.59 Months
Arm B: Nivolumab Plus Ipilimumab1.54 Months
Arm C: Platinum Doublet Chemotherapy5.45 Months
NCT02872116
CheckMate649
Stomach NeoplasmsOverall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5
From the date of randomization up to the date of death, up to approximately 17 months
Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)14.39 Months
Arm 2a: Chemotherapy (XELOX or FOLFOX)11.10 Months
NCT02872116
CheckMate649
Stomach NeoplasmsProgression Free Survival (PFS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5
From randomization to the date of the first documented progressive disease (PD) per BICR or death due to any cause (up to approximately 10 months)
Arm 1: Nivolumab + Chemotherapy (XELOX or FOLFOX)7.69 Months
Arm 2a: Chemotherapy (XELOX or FOLFOX)6.05 Months
NCT02899299
CheckMate743
MesotheliomaOverall Survival (OS)
From randomization to the date of death (Up to 40 Months)
Treatment A18.07 Months
Treatment B14.09 Months
NCT02905266MelanomaPercentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)
Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)
Fixed Ratio Combination15.1 Percent of Participants
Sequential Combination17.0 Percent of Participants
NCT02998528
CheckMate 816
Carcinoma, Non-Small-Cell LungEvent-Free Survival (EFS)
From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)
Arm B: Platinum Doublet Chemo20.80 Months
Arm B: Platinum Doublet Chemo21.06 Months
Arm C: Nivo 360 mg + Platinum Doublet Chemo59.60 Months
Arm C: Nivo 360 mg + Platinum Doublet Chemo31.57 Months
NCT02998528
CheckMate 816
Carcinoma, Non-Small-Cell LungPathologic Complete Response (pCR) Rate
From randomization up to a median of 30 months after randomization.
Arm B: Platinum Doublet Chemo4 Participants
Arm C: Nivo 360 mg + Platinum Doublet Chemo43 Participants
NCT03036098
CheckMate901
—Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study
From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
Treatment 321.72 Months
Treatment 418.86 Months
NCT03036098
CheckMate901
—Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study
From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
Treatment 119.06 Months
Treatment 213.21 Months
NCT03036098
CheckMate901
—Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study
From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)
Treatment 116.30 Months
Treatment 214.36 Months
NCT03036098
CheckMate901
—Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study
From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)
Treatment 37.92 Months
Treatment 47.56 Months
NCT03068455
CheckMate 915
MelanomaRecurrence-free Survival (RFS) - All Randomized Participants
From randomization to Primary Completion Date (up to approximately 3 years)
Arm A: Nivo + IpiNA Months
Arm B: NivoNA Months
NCT03068455
CheckMate 915
MelanomaRecurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level < 1%
From randomization to Primary Completion Date (up to approximately 3 years)
Arm A: Nivo + Ipi33.15 Months
Arm B: Nivo27.63 Months
NCT03138512
CheckMate 914
Carcinoma, Renal CellDisease-Free Survival (DFS) by BICR - Treatment Part A and B
From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)
Treatment Part A: Nivo + IpiNA Months
Treatment Part A: PlaceboNA Months
Treatment Part B: NivoNA Months
Treatment Part B: PlaceboNA Months
NCT03141177
CheckMate 9ER
Carcinoma, Renal CellProgression Free Survival (PFS)
From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)
Treatment A16.59 Months
Treatment C8.31 Months
NCT03143153
CheckMate 648
—Overall Survival (OS) in Participants With Tumor Cell PD-L1
From the date of randomization to up to the date of death (up to approximately 20 months)
Arm A: Nivolumab + Ipilimumab13.70 Months
Arm B: Nivolumab + Chemotherapy15.44 Months
Arm C: Chemotherapy9.07 Months
NCT03143153
CheckMate 648
—Progression-free Survival (PFS) as Assessed by BICR in Participants With Tumor Cell PD-L1
From the date of randomization to up to the date of the first documented disease progression or death (up to approximately 9 months)
Arm A: Nivolumab + Ipilimumab4.04 Months
Arm B: Nivolumab + Chemotherapy6.93 Months
Arm C: Chemotherapy4.44 Months
NCT03215706
CheckMate 9LA
Carcinoma, Non-Small-Cell LungOverall Survival (OS)
From date of randomization to date of death (assessed up to October 2019, approximately 23 months)
Treatment A15.80 Months
Treatment A14.13 Months
Treatment B10.96 Months
Treatment B10.74 Months
NCT03302234Carcinoma, Non-Small-Cell LungOverall Survival (OS)
Up to approximately 32 months (through data cut-off date: 01 Sep 2020)
Pembrolizumab + Ipilimumab21.4 Months
Pembrolizumab + Placebo21.9 Months
NCT03302234Carcinoma, Non-Small-Cell LungProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)
Up to approximately 32 months (through data cut-off date 01 Sep 2020)
Pembrolizumab + Ipilimumab8.2 Months
Pembrolizumab + Placebo8.4 Months
NCT03445533MelanomaSummary of Independent Reviewer-Assessed Objective Response Rate (ORR) by RECIST v1.1
Response is measured from the date of randomization, until disease progression, death, or start of new anti-cancer therapy (up to 36 months).
Arm A: Ipilimumab1 Participants
Arm A: Ipilimumab110 Participants
Arm A: Ipilimumab45 Participants
Arm A: Ipilimumab20 Participants
Arm A: Ipilimumab67 Participants
Arm B: IMO-2125 Plus Ipilimumab61 Participants
Arm B: IMO-2125 Plus Ipilimumab89 Participants
Arm B: IMO-2125 Plus Ipilimumab1 Participants
Arm B: IMO-2125 Plus Ipilimumab20 Participants
Arm B: IMO-2125 Plus Ipilimumab67 Participants
NCT03445533MelanomaSummary of Overall Survival
OS is measured from the date of randomization to the date of death from any cause (up to 36 months).
Arm A: Ipilimumab77 Participants
Arm A: Ipilimumab166 Participants
Arm B: IMO-2125 Plus Ipilimumab165 Participants
Arm B: IMO-2125 Plus Ipilimumab73 Participants
NCT03937219
COSMIC-313
Carcinoma, Renal CellDuration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)
Up to 32 months
Cabozantinib + Nivolumab + IpilimumabNA months
Placebo + Nivolumab + Ipilimumab11.30 months
NCT04008030
CheckMate 8HW
Colorectal NeoplasmsProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Arm A - Nivolumab Monotherapy39.26 Months
Arm B - Nivolumab + IpilimumabNA Months
NCT04008030
CheckMate 8HW
Colorectal NeoplasmsProgression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR
From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)
Arm B - Nivolumab + IpilimumabNA Months
Arm C - Investigator's Choice Chemotherapy5.85 Months
NCT04026412
CheckMate73L
Carcinoma, Non-Small-Cell LungArm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)
From randomization untill disease progression or death, whichever occurs first (up to approximately 53 months)
Arm A:Nivo + CCRT/Nivo + Ipi16.69 months
Arm C: CCRT/Durva15.64 months
NCT04340193
CheckMate 74W
Liver NeoplasmsNumber of Participants Who Died
From first dose and 100 days after last dose of study therapy (up to approximately 27 months)
NIVO+IPI+TACE2 Participants
NIVO+TACE2 Participants
TACE0 Participants
NCT04340193
CheckMate 74W
Liver NeoplasmsNumber of Participants With Adverse Events
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
NIVO+IPI+TACE9 Participants
NIVO+TACE9 Participants
TACE8 Participants
NCT04340193
CheckMate 74W
Liver NeoplasmsNumber of Participants With Adverse Events Leading to Study Drug Discontinuation
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
NIVO+IPI+TACE3 Participants
NIVO+TACE1 Participants
TACE1 Participants
NCT04340193
CheckMate 74W
Liver NeoplasmsNumber of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
NIVO+IPI+TACE3 Participants
NIVO+IPI+TACE3 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE2 Participants
NIVO+IPI+TACE5 Participants
NIVO+IPI+TACE3 Participants
NIVO+IPI+TACE3 Participants
NIVO+TACE2 Participants
NIVO+TACE2 Participants
NIVO+TACE0 Participants
NIVO+TACE2 Participants
NIVO+TACE5 Participants
NIVO+TACE1 Participants
NIVO+TACE1 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE5 Participants
TACE1 Participants
TACE0 Participants
TACE0 Participants
NCT04340193
CheckMate 74W
Liver NeoplasmsNumber of Participants With Laboratory Abnormalities in Specific Thyroid Tests
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
NIVO+IPI+TACE5 Participants
NIVO+IPI+TACE5 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE2 Participants
NIVO+IPI+TACE3 Participants
NIVO+IPI+TACE3 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE3 Participants
NIVO+IPI+TACE3 Participants
NIVO+IPI+TACE5 Participants
NIVO+TACE1 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE1 Participants
NIVO+TACE1 Participants
NIVO+TACE4 Participants
NIVO+TACE5 Participants
NIVO+TACE2 Participants
NIVO+TACE1 Participants
NIVO+TACE4 Participants
TACE0 Participants
TACE4 Participants
TACE0 Participants
TACE5 Participants
TACE0 Participants
TACE1 Participants
TACE0 Participants
TACE3 Participants
TACE0 Participants
TACE3 Participants
NCT04340193
CheckMate 74W
Liver NeoplasmsNumber of Participants With Serious Adverse Events (SAEs)
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
NIVO+IPI+TACE7 Participants
NIVO+TACE6 Participants
TACE2 Participants
NCT04340193
CheckMate 74W
Liver NeoplasmsNumber of Participants With Worst Grade (Grade 3/4) Laboratory Results
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
NIVO+IPI+TACE2 Participants
NIVO+IPI+TACE2 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE2 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE2 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE4 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE0 Participants
NIVO+IPI+TACE1 Participants
NIVO+IPI+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE2 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE1 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE1 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE1 Participants
NIVO+TACE0 Participants
NIVO+TACE1 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
NIVO+TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE3 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE2 Participants
TACE0 Participants
TACE1 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
TACE0 Participants
NCT04396860GliosarcomaProgression-free Survival (PFS) (Phase II)
From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
Arm I (Radiation Therapy, Temozolomide)8.5 months
Arm II (Radiation Therapy, Ipilimumab, Nivolumab)7.7 months

Publications by year

1968–2026: 1,069 publications.

1968
1
1976
1
1978
1
1982
2
1983
3
1987
1
1988
1
1989
1
1990
1
1992
1
1993
4
1994
1
1995
4
1996
5
1997
2
1998
4
1999
3
2000
10
2001
12
2002
7
2003
10
2004
22
2005
15
2006
21
2007
8
2008
21
2009
21
2010
29
2011
18
2012
22
2013
21
2014
22
2015
41
2016
41
2017
59
2018
29
2019
57
2020
60
2021
100
2022
122
2023
84
2024
83
2025
65
2026
33

Publications by indication

Melanoma (282)

  • Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
    J Immunother Precis Oncol · 2026 · PMID 39959251 · NCT02668770
  • Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
    Nat Med · 2026 · PMID 41606118 · NCT02977052
  • Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.
    J Immunother Precis Oncol · 2026 · PMID 39816915 · NCT02419495
  • Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.
    J Immunol Res · 2026 · PMID 41811823 · NCT02983045
  • Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
    N Engl J Med · 2026 · PMID 41124198 · NCT02388906

Carcinoma, Non-Small-Cell Lung (125)

  • Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
    Nat Cancer · 2026 · PMID 42129521 · NCT04026412
  • The role of the molecular tumor board: learnings from the ROME trial.
    NPJ Precis Oncol · 2026 · PMID 41963505 · NCT04591431
  • Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.
    J Thorac Oncol · 2025 · PMID 39369790 · NCT02477826
  • A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer.
    Respir Investig · 2025 · PMID 40036983 · NCT01840579
  • Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
    Nat Med · 2025 · PMID 41023484 · NCT04591431

Carcinoma, Renal Cell (70)

  • Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.
    J Immunother Cancer · 2026 · PMID 41617395 · NCT03141177
  • Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy.
    Oncol Ther · 2026 · PMID 41239083 · NCT03141177
  • Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.
    Ann Oncol · 2025 · PMID 40180121 · NCT03075423
  • Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial.
    Nat Commun · 2025 · PMID 39794332 · NCT04518046
  • Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.
    J Clin Oncol · 2025 · PMID 39303200 · NCT03138512

Mesothelioma (54)

  • Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
    J Clin Oncol · 2026 · PMID 41734361 · NCT02899299
  • YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
    Nat Med · 2025 · PMID 41111090 · NCT04665206
  • Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
    Nat Med · 2025 · PMID 40921804 · NCT03918252
  • Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementation.
    CVIR Oncol · 2025 · PMID 41425223 · NCT04840615
  • First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Lung Cancer · 2022 · PMID 35367910 · NCT02899299

Colorectal Neoplasms (54)

  • Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.
    Nat Commun · 2026 · PMID 42034603 · NCT03832621
  • Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
    Lancet · 2025 · PMID 39874977 · NCT04008030
  • Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
    N Engl J Med · 2024 · PMID 39602630 · NCT04008030
  • Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
    JAMA Oncol · 2023 · PMID 36892833 · NCT04362839
  • Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
    J Clin Oncol · 2022 · PMID 35258987 · NCT03832621

Neoplasms (47)

  • Prospective evaluation of genomics-guided off-label treatment.
    Nature · 2026 · PMID 41986720 · NCT02925234
  • Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    JCO Precis Oncol · 2026 · PMID 42018965 · NCT02693535
  • Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    JCO Precis Oncol · 2026 · PMID 42060861 · NCT02693535
  • Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    JCO Precis Oncol · 2026 · PMID 41538762 · NCT02693535
  • Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine.
    Eur J Nucl Med Mol Imaging · 2025 · PMID 39133306 · NCT04300244

Publications by journal

Trial-results highlights

Clinical trials have investigated ipilimumab in melanoma. In NCT00324155, the median Overall Survival (OS) was 11.17 months for participants receiving ipilimumab and dacarbazine, compared to 9.07 months for those receiving placebo and dacarbazine. Another study, NCT00636168, reported on recurrence or death, with 234 participants in the ipilimumab 10mg/kg arm experiencing recurrence or death, versus 294 participants in the placebo arm. In NCT00636168, the median Recurrence-Free Survival (RFS) was 26.09 months for ipilimumab 10mg/kg, compared to 17.05 months for placebo. RFS rates in NCT00636168 for ipilimumab 10mg/kg were 46.48% at 1 year, 51.45% at 2 years, and 63.50% at 3 years. For placebo, these rates were 34.79% at 1 year, 43.83% at 2 years, and 56.13% at 3 years. Furthermore, in NCT01274338, the 5-year OS rate was 0.70 proportion of participants in Arm A (HIP) and 0.65 proportion in Arm B (HDI). For prostatic neoplasms, NCT00861614 investigated ipilimumab plus radiotherapy. The median Overall Survival (OS) was 11.04 months for the ipilimumab + radiotherapy arm, versus 10.02 months for the placebo + radiotherapy arm. Overall Survival rates in NCT00861614 for ipilimumab + radiotherapy were:
  • 46.5% of participants
  • 25.2% of participants
  • 15.3% of participants
  • 10.1% of participants
  • 7.9% of participants
For placebo + radiotherapy, the Overall Survival rate was 3.3% of participants. In another study, NCT01057810, the median OS time was 28.65 months for the ipilimumab arm and 29.73 months for the placebo arm. All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Ipilimumab publications (1,069)

2026 (33 papers)

  1. A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).
    Yau T, Galle PR, Decaens T, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 41981891 · NCT04039607 (CheckMate 9DW) · Carcinoma, Hepatocellular
  2. Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.
    Walter TP, Mazieres J, Otto J, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41774886 · NCT03591731 (NIPINEC) · Carcinoma, Neuroendocrine
  3. Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma.
    Viray H, M Mantia C, Jegede OA, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41617395 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  4. Prospective evaluation of genomics-guided off-label treatment.
    Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
    PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
  5. Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.
    van den Hoek L, Burgmans M, Tong T, et al. · Lancet Oncol · 2026 · Derived
    PubMed: PMID 41785896 · NCT04283890 (CHOPIN) · Neoplasm Metastasis
  6. Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.
    Tselikas L, Susini S, Texier M, et al. · Nature · 2026 · Derived
    PubMed: PMID 42056527 · NCT02857569 (NIVIPIT)
  7. Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.
    Trédan O, Loirat D, Chabaud S, et al. · Breast · 2026 · Derived
    PubMed: PMID 41314029 · NCT03818685 (BreastImmune03) · Breast Neoplasms
  8. Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).
    Swiecicki PL, Othus M, Patel SP, et al. · Cancer · 2026 · Derived
    PubMed: PMID 41892875 · NCT02834013 · Carcinoma, Transitional Cell
  9. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
    Scherpereel A, Baas P, Nowak AK, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41734361 · NCT02899299 (CheckMate743) · Mesothelioma
  10. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Pisick E, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 42018965 · NCT02693535 (TAPUR) · Neoplasms
  11. Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
    Peters S, Tan DSW, Gerber DE, et al. · Nat Cancer · 2026 · Derived
    PubMed: PMID 42129521 · NCT04026412 (CheckMate73L) · Carcinoma, Non-Small-Cell Lung
  12. Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
    Nardo M, Gouda MA, Reilley MJ, et al. · J Immunother Precis Oncol · 2026 · Derived
    PubMed: PMID 39959251 · NCT02668770 · Melanoma
  13. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
    Morris VK, Ciombor KK, Xiao L, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41499716 · NCT02314169 · Anus Neoplasms
  14. Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
    Mellema JJ, Stockem CF, Herberts C, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41760951 · NCT05200988 (Indi-Blade) · Carcinoma, Transitional Cell
  15. The role of the molecular tumor board: learnings from the ROME trial.
    Marchetti P, Curigliano G, Westphalen CB, et al. · NPJ Precis Oncol · 2026 · Derived
    PubMed: PMID 41963505 · NCT04591431 (ROME) · Carcinoma, Non-Small-Cell Lung
  16. Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).
    Mandl A, Chen R, Das S, et al. · Oncologist · 2026 · Derived
    PubMed: PMID 41968073 · NCT04079712 · Small Cell Lung Carcinoma
  17. First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.
    Lorenzen S, Goetze TO, Thuss-Patience PC, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41760643 · NCT03647969
  18. Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration.
    Lin YJ, Ou DL, Su YY, et al. · J Hepatol · 2026 · Derived
    PubMed: PMID 40972843 · NCT03510871 · Carcinoma, Hepatocellular
  19. Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy.
    Johansen AZ, Novitski SI, Hjaltelin JX, et al. · Front Immunol · 2026 · Derived
    PubMed: PMID 37744345 · NCT02866383 (CheckPAC) · Pancreatic Neoplasms
  20. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.
    Huff AL, Haldar SD, Girgis AA, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41667470 · NCT04117087 · Pancreatic Neoplasms
  21. Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
    Hoeijmakers LL, Dimitriadis P, Wijnen SCMA, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41606118 · NCT02977052 (OpACIN-neo) · Melanoma
  22. Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy.
    Grimm MO, Karim E, Kapetanakis V, et al. · Oncol Ther · 2026 · Derived
    PubMed: PMID 41239083 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  23. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.
    Gouda MA, Zarifa A, Yang Y, et al. · J Immunother Precis Oncol · 2026 · Derived
    PubMed: PMID 39816915 · NCT02419495 · Melanoma
  24. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.
    Diefenbach CS, Jegede O, Wang V, et al. · Blood · 2026 · Derived
    PubMed: PMID 41662628 · NCT01896999
  25. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Cobain EF, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 42060861 · NCT02693535 (TAPUR) · Neoplasms
  26. Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.
    Choo J, Zhao JJ, Lau MC, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 42034603 · NCT03832621 (MAYA) · Colorectal Neoplasms
  27. DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.
    Chae YK, Othus M, Patel SP, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41672597 · NCT02834013 · Carcinoma, Transitional Cell
  28. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.
    Chae YK, Czeskleba J, Patel SP, et al. · J Gynecol Oncol · 2026 · Derived
    PubMed: PMID 41995270 · NCT02834013 · Carcinoma, Transitional Cell
  29. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Carrizosa DR, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 41538762 · NCT02693535 (TAPUR) · Neoplasms
  30. Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.
    Carlino MS, Gao B, Michael M, et al. · JAMA Oncol · 2026 · Derived
    PubMed: PMID 41231502 · NCT04969887 (MOST-CIRCUIT) · Neuroendocrine Tumors
  31. Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.
    Bautista J, Echeverría CE, Maldonado-Noboa I, et al. · J Immunol Res · 2026 · Derived
    PubMed: PMID 41811823 · NCT02983045 (PIVOT-02) · Melanoma
  32. Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
    Ascierto PA, Del Vecchio M, Merelli B, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41124198 · NCT02388906 (CheckMate 238) · Melanoma
  33. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
    Zhu HD, Fan WJ, Zhao C, et al. · J Clin Oncol · 2026 · Background
    PubMed: PMID 41734362 · NCT07482059

2025 (65 papers)

  1. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Wang Z, Fan J, Zhou S, et al. · Lancet · 2025 · Trial result
    PubMed: PMID 41125112 · NCT07487662 (ACTION-001)
  2. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Vogel A, Chan SL, Dawson LA, et al. · Ann Oncol · 2025 · Trial result
    PubMed: PMID 39986353 · NCT07487662 (ACTION-001)
  3. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.
    Dawson LA, Winter KA, Knox JJ, et al. · JAMA Oncol · 2025 · Trial result
    PubMed: PMID 39699905 · NCT07075120 · Carcinoma, Hepatocellular
  4. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.
    Bergmann L, Albiges L, Ahrens M, et al. · Ann Oncol · 2025 · Trial result
    PubMed: PMID 40180121 · NCT03075423 · Carcinoma, Renal Cell
  5. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
    Yau T, Galle PR, Decaens T, et al. · Lancet · 2025 · Derived
    PubMed: PMID 40349714 · NCT04039607 (CheckMate 9DW) · Carcinoma, Hepatocellular
  6. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
    Yap TA, Kwiatkowski DJ, Dagogo-Jack I, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41111090 · NCT04665206 · Mesothelioma
  7. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
    Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39282897 · NCT01844505 · Melanoma
  8. Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.
    Weber JS, Middleton MR, Yates G, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39378385 · NCT00636168
  9. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT03878524 · Neoplasm Metastasis
  10. Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.
    Tomita Y, Ye DW, Fujii A, et al. · Urol Oncol · 2025 · Derived
    PubMed: PMID 41015742 · NCT03036098 (CheckMate901)
  11. Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine.
    Thunold S, Hernes E, Farooqi S, et al. · Eur J Nucl Med Mol Imaging · 2025 · Derived
    PubMed: PMID 39133306 · NCT04300244 (NIPU) · Neoplasms
  12. Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.
    Tas L, Weitemeyer MB, Rohaan MW, et al. · Br J Surg · 2025 · Derived
    PubMed: PMID 40474841 · NCT02278887 (TIL) · Melanoma
  13. Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.
    Tan PB, Verschoor YL, van den Berg JG, et al. · Nature · 2025 · Derived
    PubMed: PMID 41115454 · NCT03026140 (NICHE) · Colonic Neoplasms
  14. Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial.
    Stockem CF, van Dorp J, van Dijk N, et al. · Eur J Cancer · 2025 · Derived
    PubMed: PMID 40934711 · NCT03387761 (NABUCCO) · Neoplasms
  15. First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.
    Shapiro RM, Sheffer M, Booker MA, et al. · J Hematol Oncol · 2025 · Derived
    PubMed: PMID 39948608 · NCT04290546 · Squamous Cell Carcinoma of Head and Neck
  16. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.
    Robert C, Kicinski M, Dutriaux C, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40449497 · NCT03235245 (EBIN) · Melanoma
  17. Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
    Reuss JE, Lee PK, Mehran RJ, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40921804 · NCT03918252 · Mesothelioma
  18. NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies.
    R Choo J, Jeraj SN, Sundar R, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 40502306 · NCT04850755
  19. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.
    Peters S, Paz-Ares LG, Reck M, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39369790 · NCT02477826 (CheckMate 227) · Carcinoma, Non-Small-Cell Lung
  20. Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort.
    Patel SP, Fisher J, Chae YK, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40588371 · NCT02834013 · Carcinoma, Transitional Cell
  21. Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma.
    Patel SP, Cano-Linson E, Chae YK, et al. · NPJ Precis Oncol · 2025 · Derived
    PubMed: PMID 39856213 · NCT02834013 · Carcinoma, Transitional Cell
  22. Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.
    Pandit-Taskar N, Mauguen A, Frosina D, et al. · Melanoma Res · 2025 · Derived
    PubMed: PMID 40557547 · NCT03122522 · Melanoma
  23. A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer.
    Nogami N, Umemura S, Kozuki T, et al. · Respir Investig · 2025 · Derived
    PubMed: PMID 40036983 · NCT01840579 · Carcinoma, Non-Small-Cell Lung
  24. Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.
    Nelson BE, O'Brien S, Sheth RA, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 39824531 · NCT03444753
  25. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial.
    Msaouel P, Yu K, Yuan Y, et al. · Nat Commun · 2025 · Derived
    PubMed: PMID 39794332 · NCT04518046 · Carcinoma, Renal Cell
  26. Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.
    Motzer RJ, Bex A, Russo P, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39303200 · NCT03138512 (CheckMate 914) · Carcinoma, Renal Cell
  27. Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementation.
    Morhard R, Mauda-Havakuk M, Delgado JF, et al. · CVIR Oncol · 2025 · Derived
    PubMed: PMID 41425223 · NCT04840615 · Mesothelioma
  28. Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
    Menzies AM, Salman P, Frontera OA, et al. · Cancer · 2025 · Derived
    PubMed: PMID 40614118 · NCT02905266 · Melanoma
  29. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
    Marchetti P, Curigliano G, Biffoni M, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41023484 · NCT04591431 (ROME) · Carcinoma, Non-Small-Cell Lung
  30. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
    Mangat PK, Kirkwood MK, Hinshaw DC, et al. · NPJ Precis Oncol · 2025 · Derived
    PubMed: PMID 40610648 · NCT02693535 (TAPUR) · Neoplasms
  31. Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial.
    Luke JJ, Bever K, Hodi FS, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40389374 · NCT03335540 (ADVISE)
  32. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915.
    Long GV, Tang H, Desai K, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40645660 · NCT03068455 (CheckMate 915) · Melanoma
  33. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
    Long GV, Nair N, Marbach D, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40993242 · NCT05116202 · Melanoma
  34. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
    Long GV, Larkin J, Schadendorf D, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39504507 · NCT02714218 · Melanoma
  35. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.
    Long GV, Atkinson V, Lo SN, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 39978375 · NCT02374242 (ABC) · Melanoma
  36. Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.
    Lin D, Quan W, Garretson M, et al. · Gastric Cancer · 2025 · Derived
    PubMed: PMID 40632415 · NCT02872116 (CheckMate649) · Stomach Neoplasms
  37. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H, Greillier L, Cropet C, et al. · Lancet Respir Med · 2025 · Derived
    PubMed: PMID 39486424 · NCT03351361 (eNERGY)
  38. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
    Lassman AB, Polley MC, Iwamoto FM, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40779733 · NCT04396860 · Gliosarcoma
  39. Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial.
    Laengle J, Kuehrer I, Kulu A, et al. · JAMA Netw Open · 2025 · Derived
    PubMed: PMID 40844778 · NCT04124601 (CHINOREC) · Rectal Neoplasms
  40. Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.
    Konda B, Sherman EJ, Massarelli E, et al. · J Clin Endocrinol Metab · 2025 · Derived
    PubMed: PMID 39133806 · NCT03914300 · Thyroid Neoplasms
  41. Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
    Huang RY, Youssef G, Nelson T, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39752606 · NCT02320058 (CheckMate204) · Melanoma
  42. Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update.
    Giannakodimos I, Ziogou A, Giannakodimos A, et al. · Immunotherapy · 2025 · Derived
    PubMed: PMID 40329651 · NCT03520491 · Urinary Bladder Neoplasms
  43. Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial.
    Gao B, Carlino MS, Michael M, et al. · JAMA Oncol · 2025 · Derived
    PubMed: PMID 40608313 · NCT04969887 (MOST-CIRCUIT) · Neuroendocrine Tumors
  44. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    Forde PM, Spicer JD, Provencio M, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40454642 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
  45. Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
    Diab A, Ascierto PA, Maio M, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40048691 · NCT03445533 · Melanoma
  46. Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study.
    Depotte L, Nay P, Borg C, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40389373 · NCT03350126 (NIPICOL) · Colonic Neoplasms
  47. Anti-PD-1 and anti-PD-L1 antibodies for glioma.
    de Melo SM, Elias Nunes da Silva ME, Torloni MR, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 39777725 · NCT02017717 (CheckMate 143) · Glioblastoma
  48. Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).
    Chae YK, Othus M, Patel SP, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 39583952 · NCT02834013 · Carcinoma, Transitional Cell
  49. Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.
    Chae YK, Duan R, Chung LI, et al. · Cancer Med · 2025 · Derived
    PubMed: PMID 40166913 · NCT03146650 · Salivary Gland Neoplasms
  50. Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma.
    Cella D, Motzer RJ, Suarez C, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 39452894 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  51. MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial.
    Cappuzzo F, Ricciuti B, Delmonte A, et al. · Clin Cancer Res · 2025 · Derived
    PubMed: PMID 39836372 · NCT03823625 (SQUINT)
  52. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
    Burton EM, Milton DR, Tetzlaff MT, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40638872 · NCT02519322 · Melanoma
  53. Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.
    Breukers SE, Traets JJH, van Dijk SW, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41062829 · NCT04620200 (MATISSE)
  54. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.
    Braun DA, Moranzoni G, Chea V, et al. · Nature · 2025 · Derived
    PubMed: PMID 39910301 · NCT02950766 · Kidney Neoplasms
  55. Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.
    Bhatia S, Topalian SL, Sharfman W, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39889250 · NCT02488759 (CheckMate358)
  56. Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).
    Barroso-Sousa R, Zanudo JGT, Li T, et al. · Nat Commun · 2025 · Derived
    PubMed: PMID 40360544 · NCT03789110 · Breast Neoplasms
  57. A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.
    Baretti M, Kirk AM, Ladle BH, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41286513 · NCT04248569 · Fibrolamellar hepatocellular carcinoma
  58. Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
    Awad MM, Forde PM, Girard N, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 39778121 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
  59. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
    André T, Elez E, Lenz HJ, et al. · Lancet · 2025 · Derived
    PubMed: PMID 39874977 · NCT04008030 (CheckMate 8HW) · Colorectal Neoplasms
  60. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
    Alhalabi O, Gouda MA, Milton DR, et al. · Cancer Med · 2025 · Derived
    PubMed: PMID 39945382 · NCT02419495 · Melanoma
  61. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Al Baghdadi T, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41100773 · NCT02693535 (TAPUR) · Neoplasms
  62. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
    Sangro B, Kudo M, Erinjeri JP, et al. · Lancet · 2025 · Background
    PubMed: PMID 39798579 · NCT07482059
  63. Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis.
    Lu W, Zhang T, Xia F, et al. · Front Oncol · 2025 · Background
    PubMed: PMID 39896190 · NCT07482059
  64. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Kudo M, Ren Z, Guo Y, et al. · Lancet · 2025 · Background
    PubMed: PMID 39798578 · NCT07482059
  65. Upfront Versus Deferred Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-analysis.
    Esagian SM, Karam JA, Msaouel P, et al. · Eur Urol Focus · 2025 · Background
    PubMed: PMID 39289076 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell

2024 (83 papers)

  1. The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond.
    Onderdonk BE, Chmura SJ · Front Oncol · 2024 · Trial result
    PubMed: PMID 31428580 · NCT07075120 · Carcinoma, Hepatocellular
  2. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial.
    Li Z, Liu J, Zhang B, et al. · Nat Commun · 2024 · Trial result
    PubMed: PMID 38627377 · NCT07075120 · Carcinoma, Hepatocellular
  3. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.
    Knisely A, Hinchcliff E, Fellman B, et al. · Med · 2024 · Trial result
    PubMed: PMID 38471508 · NCT03508570 · Ovarian Neoplasms
  4. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
    Boudadi K, Suzman DL, Anagnostou V, et al. · Oncotarget · 2024 · Trial result
    PubMed: PMID 29983880 · NCT02601014 (STARVE-PC) · Prostatic Neoplasms
  5. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
    Andresen NK, Røssevold AH, Quaghebeur C, et al. · J Immunother Cancer · 2024 · Trial result
    PubMed: PMID 38242720 · NCT03409198 (ICON) · Neoplasms
  6. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Abou-Alfa GK, Lau G, Kudo M, et al. · NEJM Evid · 2024 · Trial result
    PubMed: PMID 38319892 · NCT07075120 · Carcinoma, Hepatocellular
  7. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Worden FP, Pisick E, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39413339 · NCT02693535 (TAPUR) · Neoplasms
  8. Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
    Weber J, Del Vecchio M, Mandalá M, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39102624 · NCT02388906 (CheckMate 238) · Melanoma
  9. A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors.
    Vounckx M, Tijtgat J, Stevens L, et al. · Cancer Immunol Immunother · 2024 · Derived
    PubMed: PMID 38954010 · NCT04571632 (Luscid) · Carcinoma, Non-Small-Cell Lung
  10. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
    Tsukada Y, Bando H, Inamori K, et al. · Br J Cancer · 2024 · Derived
    PubMed: PMID 38834744 · NCT02948348 · Rectal Neoplasms
  11. Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.
    Tijtgat J, Geeraerts X, Boisson A, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38212127 · NCT03707808 (myDAvIpNi)
  12. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
    Stockem CF, Mellema JJJ, van Rhijn BWG, et al. · Front Oncol · 2024 · Derived
    PubMed: PMID 37711193 · NCT05200988 (Indi-Blade) · Carcinoma, Transitional Cell
  13. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Srkalovic G, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38865672 · NCT02693535 (TAPUR) · Neoplasms
  14. NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma.
    Sloan AE, Winter K, Gilbert MR, et al. · Neuro Oncol · 2024 · Derived
    PubMed: PMID 38874333 · NCT02311920 · Gliosarcoma
  15. A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.
    Seligson ND, Chen JL, Goodrich AC, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39343511 · NCT02500797 · Sarcoma
  16. Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
    Sehgal K, Pappa T, Shin KY, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 39446365 · NCT03246958 · Thyroid Neoplasms
  17. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Schuetze S, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39013131 · NCT02693535 (TAPUR) · Neoplasms
  18. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
    Schenker M, Burotto M, Richardet M, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39107131 · NCT03668119 (CheckMate 848)
  19. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
    Schenk KM, Deutsch JS, Chandra S, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38252910 · NCT03816332 · Melanoma
  20. Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.
    Root JL, Desai PN, Ly C, et al. · Cancer Res Commun · 2024 · Derived
    PubMed: PMID 38391202 · NCT02397720 · Leukemia, Myeloid, Acute
  21. Molecularly Defined Thoracic Neoplasms.
    Roden AC · Adv Anat Pathol · 2024 · Derived
    PubMed: PMID 38501690 · NCT05407441 · Sarcoma
  22. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
    Reck M, Ciuleanu TE, Schenker M, et al. · Eur J Cancer · 2024 · Derived
    PubMed: PMID 39270380 · NCT03215706 (CheckMate 9LA) · Carcinoma, Non-Small-Cell Lung
  23. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Rappaport AR, Kyi C, Lane M, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38538867 · NCT03953235 · Carcinoma, Non-Small-Cell Lung
  24. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
    Rajdev L, Jackie Wang CC, Joshi H, et al. · Cancer · 2024 · Derived
    PubMed: PMID 37962072 · NCT02408861 · Neoplasm Metastasis
  25. Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.
    Pulliam T, Jani S, Jing L, et al. · Cell Rep Med · 2024 · Derived
    PubMed: PMID 38340723 · NCT02488759 (CheckMate358)
  26. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
    Powles T, Burotto M, Escudier B, et al. · ESMO Open · 2024 · Derived
    PubMed: PMID 38642472 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  27. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
    Perez JK, Kleber J, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38564684 · NCT02693535 (TAPUR) · Neoplasms
  28. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.
    Patel SP, Othus M, Chae YK, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39067873 · NCT02834013 · Carcinoma, Transitional Cell
  29. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
    Patel SP, Guadarrama E, Chae YK, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38358334 · NCT02834013 · Carcinoma, Transitional Cell
  30. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
    Overman MJ, Gelsomino F, Aglietta M, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38821718 · NCT02060188 (CheckMate142)
  31. Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
    Ornstein MC, George L, Wei W, et al. · Clin Genitourin Cancer · 2024 · Derived
    PubMed: PMID 39208489 · NCT03126331 · Carcinoma, Renal Cell
  32. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
    Oaknin A, Moore K, Meyer T, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38608691 · NCT02488759 (CheckMate358)
  33. Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
    Nogami N, Tokito T, Zenke Y, et al. · Invest New Drugs · 2024 · Derived
    PubMed: PMID 38300341 · NCT01840579 · Carcinoma, Non-Small-Cell Lung
  34. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
    Nederlof I, Isaeva OI, de Graaf M, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39284953 · NCT03815890 (BELLINI) · Breast Neoplasms
  35. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
    Mu-Mosley H, von Itzstein MS, Fattah F, et al. · Oncoimmunology · 2024 · Derived
    PubMed: PMID 38737792 · NCT01896999
  36. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
    Mok T, Nakagawa K, Park K, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38252907 · NCT02864251 (CheckMate722) · Carcinoma, Non-Small-Cell Lung
  37. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.
    Mason M, Lapuente-Santana Ó, Halkola AS, et al. · J Transl Med · 2024 · Derived
    PubMed: PMID 38383458 · NCT02477826 (CheckMate 227) · Carcinoma, Non-Small-Cell Lung
  38. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
    Mantia CM, Jegede OA, Plimack ER, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39060019 · NCT02231749 · Carcinoma, Renal Cell
  39. Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.
    Malhotra J, Chiappori A, Fujioka N, et al. · Lung Cancer · 2024 · Derived
    PubMed: PMID 39173229 · NCT03575793 · Lung Neoplasms
  40. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
    Long GV, Carlino MS, McNeil C, et al. · Ann Oncol · 2024 · Derived
    PubMed: PMID 39306585 · NCT01866319 · Melanoma
  41. Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study.
    Li M, Meindl-Beinker NM, Maenz M, et al. · J Geriatr Oncol · 2024 · Derived
    PubMed: PMID 39097500 · NCT03416244 (RAMONA) · Esophageal Neoplasms
  42. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
    Kozono D, Hua X, Wu MC, et al. · J Thorac Oncol · 2024 · Derived
    PubMed: PMID 39111731 · NCT02154490
  43. Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
    Kesari S, Wojcinski A, Pabla S, et al. · Oncoimmunology · 2024 · Derived
    PubMed: PMID 39572979 · NCT03425292
  44. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.
    Jun S, Shukla NA, Durm G, et al. · J Thorac Oncol · 2024 · Derived
    PubMed: PMID 38971369 · NCT03285321 · Carcinoma, Non-Small-Cell Lung
  45. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
    Joerger M, Calvo E, Laubli H, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38243906 · NCT04855929 (ANV419-001) · Neoplasms
  46. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    Janjigian YY, Ajani JA, Moehler M, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38382001 · NCT02872116 (CheckMate649) · Stomach Neoplasms
  47. Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy.
    Hoogland AI, Brohl AS, Small BJ, et al. · Cancer Med · 2024 · Derived
    PubMed: PMID 39021272 · NCT03071406 · Neoplasm Metastasis
  48. Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
    Grimm MO, Schostak M, Grün CB, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 38722641 · NCT03219775 (TITAN-TCC) · Neoplasm Metastasis
  49. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.
    Gonzalez-Kozlova E, Huang HH, Jagede OA, et al. · Cancer Res Commun · 2024 · Derived
    PubMed: PMID 38934093 · NCT01896999
  50. The Age of Cyclic Dinucleotide Vaccine Adjuvants.
    Gogoi H, Mansouri S, Jin L, et al. · Vaccines (Basel) · 2024 · Derived
    PubMed: PMID 32823563 · NCT02675439 · Lymphoma
  51. Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
  52. An LC-MS/MS method for determination of the bromodomain inhibitor ZEN-3694 and its metabolite ZEN-3791 in human plasma.
    Feng Y, Mahdi H, Piekarz R, et al. · Bioanalysis · 2024 · Derived
    PubMed: PMID 38497709 · NCT04840589 · Neoplasm Metastasis
  53. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
    Elez E, Cubillo A, Alfonso PG, et al. · BMC Cancer · 2024 · Derived
    PubMed: PMID 38600471 · NCT03271047 · Neoplasms
  54. Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
    Duerinck J, Lescrauwaet L, Dirven I, et al. · Neuro Oncol · 2024 · Derived
    PubMed: PMID 39406392 · NCT03233152 (GlitIpNi) · Glioblastoma
  55. Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
    Deutsch JS, Cimino-Mathews A, Thompson E, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 37903504 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
  56. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.
    de Gooyer PGM, Verschoor YL, van den Dungen LDW, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39278994 · NCT03026140 (NICHE) · Colonic Neoplasms
  57. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.
    D'Alessio A, Stefanini B, Blanter J, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 39437804 · NCT03510871 · Carcinoma, Hepatocellular
  58. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies.
    Chang JY, Xu X, Shroff GS, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39384194 · NCT04021043 · Neoplasm Metastasis
  59. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
    Chalabi M, Verschoor YL, Tan PB, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38838311 · NCT03026140 (NICHE) · Colonic Neoplasms
  60. Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
    Chae YK, Othus M, Patel S, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39343510 · NCT02834013 · Carcinoma, Transitional Cell
  61. Neoadjuvant Treatment of Mismatch Repair-Deficient Colon Cancer - Clinically Meaningful?
    Cercek A · N Engl J Med · 2024 · Derived
    PubMed: PMID 38838316 · NCT03026140 (NICHE) · Colonic Neoplasms
  62. The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
    Cella D, Choueiri TK, Hamilton M, et al. · Oncologist · 2024 · Derived
    PubMed: PMID 38280218 · NCT02231749 · Carcinoma, Renal Cell
  63. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Cannon TL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38748939 · NCT02693535 (TAPUR) · Neoplasms
  64. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Calfa CJ, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38354330 · NCT02693535 (TAPUR) · Neoplasms
  65. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
    Blank CU, Lucas MW, Scolyer RA, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38828984 · NCT04949113 (NADINA) · Melanoma
  66. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
    Ascierto PA, Mandalà M, Ferrucci PF, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 39315864 · NCT02631447 (SECOMBIT) · Melanoma
  67. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
    Ascierto PA, Casula M, Bulgarelli J, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 38167503 · NCT02631447 (SECOMBIT) · Melanoma
  68. ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.
    Arrieta VA, Duerinck J, Burdett KB, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 37939133 · NCT03233152 (GlitIpNi) · Glioblastoma
  69. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
    Apolo AB, Girardi DM, Niglio SA, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38954785 · NCT02496208 · Carcinoma, Renal Cell
  70. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
    Andre T, Elez E, Van Cutsem E, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 39602630 · NCT04008030 (CheckMate 8HW) · Colorectal Neoplasms
  71. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.
    Altan M, Li R, Li Z, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39721752 · NCT03391869 · Carcinoma, Non-Small-Cell Lung
  72. Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.
    Aden D, Sureka N, Zaheer S, et al. · Immunology · 2024 · Derived
    PubMed: PMID 39462179 · NCT04899921 · Melanoma
  73. Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy.
    Wang C, Zeng Q, Gül ZM, et al. · Cell · 2024 · Background
    PubMed: PMID 38723627 · NCT07338981
  74. Metabolic Dependencies in Pancreatic Cancer.
    Vaziri-Gohar A, Zarei M, Brody JR, et al. · Front Oncol · 2024 · Background
    PubMed: PMID 30631752 · NCT04787991 (REVOLUTION)
  75. Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations.
    Tomita Y, Sakata S, Imamura K, et al. · Cancers (Basel) · 2024 · Background
    PubMed: PMID 38201474 · NCT06399419 · Carcinoma, Renal Cell
  76. The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt+Treg and PD-1 blockade efficacy.
    Paz Del Socorro T, Oka K, Boulard O, et al. · Gut Microbes · 2024 · Background
    PubMed: PMID 38385162 · NCT06399419 · Carcinoma, Renal Cell
  77. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis.
    Patel JS, Woo Y, Draper A, et al. · J Immunother Cancer · 2024 · Background
    PubMed: PMID 38531662 · NCT07338981
  78. Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
    Mejait A, Roux C, Soret M, et al. · Clin Res Hepatol Gastroenterol · 2024 · Background
    PubMed: PMID 38191073 · NCT07482059
  79. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Luke JJ, Rutkowski P, Queirolo P, et al. · Lancet · 2024 · Background
    PubMed: PMID 35367007 · NCT06365619 (NeoRelapse) · Melanoma
  80. Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?
    Karaboué A, Innominato PF, Wreglesworth NI, et al. · Br J Cancer · 2024 · Background
    PubMed: PMID 38834742 · NCT07338981
  81. Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.
    Herbreteau G, Langlais A, Greillier L, et al. · J Clin Med · 2024 · Background
    PubMed: PMID 33261056 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  82. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade.
    Fortin BM, Pfeiffer SM, Insua-Rodríguez J, et al. · Nat Immunol · 2024 · Background
    PubMed: PMID 38806707 · NCT07338981
  83. Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study.
    Braud A, Auloge P, Meyer N, et al. · Cardiovasc Intervent Radiol · 2024 · Background
    PubMed: PMID 38570342 · NCT03949153 (CRIRIN) · Melanoma

2023 (84 papers)

  1. Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.
    Lutzky J, Sullivan RJ, Cohen JV, et al. · J Cancer Res Clin Oncol · 2023 · Trial result
    PubMed: PMID 36651961 · NCT03408587 (CLEVER) · Uveal Melanoma
  2. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.
    Zijlker LP, van der Burg SJC, Blank CU, et al. · Eur J Cancer · 2023 · Derived
    PubMed: PMID 36989829 · NCT02437279 (OpACIN) · Melanoma
  3. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis.
    Zhou X, Cao J, Topatana W, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 36852452 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  4. Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis.
    Zhang Y, Li C, Du K, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 37139963 · NCT03143153 (CheckMate 648)
  5. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37424386 · NCT02925234 (DRUP) · Neoplasms
  6. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
    Yau T, Zagonel V, Santoro A, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36512738 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  7. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
    Yang ES, Halabi S, Rothe M, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 36753688 · NCT02693535 (TAPUR) · Neoplasms
  8. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
    Weber JS, Schadendorf D, Del Vecchio M, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36162037 · NCT03068455 (CheckMate 915) · Melanoma
  9. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.
    Vos JL, Burman B, Jain S, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37620627 · NCT03172624 · Salivary Gland Neoplasms
  10. The heightened importance of the microbiome in cancer immunotherapy.
    Villemin C, Six A, Neville BA, et al. · Trends Immunol · 2023 · Derived
    PubMed: PMID 36464584 · NCT03829111 · Carcinoma, Renal Cell
  11. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
    VanderWalde A, Bellasea SL, Kendra KL, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37592104 · NCT03033576
  12. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
    van Dorp J, Pipinikas C, Suelmann BBM, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 36732628 · NCT03387761 (NABUCCO) · Neoplasms
  13. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
    van der Heijden MS, Sonpavde G, Powles T, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37870949 · NCT03036098 (CheckMate901)
  14. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
    Unger JM, Darke A, Othus M, et al. · JAMA Oncol · 2023 · Derived
    PubMed: PMID 36416836 · NCT02506153 · Melanoma
  15. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
    Tran BD, Li J, Ly N, et al. · Cancer Chemother Pharmacol · 2023 · Derived
    PubMed: PMID 36625894 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  16. Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.
    Thompson JR, Lai-Kwon J, Morton RL, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 37132182 · NCT02374242 (ABC) · Melanoma
  17. Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol.
    Spindler NJ, Persson GF, Theile S, et al. · BMJ Open · 2023 · Derived
    PubMed: PMID 36717150 · NCT05655715 (CheckPRO) · Neoplasms
  18. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Rohatgi N, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 38039429 · NCT02693535 (TAPUR) · Neoplasms
  19. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
    Rohaan MW, Borch TH, van den Berg JH, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 36477031 · NCT02278887 (TIL) · Melanoma
  20. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
    Robert C, Carlino MS, McNeil C, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37348035 · NCT01866319 · Melanoma
  21. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
    Ready NE, Audigier-Valette C, Goldman JW, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 36725084 · NCT02869789 · Lung Neoplasms
  22. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.
    Ratovomanana T, Nicolle R, Cohen R, et al. · Ann Oncol · 2023 · Derived
    PubMed: PMID 37269904 · NCT03350126 (NIPICOL) · Colonic Neoplasms
  23. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
    Pouyiourou M, Kraft BN, Wohlfromm T, et al. · Nat Commun · 2023 · Derived
    PubMed: PMID 37875494 · NCT04131621 (CheCUP) · Neoplasms, Unknown Primary
  24. Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.
    Petersohn S, McGregor B, Klijn SL, et al. · J Comp Eff Res · 2023 · Derived
    PubMed: PMID 37431849 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  25. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
    Penter L, Liu Y, Wolff JO, et al. · Blood · 2023 · Derived
    PubMed: PMID 36706355 · NCT02890329 · Leukemia, Myeloid, Acute
  26. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
    Noviello TMR, Di Giacomo AM, Caruso FP, et al. · Nat Commun · 2023 · Derived
    PubMed: PMID 37739939 · NCT02608437 (NIBIT-M4) · Melanoma
  27. A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.
    Nguyen VP, Campbell KM, Nowicki TS, et al. · Cancer Res Commun · 2023 · Derived
    PubMed: PMID 37621406 · NCT04185311 · Triple Negative Breast Neoplasms
  28. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
    Motzer RJ, Russo P, Grünwald V, et al. · Lancet · 2023 · Derived
    PubMed: PMID 36774933 · NCT03138512 (CheckMate 914) · Carcinoma, Renal Cell
  29. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
    Moehler M, Xiao H, Blum SI, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37713657 · NCT02872116 (CheckMate649) · Stomach Neoplasms
  30. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Meric-Bernstam F, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 38096472 · NCT02693535 (TAPUR) · Neoplasms
  31. Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
    McLouth LE, Zheng Y, Smith S, et al. · Qual Life Res · 2023 · Derived
    PubMed: PMID 36029412 · NCT01274338 · Melanoma
  32. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.
    Mangat PK, Garrett-Mayer E, Perez JK, et al. · Clin Trials · 2023 · Derived
    PubMed: PMID 37489819 · NCT02693535 (TAPUR) · Neoplasms
  33. Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?
    Macapagal SC, Bennani NN · Blood Rev · 2023 · Derived
    PubMed: PMID 36898933 · NCT03017820 · Multiple Myeloma
  34. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
    Long GV, Menzies AM, Scolyer RA, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37104746 · NCT04949113 (NADINA) · Melanoma
  35. Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).
    Lee SM, Fan W, Wang A, et al. · JCO Clin Cancer Inform · 2023 · Derived
    PubMed: PMID 37084329 · NCT02785952
  36. A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab.
    Kobeissi I, Eljilany I, Achkar T, et al. · Int J Mol Sci · 2023 · Derived
    PubMed: PMID 37175874 · NCT00972933 · Melanoma
  37. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
    Kato K, Doki Y, Ogata T, et al. · Esophagus · 2023 · Derived
    PubMed: PMID 36401133 · NCT03143153 (CheckMate 648)
  38. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
    Johnson JM, Vathiotis IA, Harshyne LA, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37536941 · NCT03162731 · Laryngeal Diseases
  39. A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
    Janjigian YY, Shitara K, Moehler M, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 36919706 · NCT02872116 (CheckMate649) · Stomach Neoplasms
  40. Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.
    Hoefsmit EP, Völlmy F, Rozeman EA, et al. · Cancer Res Commun · 2023 · Derived
    PubMed: PMID 37089863 · NCT02977052 (OpACIN-neo) · Melanoma
  41. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease.
    He K, Hong DS, Tang C, et al. · Radiother Oncol · 2023 · Derived
    PubMed: PMID 36921766 · NCT02239900 · Neoplasm Metastasis
  42. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
    Hassel JC, Piperno-Neumann S, Rutkowski P, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37870955 · NCT03070392 · Melanoma
  43. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.
    Hassan R, Butler M, O'Cearbhaill RE, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37501016 · NCT03907852 · Carcinoma, Non-Small-Cell Lung
  44. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
    Harrington KJ, Ferris RL, Gillison M, et al. · JAMA Oncol · 2023 · Derived
    PubMed: PMID 37022706 · NCT02823574 (CheckMate 714) · Head and Neck Neoplasms
  45. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
    Haddad RI, Harrington K, Tahara M, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36473143 · NCT02741570 (CheckMate 651) · Head and Neck Neoplasms
  46. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
    Grimm MO, Grün CB, Niegisch G, et al. · Lancet Oncol · 2023 · Derived
    PubMed: PMID 36868252 · NCT03219775 (TITAN-TCC) · Neoplasm Metastasis
  47. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
    Grimm MO, Esteban E, Barthélémy P, et al. · Lancet Oncol · 2023 · Derived
    PubMed: PMID 37844597 · NCT02917772 (TITAN-RCC) · Carcinoma, Renal Cell
  48. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
    Gorry C, McCullagh L, O'Donnell H, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 36648215 · NCT01608594 · Melanoma
  49. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
    Gijtenbeek RG, de Jong K, Venmans BJ, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37419867 · NCT03351361 (eNERGY)
  50. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36870947 · NCT02925234 (DRUP) · Neoplasms
  51. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Ganti AK, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37315265 · NCT02693535 (TAPUR) · Neoplasms
  52. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
    Fraterman I, Reijers ILM, Dimitriadis P, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37957378 · NCT02977052 (OpACIN-neo) · Melanoma
  53. Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
    Forde PM, Spicer J, Lu S, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 36815433 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
  54. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
    Fakih M, Sandhu J, Lim D, et al. · JAMA Oncol · 2023 · Derived
    PubMed: PMID 36892833 · NCT04362839 · Colorectal Neoplasms
  55. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
    Fa'ak F, Buni M, Falohun A, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37328287 · NCT04940299 · Melanoma
  56. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Duvivier HL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37561967 · NCT02693535 (TAPUR) · Neoplasms
  57. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.
    Dunkel IJ, Doz F, Foreman NK, et al. · Neuro Oncol · 2023 · Derived
    PubMed: PMID 36808285 · NCT03130959 (CheckMate 908)
  58. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
    Dummer R, Corrie P, Gutzmer R, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37307514 · NCT02599402 (CheckMate 401) · Melanoma
  59. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
    Desai AP, Kosari F, Disselhorst M, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37279993 · NCT03048474 (INITIATE) · Mesothelioma, Malignant
  60. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
    Davidson G, Helleux A, Vano YA, et al. · Cancer Res · 2023 · Derived
    PubMed: PMID 37335139 · NCT02960906 (BIONIKK) · Clear-cell metastatic renal cell carcinoma
  61. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
    Choueiri TK, Powles T, Albiges L, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37163623 · NCT03937219 (COSMIC-313) · Carcinoma, Renal Cell
  62. Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia.
    Cheng Y, Yang JC, Okamoto I, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 37465924 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  63. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
    Chen IM, Donia M, Chamberlain CA, et al. · Eur J Cancer · 2023 · Derived
    PubMed: PMID 36592507 · NCT04258150 (TRIPPLE-R) · Pancreatic Neoplasms
  64. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.
    Castellino SM, Giulino-Roth L, Harker-Murray P, et al. · Pediatr Blood Cancer · 2023 · Derived
    PubMed: PMID 37505794 · NCT01896999
  65. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Cascone T, Leung CH, Weissferdt A, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 36928818 · NCT03158129 · Carcinoma, Non-Small-Cell Lung
  66. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
    Brahmer JR, Lee JS, Ciuleanu TE, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36223558 · NCT02477826 (CheckMate 227) · Carcinoma, Non-Small-Cell Lung
  67. Onconephrology 2022: An Update.
    Bonilla M, Gudsoorkar P, Wanchoo R, et al. · Kidney360 · 2023 · Derived
    PubMed: PMID 36821617 · NCT03816332 · Melanoma
  68. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
    Atkins MB, Lee SJ, Chmielowski B, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36166727 · NCT02224781 · Melanoma
  69. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
    Atkins MB, Jegede OA, Haas NB, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 36948504 · NCT03117309
  70. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
    Ascierto PA, Mandalà M, Ferrucci PF, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36049147 · NCT02631447 (SECOMBIT) · Melanoma
  71. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T, Tougeron D, Piessen G, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 35969830 · NCT04006262 (NEONIPIGA) · Microsatellite Instability
  72. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.
    Amaro A, Reggiani F, Fenoglio D, et al. · J Exp Clin Cancer Res · 2023 · Derived
    PubMed: PMID 36934257 · NCT02608437 (NIBIT-M4) · Melanoma
  73. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
    Altan M, Tu J, Milton DR, et al. · Cancer · 2023 · Derived
    PubMed: PMID 37129197 · NCT02419495 · Melanoma
  74. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events.
    Altan M, Li QZ, Wang Q, et al. · Front Immunol · 2023 · Derived
    PubMed: PMID 38152395 · NCT03391869 · Carcinoma, Non-Small-Cell Lung
  75. In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Ali AS, Manukian G, Johnson JM, et al. · Int J Radiat Oncol Biol Phys · 2023 · Derived
    PubMed: PMID 37019367 · NCT03162731 · Laryngeal Diseases
  76. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Aldin A, Besiroglu B, Adams A, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37146227 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  77. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.
    Akinboro O, Drezner N, Amatya A, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37141544 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
  78. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
    Ahn ER, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37027810 · NCT02693535 (TAPUR) · Neoplasms
  79. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.
    Rosenberg A, Mahalingam D · J Gastrointest Oncol · 2023 · Background
    PubMed: PMID 29564181 · NCT04787991 (REVOLUTION)
  80. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
    Patel SP, Othus M, Chen Y, et al. · N Engl J Med · 2023 · Background
    PubMed: PMID 36856617 · NCT06365619 (NeoRelapse) · Melanoma
  81. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Kirkwood JM, Del Vecchio M, Weber J, et al. · Nat Med · 2023 · Background
    PubMed: PMID 37845511 · NCT06365619 (NeoRelapse) · Melanoma
  82. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
    Dizman N, Govindarajan A, Zengin ZB, et al. · Clin Genitourin Cancer · 2023 · Background
    PubMed: PMID 37495481 · NCT07338981
  83. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
    Chesney JA, Puzanov I, Collichio FA, et al. · J Immunother Cancer · 2023 · Background
    PubMed: PMID 37142291 · NCT01740297 · Melanoma
  84. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
    Ascierto PA, Lipson EJ, Dummer R, et al. · J Clin Oncol · 2023 · Background
    PubMed: PMID 36780608 · NCT06365619 (NeoRelapse) · Melanoma

2022 (122 papers)

  1. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
    Yau T, Kang YK, Kim TY, et al. · JAMA Oncol · 2022 · Trial result
    PubMed: PMID 33001135 · NCT07075120 · Carcinoma, Hepatocellular
  2. Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases.
    Nilsen LB, Digernes I, Grøvik E, et al. · Neurooncol Adv · 2022 · Trial result
    PubMed: PMID 32642687 · NCT03458455 (TREATMENT) · Brain Neoplasms
  3. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial.
    Montfort A, Filleron T, Virazels M, et al. · Clin Cancer Res · 2022 · Trial result
    PubMed: PMID 33272982 · NCT03293784 (TICIMEL) · Melanoma
  4. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.
    Juloori A, Katipally RR, Lemons JM, et al. · Int J Radiat Oncol Biol Phys · 2022 · Trial result
    PubMed: PMID 36108891 · NCT07075120 · Carcinoma, Hepatocellular
  5. Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery.
    Digernes I, Grøvik E, Nilsen LB, et al. · Adv Radiat Oncol · 2022 · Trial result
    PubMed: PMID 30370356 · NCT03458455 (TREATMENT) · Brain Neoplasms
  6. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
    Curti BD, Richards J, Hyngstrom JR, et al. · J Immunother Cancer · 2022 · Trial result
    PubMed: PMID 36564126 · NCT02307149 (MITCI) · Melanoma
  7. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
    Cook J, Peng KW, Witzig TE, et al. · Blood Adv · 2022 · Trial result
    PubMed: PMID 35175355 · NCT06508463 · Lymphoma, Large-Cell, Anaplastic
  8. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
    Zhou JG, Donaubauer AJ, Frey B, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 33593828 · NCT03453892 (ST-ICI) · Neoplasm Metastasis
  9. Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
    Yoshino T, Oki E, Misumi T, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35512259 · NCT03068455 (CheckMate 915) · Melanoma
  10. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
    Yang Y, Psutka SP, Parikh AB, et al. · Cancer Med · 2022 · Derived
    PubMed: PMID 35304832 · NCT03793166 · Carcinoma, Renal Cell
  11. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34818112 · NCT01844505 · Melanoma
  12. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.
    Weber JS, Levinson BA, Laino AS, et al. · Melanoma Res · 2022 · Derived
    PubMed: PMID 35678233 · NCT03565406 · Melanoma
  13. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer.
    Wang D, Cabalag CS, Clemons NJ, et al. · Gastroenterology · 2022 · Derived
    PubMed: PMID 34606846 · NCT03026140 (NICHE) · Colonic Neoplasms
  14. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
    Wagner MJ, Othus M, Patel SP, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34380663 · NCT02834013 · Carcinoma, Transitional Cell
  15. [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.
    Vos JL, Zuur CL, Smit LA, et al. · Eur J Nucl Med Mol Imaging · 2022 · Derived
    PubMed: PMID 34957526 · NCT03003637 (IMCISION) · Head and Neck Neoplasms
  16. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
    Vos JL, Elbers JBW, Krijgsman O, et al. · Nat Commun · 2022 · Derived
    PubMed: PMID 34937871 · NCT03003637 (IMCISION) · Head and Neck Neoplasms
  17. Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan.
    Vaziri H, Turshudzhyan A, Vecchio E, et al. · J Clin Gastroenterol · 2022 · Derived
    PubMed: PMID 35470301 · NCT03816345 · Hematologic Neoplasms
  18. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
    Vano YA, Elaidi R, Bennamoun M, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35390339 · NCT02960906 (BIONIKK) · Clear-cell metastatic renal cell carcinoma
  19. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
    van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35598186 · NCT02925234 (DRUP) · Neoplasms
  20. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
    Tykodi SS, Gordan LN, Alter RS, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35210307 · NCT02982954 (CHECKMATE 920) · Carcinoma, Renal Cell
  21. Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
    Tulokas SKA, Kohtamäki LM, Mäkelä SP, et al. · Melanoma Res · 2022 · Derived
    PubMed: PMID 34132224 · NCT02094391 (ILP+/-IPI)
  22. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
    Tong TML, van der Kooij MK, Speetjens FM, et al. · Trials · 2022 · Derived
    PubMed: PMID 35152908 · NCT04283890 (CHOPIN) · Neoplasm Metastasis
  23. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
    Thompson NA, Stewart GD, Welsh SJ, et al. · BMC Cancer · 2022 · Derived
    PubMed: PMID 35073853 · NCT04107168 · Melanoma
  24. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ, Piha-Paul SA, Tsimberidou A, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 33909232 · NCT02419495 · Melanoma
  25. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
    Thein KZ, Piha-Paul SA, Tsimberidou A, et al. · Exp Hematol Oncol · 2022 · Derived
    PubMed: PMID 34965890 · NCT02419495 · Melanoma
  26. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
    Thein KZ, Karp DD, Tsimberidou A, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 34562230 · NCT02419495 · Melanoma
  27. Salivary Gland Cancers.
    Tchekmedyian V · Hematol Oncol Clin North Am · 2022 · Derived
    PubMed: PMID 34503735 · NCT03146650 · Salivary Gland Neoplasms
  28. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
    Tawbi HA, Forsyth PA, Hodi FS, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 34774225 · NCT02320058 (CheckMate204) · Melanoma
  29. Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
    Stein A, Paschold L, Tintelnot J, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 35737383 · NCT03409848 (INTEGA) · Stomach Neoplasms
  30. Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
    Spicer J, Marabelle A, Baurain JF, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 33542073 · NCT01986426 · Melanoma
  31. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model.
    Sové RJ, Verma BK, Wang H, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 36323435 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  32. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M, Zhang L, Subudhi S, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 33986125 · NCT01804465 · Neoplasms
  33. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
    Siefker-Radtke AO, Cho DC, Diab A, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 35643589 · NCT02983045 (PIVOT-02) · Melanoma
  34. Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study.
    Short SS, Kastenberg ZJ, Wei G, et al. · Cancer · 2022 · Derived
    PubMed: PMID 35561331 · NCT04248569 · Fibrolamellar hepatocellular carcinoma
  35. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.
    Shi Z, Zhu Y, Zhang J, et al. · Hematology · 2022 · Derived
    PubMed: PMID 35622074 · NCT02879695 · Burkitt Lymphoma
  36. Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
    Shah H, Wang Y, Cheng SC, et al. · JAMA Otolaryngol Head Neck Surg · 2022 · Derived
    PubMed: PMID 35050348 · NCT02919683 · Head and Neck Neoplasms
  37. Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.
    Schild SE, Wang X, Bestvina CM, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 35613998 · NCT04929041 · Carcinoma, Non-Small-Cell Lung
  38. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Scherpereel A, Antonia S, Bautista Y, et al. · Lung Cancer · 2022 · Derived
    PubMed: PMID 35367910 · NCT02899299 (CheckMate743) · Mesothelioma
  39. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
    Sanborn RE, Hamid O, de Vries EG, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34301808 · NCT03013491 · Neoplasms
  40. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
    Sahai V, Griffith KA, Beg MS, et al. · Cancer · 2022 · Derived
    PubMed: PMID 35895381 · NCT03101566 · Biliary Tract Neoplasms
  41. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
    Saad M, Lee SJ, Tan AC, et al. · J Transl Med · 2022 · Derived
    PubMed: PMID 35659704 · NCT01274338 · Melanoma
  42. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
    Rini BI, Signoretti S, Choueiri TK, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 36549781 · NCT02231749 · Carcinoma, Renal Cell
  43. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
    Reiss KA, Mick R, Teitelbaum U, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35810751 · NCT03404960 (Parpvax)
  44. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
    Reijers ILM, Menzies AM, van Akkooi ACJ, et al. · Nat Med · 2022 · Derived
    PubMed: PMID 35661157 · NCT02977052 (OpACIN-neo) · Melanoma
  45. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T, Cohen R, Svrcek M, et al. · Gastroenterology · 2022 · Derived
    PubMed: PMID 33992635 · NCT03350126 (NIPICOL) · Colonic Neoplasms
  46. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
    Postow MA, Goldman DA, Shoushtari AN, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34928709 · NCT03122522 · Melanoma
  47. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Peters S, Scherpereel A, Cornelissen R, et al. · Ann Oncol · 2022 · Derived
    PubMed: PMID 35124183 · NCT02899299 (CheckMate743) · Mesothelioma
  48. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
    Patel SP, Mayerson E, Chae YK, et al. · Cancer · 2022 · Derived
    PubMed: PMID 33882143 · NCT02834013 · Carcinoma, Transitional Cell
  49. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial.
    Parikh AR, Szabolcs A, Allen JN, et al. · Nat Cancer · 2022 · Derived
    PubMed: PMID 35122060 · NCT03104439 · Pancreatic Neoplasms
  50. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
    Palmer CD, Rappaport AR, Davis MJ, et al. · Nat Med · 2022 · Derived
    PubMed: PMID 35970920 · NCT03639714 · Carcinoma, Non-Small-Cell Lung
  51. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
    Nissani A, Lev-Ari S, Meirson T, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 33990415 · NCT03166397 · Melanoma
  52. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 35086719 · NCT02925234 (DRUP) · Neoplasms
  53. CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
    Naing A, Thistlethwaite F, De Vries EGE, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34301809 · NCT03013491 · Neoplasms
  54. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ, Powles T, Burotto M, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35688173 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  55. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
    Motzer RJ, McDermott DF, Escudier B, et al. · Cancer · 2022 · Derived
    PubMed: PMID 35383908 · NCT02231749 · Carcinoma, Renal Cell
  56. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
    Morano F, Raimondi A, Pagani F, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35258987 · NCT03832621 (MAYA) · Colorectal Neoplasms
  57. Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy.
    Mooney KL, Czerwinski DK, Shree T, et al. · Cancer Cytopathol · 2022 · Derived
    PubMed: PMID 34780125 · NCT02254772 · Leukemia, Lymphocytic, Chronic, B-Cell
  58. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
    Minor DR, Kim KB, Tong RT, et al. · Cancer Biother Radiopharm · 2022 · Derived
    PubMed: PMID 35021863 · NCT02913417 · Uveal Melanoma
  59. Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges.
    Mar N, Kaakour D, Rezazadeh Kalebasty A, et al. · JCO Oncol Pract · 2022 · Derived
    PubMed: PMID 34550754 · NCT03937219 (COSMIC-313) · Carcinoma, Renal Cell
  60. Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
    Mantia CM, Werner L, Stwalley B, et al. · Melanoma Res · 2022 · Derived
    PubMed: PMID 34855329 · NCT01844505 · Melanoma
  61. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
    Mandala M, Larkin J, Ascierto PA, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34452930 · NCT02388906 (CheckMate 238) · Melanoma
  62. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Livingstone E, Zimmer L, Hassel JC, et al. · Lancet · 2022 · Derived
    PubMed: PMID 36099927 · NCT02523313 · Melanoma
  63. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
    Liu T, Bai Y, Lin X, et al. · Int J Cancer · 2022 · Derived
    PubMed: PMID 36121651 · NCT02872116 (CheckMate649) · Stomach Neoplasms
  64. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ, Van Cutsem E, Luisa Limon M, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34637336 · NCT02060188 (CheckMate142)
  65. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
    Larkin J, Weber J, Del Vecchio M, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35964471 · NCT02388906 (CheckMate 238) · Melanoma
  66. Setting a new standard for long-term survival in metastatic kidney cancer.
    Labriola MK, George DJ · Cancer · 2022 · Derived
    PubMed: PMID 35383907 · NCT03937219 (COSMIC-313) · Carcinoma, Renal Cell
  67. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
    Kverneland AH, Chamberlain CA, Borch TH, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34607899 · NCT03296137 · Neoplasms
  68. Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC.
    Kurata T, Nakagawa K, Satouchi M, et al. · Cancer Treat Res Commun · 2022 · Derived
    PubMed: PMID 34607222 · NCT01840579 · Carcinoma, Non-Small-Cell Lung
  69. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    Kudo M, Matilla A, Santoro A, et al. · J Hepatol · 2022 · Derived
    PubMed: PMID 34051329 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  70. Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.
    Koguchi Y, Iwamoto N, Shimada T, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34620702 · NCT00495066 · Melanoma
  71. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
    Khushalani NI, Vassallo M, Goldberg JD, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 36450385 · NCT01176474 · Melanoma
  72. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
    Kaseb AO, Hasanov E, Cao HST, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 35065057 · NCT03222076 · Carcinoma, Hepatocellular
  73. Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.
    Kang YK, Reck M, Nghiem P, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35383114 · NCT02538666 (CheckMate 451) · Lung Neoplasms
  74. Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma.
    Johannet P, Simons M, Qian Y, et al. · Cancer · 2022 · Derived
    PubMed: PMID 36006879 · NCT02320058 (CheckMate204) · Melanoma
  75. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy.
    Hensel J, Metts J, Gupta A, et al. · Cancer J · 2022 · Derived
    PubMed: PMID 35880942 · NCT03645928 · Melanoma
  76. Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
    Hamuro L, Hu Z, Passarell J, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34980597 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  77. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
    Hailemichael Y, Johnson DH, Abdel-Wahab N, et al. · Cancer Cell · 2022 · Derived
    PubMed: PMID 35537412 · NCT04940299 · Melanoma
  78. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
    Gutierrez M, Moreno V, Heinhuis KM, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 33148673 · NCT02737475
  79. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
    Gupta R, Meric-Bernstam F, Rothe M, et al. · JCO Precis Oncol · 2022 · Derived
    PubMed: PMID 36315917 · NCT02693535 (TAPUR) · Neoplasms
  80. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
    Grimm MO, Schmitz-Dräger BJ, Zimmermann U, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35275706 · NCT03219775 (TITAN-TCC) · Neoplasm Metastasis
  81. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
    Girardi DM, Niglio SA, Mortazavi A, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35031545 · NCT03866382 · Carcinoma, Renal Cell
  82. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
    Gettinger SN, Redman MW, Bazhenova L, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 34264316 · NCT02785952
  83. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
    George DJ, Spigel DR, Gordan LN, et al. · BMJ Open · 2022 · Derived
    PubMed: PMID 36104138 · NCT02982954 (CHECKMATE 920) · Carcinoma, Renal Cell
  84. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
    Friedman CF, Spencer C, Cabanski CR, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35074903 · NCT02731729 · Melanoma
  85. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    Forde PM, Spicer J, Lu S, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 35403841 · NCT02998528 (CheckMate 816) · Carcinoma, Non-Small-Cell Lung
  86. Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer.
    Ferris RL, Moskovitz J, Kunning S, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35091445 · NCT01935921 · Squamous Cell Carcinoma of Head and Neck
  87. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
    Ellingsen EB, Bounova G, Kerzeli I, et al. · J Transl Med · 2022 · Derived
    PubMed: PMID 36089578 · NCT02275416 · Melanoma
  88. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature.
    El Hussein S, Daver N, Liu JL, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 34980577 · NCT02397720 · Leukemia, Myeloid, Acute
  89. Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.
    Ebert MP, Meindl-Beinker NM, Gutting T, et al. · Lancet Healthy Longev · 2022 · Derived
    PubMed: PMID 36098320 · NCT03416244 (RAMONA) · Esophageal Neoplasms
  90. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.
    Duerinck J, Schwarze JK, Awada G, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34168003 · NCT03233152 (GlitIpNi) · Glioblastoma
  91. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
    Doki Y, Ajani JA, Kato K, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 35108470 · NCT03143153 (CheckMate 648)
  92. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
    Dizman N, Meza L, Bergerot P, et al. · Nat Med · 2022 · Derived
    PubMed: PMID 35228755 · NCT03829111 · Carcinoma, Renal Cell
  93. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    De Ruysscher D, Ramalingam S, Urbanic J, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 34489161 · NCT04026412 (CheckMate73L) · Carcinoma, Non-Small-Cell Lung
  94. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
    Choueiri TK, Kluger H, George S, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 36328377 · NCT02996110 (FRACTION-RCC)
  95. Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).
    Chen IM, Johansen JS, Theile S, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35476508 · NCT02866383 (CheckPAC) · Pancreatic Neoplasms
  96. The current management and biomarkers of immunotherapy in advanced gastric cancer.
    Chang X, Ge X, Zhang Y, et al. · Medicine (Baltimore) · 2022 · Derived
    PubMed: PMID 35623069 · NCT01585987
  97. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D, Motzer RJ, Suarez C, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35032437 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  98. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma.
    Bootsma M, McKay RR, Emamekhoo H, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35617646 · NCT03203473 · Kidney Neoplasms
  99. Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.
    Bade RM, Schehr JL, Emamekhoo H, et al. · Mol Oncol · 2022 · Derived
    PubMed: PMID 33604999 · NCT03203473 · Kidney Neoplasms
  100. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
    Atkins MB, Jegede OA, Haas NB, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35442713 · NCT03117309
  101. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
    Apolo AB, Powles T, Escudier B, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 36327527 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  102. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
    Anagnostou V, Bruhm DC, Niknafs N, et al. · Cell Rep Med · 2022 · Derived
    PubMed: PMID 33294860 · NCT01621490 (PD-1) · Melanoma
  103. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
    Albiges L, Tannir NM, Burotto M, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 34750035 · NCT02231749 · Carcinoma, Renal Cell
  104. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
    Adams S, Othus M, Patel SP, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34716198 · NCT02834013 · Carcinoma, Transitional Cell
  105. Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment.
    Aamdal E, Skovlund E, Jacobsen KD, et al. · ESMO Open · 2022 · Derived
    PubMed: PMID 36116420 · NCT02068196 (Ipi4) · Melanoma
  106. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Yoshino M, Ishihara H, Nemoto Y, et al. · Jpn J Clin Oncol · 2022 · Background
    PubMed: PMID 35780441 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  107. Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Weber S, van der Leest P, Donker HC, et al. · JCO Precis Oncol · 2022 · Background
    PubMed: PMID 34994642 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  108. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors.
    Tomita Y, Goto Y, Sakata S, et al. · Oncoimmunology · 2022 · Background
    PubMed: PMID 35655708 · NCT06399419 · Carcinoma, Renal Cell
  109. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.
    Thompson JC, Carpenter EL, Silva BA, et al. · JCO Precis Oncol · 2022 · Background
    PubMed: PMID 34095713 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  110. Roles of circadian clocks in cancer pathogenesis and treatment.
    Lee Y · Exp Mol Med · 2022 · Background
    PubMed: PMID 34615982 · NCT07338981
  111. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
    Kok PS, Forde PM, Hughes B, et al. · BMJ Open · 2022 · Background
    PubMed: PMID 35078853 · NCT04334759 (DREAM3R) · Mesothelioma
  112. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S, Wuthrick E, Blakaj D, et al. · Lancet · 2022 · Background
    PubMed: PMID 36108657 · NCT03071406 · Neoplasm Metastasis
  113. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
    Grossmann KF, Othus M, Patel SP, et al. · Cancer Discov · 2022 · Background
    PubMed: PMID 34764195 · NCT06365619 (NeoRelapse) · Melanoma
  114. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
    Gross EE, Li M, Yin M, et al. · Urol Oncol · 2022 · Background
    PubMed: PMID 36441070 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  115. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
    Eroglu Z, Broman KK, Thompson JF, et al. · J Immunother Cancer · 2022 · Background
    PubMed: PMID 36002183 · NCT06365619 (NeoRelapse) · Melanoma
  116. Optimal systemic therapy for high-risk resectable melanoma.
    Eggermont AMM, Hamid O, Long GV, et al. · Nat Rev Clin Oncol · 2022 · Background
    PubMed: PMID 35468949 · NCT06365619 (NeoRelapse) · Melanoma
  117. Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study.
    Du Z, Chen W, Xia Q, et al. · Biomark Res · 2022 · Background
    PubMed: PMID 32435498 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  118. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
    Bratman SV, Yang SYC, Iafolla MAJ, et al. · Nat Cancer · 2022 · Background
    PubMed: PMID 35121950 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  119. Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.
    Branchoux S, Sofeu CL, Gaudin AF, et al. · ESMO Open · 2022 · Background
    PubMed: PMID 34929616 · NCT03963518 (SURROGATE-ICI) · Neoplasms
  120. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.
    Beebe-Dimmer JL, Fryzek JP, Yee CL, et al. · Clin Epidemiol · 2022 · Background
    PubMed: PMID 27822122 · NCT03918252 · Mesothelioma
  121. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
    Attrill GH, Owen CN, Ahmed T, et al. · J Immunother Cancer · 2022 · Background
    PubMed: PMID 35688560 · NCT06365619 (NeoRelapse) · Melanoma
  122. Neoadjuvant relatlimab and nivolumab in resectable melanoma.
    Amaria RN, Postow M, Burton EM, et al. · Nature · 2022 · Background
    PubMed: PMID 36289334 · NCT06365619 (NeoRelapse) · Melanoma

2021 (100 papers)

  1. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
    Shenderov E, Boudadi K, Fu W, et al. · Prostate · 2021 · Trial result
    PubMed: PMID 33636027 · NCT02601014 (STARVE-PC) · Prostatic Neoplasms
  2. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
    Luke JJ, Onderdonk BE, Bhave SR, et al. · Clin Cancer Res · 2021 · Trial result
    PubMed: PMID 33028595 · NCT07075120 · Carcinoma, Hepatocellular
  3. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
    Llovet JM, De Baere T, Kulik L, et al. · Nat Rev Gastroenterol Hepatol · 2021 · Trial result
    PubMed: PMID 33510460 · NCT07487662 (ACTION-001)
  4. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
    Korpics MC, Polley MY, Bhave SR, et al. · Int J Radiat Oncol Biol Phys · 2021 · Trial result
    PubMed: PMID 32569799 · NCT07075120 · Carcinoma, Hepatocellular
  5. Health Disparities in Screening, Diagnosis, and Treatment of Hepatocellular Carcinoma.
    Guo A, Pomenti S, Wattacheril J, et al. · Clin Liver Dis (Hoboken) · 2021 · Trial result
    PubMed: PMID 34136141 · NCT07075120 · Carcinoma, Hepatocellular
  6. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
    Carlino MS, Menzies AM, Atkinson V, et al. · Clin Cancer Res · 2021 · Trial result
    PubMed: PMID 32605909 · NCT02089685 · Melanoma
  7. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
    Zech HB, Moeckelmann N, Boettcher A, et al. · Future Oncol · 2021 · Derived
    PubMed: PMID 32902312 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  8. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma.
    Yoshida T, Ichikawa J, Giuroiu I, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32303612 · NCT01783938 · Melanoma
  9. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
    Wright K · Oncology (Williston Park) · 2021 · Derived
    PubMed: PMID 33206991 · NCT02899299 (CheckMate743) · Mesothelioma
  10. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma.
    Woroniecka K, Fecci PE · Neuro Oncol · 2021 · Derived
    PubMed: PMID 32691060 · NCT02017717 (CheckMate 143) · Glioblastoma
  11. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
    Weber JS, Ascierto PA, Middleton MR, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34663559 · NCT02388906 (CheckMate 238) · Melanoma
  12. IL-15 in the Combination Immunotherapy of Cancer.
    Waldmann TA, Dubois S, Miljkovic MD, et al. · Front Immunol · 2021 · Derived
    PubMed: PMID 32508818 · NCT03388632
  13. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
    Versluis JM, Reijers ILM, Rozeman EA, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 33735809 · NCT02437279 (OpACIN) · Melanoma
  14. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab.
    Veatch JR, Singhi N, Jesernig B, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 33298619 · NCT02983045 (PIVOT-02) · Melanoma
  15. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges.
    Vatner R, James CD, Sathiaseelan V, et al. · Pediatr Blood Cancer · 2021 · Derived
    PubMed: PMID 32827353 · NCT03463408 · Sarcoma
  16. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
    van Dijk N, Gil-Jimenez A, Silina K, et al. · Nat Med · 2021 · Derived
    PubMed: PMID 33046870 · NCT03387761 (NABUCCO) · Neoplasms
  17. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Uprety D · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 33358660 · NCT04334759 (DREAM3R) · Mesothelioma
  18. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
    Trager MH, Coley SM, Dube G, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32503950 · NCT03816332 · Melanoma
  19. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
    Topalian SL, Bhatia S, Amin A, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32324435 · NCT02488759 (CheckMate358)
  20. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    Tintelnot J, Goekkurt E, Binder M, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 32487035 · NCT03409848 (INTEGA) · Stomach Neoplasms
  21. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
    Tawbi HA, Forsyth PA, Hodi FS, et al. · Neuro Oncol · 2021 · Derived
    PubMed: PMID 33880555 · NCT02320058 (CheckMate204) · Melanoma
  22. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
    Sharma P, Pachynski RK, Narayan V, et al. · Cancer Cell · 2021 · Derived
    PubMed: PMID 32916128 · NCT02985957 (CheckMate 650) · Prostatic Neoplasms
  23. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
    Schoenfeld JD, Hanna GJ, Jo VY, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32852531 · NCT02919683 · Head and Neck Neoplasms
  24. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    Sangro B, Melero I, Wadhawan S, et al. · J Hepatol · 2021 · Derived
    PubMed: PMID 32710922 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  25. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
    Rozeman EA, Hoefsmit EP, Reijers ILM, et al. · Nat Med · 2021 · Derived
    PubMed: PMID 33558721 · NCT02977052 (OpACIN-neo) · Melanoma
  26. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
    Robert C, Hwu WJ, Hamid O, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 33360855 · NCT01866319 · Melanoma
  27. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33125909 · NCT02154490
  28. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
    Reck M, Ciuleanu TE, Lee JS, et al. · J Thorac Oncol · 2021 · Derived
    PubMed: PMID 33485960 · NCT02477826 (CheckMate 227) · Carcinoma, Non-Small-Cell Lung
  29. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA, Brandes AA, Omuro A, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32437507 · NCT02017717 (CheckMate 143) · Glioblastoma
  30. Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.
    Rasmussen TA, Rajdev L, Rhodes A, et al. · Clin Infect Dis · 2021 · Derived
    PubMed: PMID 33677480 · NCT02408861 · Neoplasm Metastasis
  31. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    Piulats JM, Espinosa E, de la Cruz Merino L, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33417511 · NCT02626962 (GEM1402) · Melanoma
  32. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
    Pinato DJ, Cortellini A, Sukumaran A, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 33757459 · NCT03682276 (PRIME-HCC) · Carcinoma, Hepatocellular
  33. A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases.
    Phillips WJ, Baghai T, Ong M, et al. · Curr Oncol · 2021 · Derived
    PubMed: PMID 33450821 · NCT03340129 (ABC-X) · Melanoma
  34. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
    Perez BA, Kim S, Wang M, et al. · Int J Radiat Oncol Biol Phys · 2021 · Derived
    PubMed: PMID 33002543 · NCT03043599 · Small Cell Lung Carcinoma
  35. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
    Penter L, Zhang Y, Savell A, et al. · Blood · 2021 · Derived
    PubMed: PMID 33720354 · NCT01822509 · Multiple Myeloma
  36. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    Pelster MS, Gruschkus SK, Bassett R, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33125309 · NCT01585194 · Uveal Melanoma
  37. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
    Paz-Ares L, Ciuleanu TE, Cobo M, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33476593 · NCT03215706 (CheckMate 9LA) · Carcinoma, Non-Small-Cell Lung
  38. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
    Patel SP, Othus M, Chae YK, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 31969335 · NCT02834013 · Carcinoma, Transitional Cell
  39. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
    Owonikoko TK, Park K, Govindan R, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33683919 · NCT02538666 (CheckMate 451) · Lung Neoplasms
  40. Fibrolamellar carcinoma: An entity all its own.
    O'Neill AF, Church AJ, Perez-Atayde AR, et al. · Curr Probl Cancer · 2021 · Derived
    PubMed: PMID 34272087 · NCT04248569 · Fibrolamellar hepatocellular carcinoma
  41. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P, Hassel JC, Rutkowski P, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34551229 · NCT03070392 · Melanoma
  42. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
    Motzer RJ, Escudier B, McDermott DF, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32661118 · NCT02231749 · Carcinoma, Renal Cell
  43. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
    McKay RR, McGregor BA, Xie W, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33108238 · NCT03203473 · Kidney Neoplasms
  44. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
    McGregor BA, Campbell MT, Xie W, et al. · Cancer · 2021 · Derived
    PubMed: PMID 33216356 · NCT03333616 · Urogenital Neoplasms
  45. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
    Marconi L, Sun M, Beisland C, et al. · Clin Genitourin Cancer · 2021 · Derived
    PubMed: PMID 33526329 · NCT03138512 (CheckMate 914) · Carcinoma, Renal Cell
  46. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
    Mankor JM, Disselhorst MJ, Poncin M, et al. · EBioMedicine · 2021 · Derived
    PubMed: PMID 33166791 · NCT03048474 (INITIATE) · Mesothelioma, Malignant
  47. A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes.
    Maity A, Mick R, Rengan R, et al. · Oncoimmunology · 2021 · Derived
    PubMed: PMID 33643689 · NCT01497808 · Melanoma
  48. A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors.
    Ma Y, Fang W, Zhao H, et al. · Oncologist · 2021 · Derived
    PubMed: PMID 33105036 · NCT02516527 · Melanoma
  49. ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer.
    Kyte JA, Andresen NK, Russnes HG, et al. · J Transl Med · 2021 · Derived
    PubMed: PMID 32620163 · NCT03409198 (ICON) · Neoplasms
  50. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
    Klein O, Kee D, Nagrial A, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32729929 · NCT02923934 · Neuroendocrine Tumors
  51. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.
    Kitano S, Shimizu T, Koyama T, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33146741 · NCT03233139
  52. Understanding the new therapeutic options for mesothelioma.
    Kindler HL · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34499875 · NCT04334759 (DREAM3R) · Mesothelioma
  53. Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapy.
    Kim YJ, Sheu KM, Tsoi J, et al. · J Clin Invest · 2021 · Derived
    PubMed: PMID 33914706 · NCT01621490 (PD-1) · Melanoma
  54. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
    Janjigian YY, Shitara K, Moehler M, et al. · Lancet · 2021 · Derived
    PubMed: PMID 34102137 · NCT02872116 (CheckMate649) · Stomach Neoplasms
  55. Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
    Hwang M, Seiwert TY · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33684371 · NCT02741570 (CheckMate 651) · Head and Neck Neoplasms
  56. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
    Hodi FS, Chapman PB, Sznol M, et al. · Melanoma Res · 2021 · Derived
    PubMed: PMID 33234846 · NCT02186249 (CheckMate218) · Melanoma
  57. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
    Hamid O, Robert C, Daud A, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34571336 · NCT01866319 · Melanoma
  58. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD, Nowak AK, Ellingsen EB, et al. · J Transl Med · 2021 · Derived
    PubMed: PMID 34059094 · NCT04300244 (NIPU) · Neoplasms
  59. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
    Griewing LM, Schweizer C, Schubert P, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 33761922 · NCT03453892 (ST-ICI) · Neoplasm Metastasis
  60. Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue.
    Giesen D, Broer LN, Lub-de Hooge MN, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 31953313 · NCT03013491 · Neoplasms
  61. Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy.
    Garg SK, Ott MJ, Mostofa AGM, et al. · Front Immunol · 2021 · Derived
    PubMed: PMID 32161584 · NCT00084656 · Melanoma
  62. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Fisher JG, Tait D, Garrett-Mayer E, et al. · Target Oncol · 2021 · Derived
    PubMed: PMID 33090333 · NCT02693535 (TAPUR) · Neoplasms
  63. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
    Ferris RL, Spanos WC, Leidner R, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 34083421 · NCT02488759 (CheckMate358)
  64. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
    Diab A, Tykodi SS, Daniels GA, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34255535 · NCT02983045 (PIVOT-02) · Melanoma
  65. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
    De Keersmaecker B, Claerhout S, Carrasco J, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32114500 · NCT01302496 (TriMix-Ipi) · Melanoma
  66. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
    Davids MS, Kim HT, Costello C, et al. · Blood · 2021 · Derived
    PubMed: PMID 32478814 · NCT01822509 · Multiple Myeloma
  67. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C, Liang S, Sun B, et al. · Front Endocrinol (Lausanne) · 2021 · Derived
    PubMed: PMID 33362722 · NCT02834013 · Carcinoma, Transitional Cell
  68. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
    Da Silva DM, Enserro DM, Mayadev JS, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 32816895 · NCT01711515 · Uterine Cervical Neoplasms
  69. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
    Cohen R, Bennouna J, Meurisse A, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 33148693 · NCT03350126 (NIPICOL) · Colonic Neoplasms
  70. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Choueiri TK, Powles T, Burotto M, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33657295 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  71. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
    Cham J, Zhang L, Kwek S, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32376721 · NCT01363206 (GIPI) · Melanoma
  72. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
    Cascone T, William WN, Weissferdt A, et al. · Nat Med · 2021 · Derived
    PubMed: PMID 33603241 · NCT03158129 · Carcinoma, Non-Small-Cell Lung
  73. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
    Cascone T, Weissferdt A, Godoy MCB, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34413300 · NCT03158129 · Carcinoma, Non-Small-Cell Lung
  74. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
    Brastianos PK, Strickland MR, Lee EQ, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34642329 · NCT02939300 · Meningeal Carcinomatosis
  75. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
    Boyer M, Şendur MAN, Rodríguez-Abreu D, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33513313 · NCT03302234 · Carcinoma, Non-Small-Cell Lung
  76. Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
    Boutros C, Chaput-Gras N, Lanoy E, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32819972 · NCT01557114 (Mel-Ipi-Rx) · Melanoma
  77. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Baas P, Scherpereel A, Nowak AK, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33485464 · NCT02899299 (CheckMate743) · Mesothelioma
  78. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
    Ascierto PA, Del Vecchio M, Mackiewicz A, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32503946 · NCT01515189 · Melanoma
  79. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
    Apolo AB, Nadal R, Girardi DM, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32915679 · NCT02496208 · Carcinoma, Renal Cell
  80. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Alva AS, Mangat PK, Garrett-Mayer E, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33844595 · NCT02693535 (TAPUR) · Neoplasms
  81. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
    Albiges L, Tannir NM, Burotto M, et al. · ESMO Open · 2021 · Derived
    PubMed: PMID 33246931 · NCT02231749 · Carcinoma, Renal Cell
  82. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Al Baghdadi T, Garrett-Mayer E, Halabi S, et al. · Target Oncol · 2021 · Derived
    PubMed: PMID 33068284 · NCT02693535 (TAPUR) · Neoplasms
  83. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
    Aamdal E, Inderberg EM, Ellingsen EB, et al. · Front Immunol · 2021 · Derived
    PubMed: PMID 34046035 · NCT02275416 · Melanoma
  84. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
    Zhang Q, Luo J, Wu S, et al. · Cancer Discov · 2021 · Background
    PubMed: PMID 32816849 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  85. Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.
    Zambrana F, Carril-Ajuria L, Gómez de Liaño A, et al. · Cancer Treat Rev · 2021 · Background
    PubMed: PMID 34157582 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  86. Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer.
    Tomita Y, Ikeda T, Sakata S, et al. · Cancer Immunol Res · 2021 · Background
    PubMed: PMID 32665261 · NCT06399419 · Carcinoma, Renal Cell
  87. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
    Singla N, Hutchinson RC, Ghandour RA, et al. · Urol Oncol · 2021 · Background
    PubMed: PMID 32253116 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  88. Cancer Statistics, 2021.
    Siegel RL, Miller KD, Fuchs HE, et al. · CA Cancer J Clin · 2021 · Background
    PubMed: PMID 33433946 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  89. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.
    Robert L, Harview C, Emerson R, et al. · Oncoimmunology · 2021 · Background
    PubMed: PMID 25083336 · NCT03233152 (GlitIpNi) · Glioblastoma
  90. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
    Ricciuti B, Jones G, Severgnini M, et al. · J Immunother Cancer · 2021 · Background
    PubMed: PMID 33771889 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  91. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆.
    Owen CN, Shoushtari AN, Chauhan D, et al. · Ann Oncol · 2021 · Background
    PubMed: PMID 32387454 · NCT06365619 (NeoRelapse) · Melanoma
  92. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
    Olson DJ, Eroglu Z, Brockstein B, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 33945288 · NCT06365619 (NeoRelapse) · Melanoma
  93. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
    O'Hara MH, O'Reilly EM, Varadhachary G, et al. · Lancet Oncol · 2021 · Background
    PubMed: PMID 33387490 · NCT04787991 (REVOLUTION)
  94. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
    Menzies AM, Amaria RN, Rozeman EA, et al. · Nat Med · 2021 · Background
    PubMed: PMID 33558722 · NCT06365619 (NeoRelapse) · Melanoma
  95. Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature.
    Mazzaschi G, Quaini F, Bersanelli M, et al. · Crit Rev Oncol Hematol · 2021 · Background
    PubMed: PMID 33667661 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  96. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
    Kluger HM, Tawbi HA, Ascierto ML, et al. · J Immunother Cancer · 2021 · Background
    PubMed: PMID 32238470 · NCT06365619 (NeoRelapse) · Melanoma
  97. Characterization of the cryoablation-induced immune response in kidney cancer patients.
    Kato T, Iwasaki T, Uemura M, et al. · Oncoimmunology · 2021 · Background
    PubMed: PMID 28811963 · NCT04429321 · Carcinoma, Renal Cell
  98. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
    Hellmann MD, Nabet BY, Rizvi H, et al. · Clin Cancer Res · 2021 · Background
    PubMed: PMID 32046999 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  99. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
    Eggermont AMM, Blank CU, Mandalà M, et al. · Lancet Oncol · 2021 · Background
    PubMed: PMID 33857412 · NCT06365619 (NeoRelapse) · Melanoma
  100. Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
    Aggarwal C, Thompson JC, Chien AL, et al. · Clin Cancer Res · 2021 · Background
    PubMed: PMID 32102950 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung

2020 (60 papers)

  1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS, Qin S, Ikeda M, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 32402160 · NCT07075120 · Carcinoma, Hepatocellular
  2. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Borghaei H, Langer CJ, Gadgeel S, et al. · J Thorac Oncol · 2020 · Trial result
    PubMed: PMID 30138764 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  3. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L, Livingstone E, Hassel JC, et al. · Lancet · 2020 · Derived
    PubMed: PMID 32416781 · NCT02523313 · Melanoma
  4. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.
    Zhang J, Ji Z, Caushi JX, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 31754049 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  5. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
    Yau T, Hsu C, Kim TY, et al. · J Hepatol · 2020 · Derived
    PubMed: PMID 31176752 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  6. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
    Yang JC, Gadgeel SM, Sequist LV, et al. · J Thorac Oncol · 2020 · Derived
    PubMed: PMID 30529597 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  7. Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
    Wang M, Chen C, Jemielita T, et al. · J Immunother Cancer · 2020 · Derived
    PubMed: PMID 30736858 · NCT01866319 · Melanoma
  8. Immunogenicity of pembrolizumab in patients with advanced tumors.
    van Vugt MJH, Stone JA, De Greef RHJMM, et al. · J Immunother Cancer · 2020 · Derived
    PubMed: PMID 31395089 · NCT01866319 · Melanoma
  9. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y, Kondo T, Kimura G, et al. · Jpn J Clin Oncol · 2020 · Derived
    PubMed: PMID 31633185 · NCT02231749 · Carcinoma, Renal Cell
  10. Drug development for glioma: are we repeating the same mistakes?
    Stupp R · Lancet Oncol · 2020 · Derived
    PubMed: PMID 30522968 · NCT02017717 (CheckMate 143) · Glioblastoma
  11. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
    Stein JE, Soni A, Danilova L, et al. · Ann Oncol · 2020 · Derived
    PubMed: PMID 30689736 · NCT01621490 (PD-1) · Melanoma
  12. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.
    Smyth E, Knödler M, Giraut A, et al. · Front Oncol · 2020 · Derived
    PubMed: PMID 32083013 · NCT03443856 (VESTIGE)
  13. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma.
    Silk AW, Kaufman HL, Curti B, et al. · Front Oncol · 2020 · Derived
    PubMed: PMID 31998643 · NCT02203604 · Melanoma
  14. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
    Sharma P, Siefker-Radtke A, de Braud F, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 31100038 · NCT01928394
  15. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A, Mazieres J, Greillier L, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 30660609 · NCT02716272 (MAPS2) · Mesothelioma
  16. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA, Menzies AM, van Akkooi ACJ, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31160251 · NCT02977052 (OpACIN-neo) · Melanoma
  17. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
    Robert C, Ribas A, Schachter J, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31345627 · NCT01866319 · Melanoma
  18. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
    Reck M, Schenker M, Lee KH, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 31195357 · NCT02477826 (CheckMate 227) · Carcinoma, Non-Small-Cell Lung
  19. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
    Ready N, Hellmann MD, Awad MM, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 30785829 · NCT02659059 (CheckMate 568) · Carcinoma, Non-Small-Cell Lung
  20. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
    Ornstein MC, Wood LS, Hobbs BP, et al. · J Immunother Cancer · 2020 · Derived
    PubMed: PMID 31097024 · NCT03126331 · Carcinoma, Renal Cell
  21. Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.
    Nyakas M, Aamdal E, Jacobsen KD, et al. · Clin Exp Immunol · 2020 · Derived
    PubMed: PMID 30821848 · NCT02068196 (Ipi4) · Melanoma
  22. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
    Naumann RW, Hollebecque A, Meyer T, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 31487218 · NCT02488759 (CheckMate358)
  23. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ, Rini BI, McDermott DF, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31427204 · NCT02231749 · Carcinoma, Renal Cell
  24. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C, Meyer N, Mortier L, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 30811280 · NCT02714218 · Melanoma
  25. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
    Lala M, Li TR, de Alwis DP, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 32305010 · NCT01866319 · Melanoma
  26. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
    Jafarnejad M, Gong C, Gabrielson E, et al. · AAPS J · 2020 · Derived
    PubMed: PMID 31236847 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  27. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F, Hwang EC, Lam TB, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 33058158 · NCT03141177 (CheckMate 9ER) · Carcinoma, Renal Cell
  28. An update on emerging drugs in osteosarcoma: towards tailored therapies?
    Hattinger CM, Patrizio MP, Magagnoli F, et al. · Expert Opin Emerg Drugs · 2020 · Derived
    PubMed: PMID 31401903 · NCT02304458 · Melanoma
  29. Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy.
    Graff JN, Stein MN, Surana R, et al. · Front Oncol · 2020 · Derived
    PubMed: PMID 32850444 · NCT01498978 · Prostatic Neoplasms
  30. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
    Gibney GT, Hamid O, Lutzky J, et al. · J Immunother Cancer · 2020 · Derived
    PubMed: PMID 30894212 · NCT01604889 · Melanoma
  31. Linking Tumor Growth Dynamics to Survival in Ipilimumab-Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling.
    Feng Y, Wang X, Suryawanshi S, et al. · CPT Pharmacometrics Syst Pharmacol · 2020 · Derived
    PubMed: PMID 31334596 · NCT01515189 · Melanoma
  32. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
    Epaillard N, Simonaggio A, Elaidi R, et al. · Bull Cancer · 2020 · Derived
    PubMed: PMID 32620212 · NCT02960906 (BIONIKK) · Clear-cell metastatic renal cell carcinoma
  33. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. · Lancet Respir Med · 2020 · Derived
    PubMed: PMID 30660511 · NCT03048474 (INITIATE) · Mesothelioma, Malignant
  34. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS, Hong F, Ambinder RF, et al. · Lancet Haematol · 2020 · Derived
    PubMed: PMID 32853585 · NCT01896999
  35. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
    Davis KL, Fox E, Merchant MS, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32192573 · NCT02304458 · Melanoma
  36. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.
    Chen D, Menon H, Verma V, et al. · J Immunother Cancer · 2020 · Derived
    PubMed: PMID 31996395 · NCT02239900 · Neoplasm Metastasis
  37. Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
    Chalmers AW, Patel S, Boucher K, et al. · Target Oncol · 2020 · Derived
    PubMed: PMID 31346927 · NCT01998126 · Carcinoma, Non-Small-Cell Lung
  38. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
    Chalabi M, Fanchi LF, Dijkstra KK, et al. · Nat Med · 2020 · Derived
    PubMed: PMID 32251400 · NCT03026140 (NICHE) · Colonic Neoplasms
  39. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
    Cella D, Grünwald V, Escudier B, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 30658932 · NCT02231749 · Carcinoma, Renal Cell
  40. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
    Ascierto PA, Del Vecchio M, Mandalá M, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32961119 · NCT02388906 (CheckMate 238) · Melanoma
  41. Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.
    Ambavane A, Yang S, Atkins MB, et al. · Immunotherapy · 2020 · Derived
    PubMed: PMID 31992108 · NCT02231749 · Carcinoma, Renal Cell
  42. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
    Zhan C, Ruohoniemi D, Shanbhogue KP, et al. · J Vasc Interv Radiol · 2020 · Background
    PubMed: PMID 31422022 · NCT07482059
  43. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
    Yang JC, Shepherd FA, Kim DW, et al. · J Thorac Oncol · 2020 · Background
    PubMed: PMID 30763730 · NCT04141644 (Osi+Ipi)
  44. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
    Yamamoto K, Venida A, Yano J, et al. · Nature · 2020 · Background
    PubMed: PMID 32376951 · NCT04787991 (REVOLUTION)
  45. CD40 Agonist Antibodies in Cancer Immunotherapy.
    Vonderheide RH · Annu Rev Med · 2020 · Background
    PubMed: PMID 31412220 · NCT04787991 (REVOLUTION)
  46. Cancer statistics, 2020.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2020 · Background
    PubMed: PMID 31912902 · NCT04787991 (REVOLUTION)
  47. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
    Santin AD, Deng W, Frumovitz M, et al. · Gynecol Oncol · 2020 · Background
    PubMed: PMID 31924334 · NCT05492123 · Uterine Cervical Neoplasms
  48. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
    Riquelme E, Zhang Y, Zhang L, et al. · Cell · 2020 · Background
    PubMed: PMID 31398337 · NCT04787991 (REVOLUTION)
  49. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M, Mok TSK, Nishio M, et al. · Lancet Respir Med · 2020 · Background
    PubMed: PMID 30922878 · NCT04141644 (Osi+Ipi)
  50. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.
    Menon H, Chen D, Ramapriyan R, et al. · J Immunother Cancer · 2020 · Background
    PubMed: PMID 31484556 · NCT05088889 · Pancreatic Neoplasms
  51. The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond.
    McAllister F, Khan MAW, Helmink B, et al. · Cancer Cell · 2020 · Background
    PubMed: PMID 31951558 · NCT04787991 (REVOLUTION)
  52. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
    Marabelle A, Le DT, Ascierto PA, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31682550 · NCT04787991 (REVOLUTION)
  53. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
    Long GV, Saw RPM, Lo S, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 31171444 · NCT06365619 (NeoRelapse) · Melanoma
  54. The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
    Howlader N, Forjaz G, Mooradian MJ, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32786189 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  55. Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis.
    Guo CY, Jiang SC, Kuang YK, et al. · J Cancer · 2020 · Background
    PubMed: PMID 30662532 · NCT04141644 (Osi+Ipi)
  56. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N, Jones G, Beeler JF, et al. · Lung Cancer · 2020 · Background
    PubMed: PMID 31518912 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  57. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.
    Elyada E, Bolisetty M, Laise P, et al. · Cancer Discov · 2020 · Background
    PubMed: PMID 31197017 · NCT04787991 (REVOLUTION)
  58. Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
    Di Giacomo AM, Covre A, Finotello F, et al. · Clin Cancer Res · 2020 · Background
    PubMed: PMID 31530631 · NCT04250246 (NIBIT-ML1) · Melanoma
  59. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
    Craciun L, de Wind R, Demetter P, et al. · BMC Cancer · 2020 · Background
    PubMed: PMID 32075608 · NCT07482059
  60. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.
    Chesney J, Puzanov I, Collichio F, et al. · Br J Cancer · 2020 · Background
    PubMed: PMID 31353364 · NCT01740297 · Melanoma

2019 (57 papers)

  1. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX, Finn RS, Edeline J, et al. · Lancet Oncol · 2019 · Trial result
    PubMed: PMID 29875066 · NCT07075120 · Carcinoma, Hepatocellular
  2. A global view of hepatocellular carcinoma: trends, risk, prevention and management.
    Yang JD, Hainaut P, Gores GJ, et al. · Nat Rev Gastroenterol Hepatol · 2019 · Trial result
    PubMed: PMID 31439937 · NCT07075120 · Carcinoma, Hepatocellular
  3. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium.
    Seano G, Nia HT, Emblem KE, et al. · Nat Biomed Eng · 2019 · Trial result
    PubMed: PMID 30948807 · NCT03458455 (TREATMENT) · Brain Neoplasms
  4. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
    Luke JJ, Lemons JM, Karrison TG, et al. · J Clin Oncol · 2019 · Trial result
    PubMed: PMID 29437535 · NCT07075120 · Carcinoma, Hepatocellular
  5. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
    Galon J, Bruni D · Nat Rev Drug Discov · 2019 · Trial result
    PubMed: PMID 30610226 · NCT04850755
  6. Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit.
    Chopra S, George K, Engineer R, et al. · Br J Radiol · 2019 · Trial result
    PubMed: PMID 31219706 · NCT07075120 · Carcinoma, Hepatocellular
  7. Towards patient-specific modeling of brain tumor growth and formation of secondary nodes guided by DTI-MRI.
    Angeli S, Emblem KE, Due-Tonnessen P, et al. · Neuroimage Clin · 2019 · Trial result
    PubMed: PMID 30211003 · NCT03458455 (TREATMENT) · Brain Neoplasms
  8. Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer.
    Yang CJ, McSherry F, Mayne NR, et al. · Ann Thorac Surg · 2019 · Derived
    PubMed: PMID 29258674 · NCT01820754 (TOP1201 IPI) · Carcinoma, Non-Small-Cell Lung
  9. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
    Teo MY, Seier K, Ostrovnaya I, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29489427 · NCT02553642 · Melanoma
  10. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
    Tarhini A, Lin Y, Lin H, et al. · J Immunother Cancer · 2019 · Derived
    PubMed: PMID 30352626 · NCT01608594 · Melanoma
  11. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
    Retseck J, Nasr A, Lin Y, et al. · J Transl Med · 2019 · Derived
    PubMed: PMID 29973204 · NCT00972933 · Melanoma
  12. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    Overman MJ, Lonardi S, Wong KYM, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29355075 · NCT02060188 (CheckMate142)
  13. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
    Meindl-Beinker NM, Betge J, Gutting T, et al. · BMC Cancer · 2019 · Derived
    PubMed: PMID 30871493 · NCT03416244 (RAMONA) · Esophageal Neoplasms
  14. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV, Atkinson V, Lo S, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 29602646 · NCT02374242 (ABC) · Melanoma
  15. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
    Larkin J, Chiarion-Sileni V, Gonzalez R, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31562797 · NCT01844505 · Melanoma
  16. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.
    Khouri IF, Fernandez Curbelo I, Turturro F, et al. · Clin Cancer Res · 2019 · Derived
    PubMed: PMID 29246938 · NCT01919619 · Multiple Myeloma
  17. Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report.
    Jebsen NL, Apelseth TO, Haugland HK, et al. · J Med Case Rep · 2019 · Derived
    PubMed: PMID 31177991 · NCT01986426 · Melanoma
  18. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
    Janjigian YY, Bendell J, Calvo E, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 30110194 · NCT01928394
  19. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
    Hopkins AC, Yarchoan M, Durham JN, et al. · JCI Insight · 2019 · Derived
    PubMed: PMID 29997287 · NCT00836407 · Pancreatic Neoplasms
  20. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 30361170 · NCT01844505 · Melanoma
  21. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
    Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31562796 · NCT02477826 (CheckMate 227) · Carcinoma, Non-Small-Cell Lung
  22. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
    Hamid O, Robert C, Ribas A, et al. · Br J Cancer · 2019 · Derived
    PubMed: PMID 30202085 · NCT01866319 · Melanoma
  23. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
    Galsky MD, Wang H, Hahn NM, et al. · Eur Urol · 2019 · Derived
    PubMed: PMID 29248319 · NCT01524991 · Carcinoma, Transitional Cell
  24. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Gadgeel SM, Stevenson JP, Langer CJ, et al. · Lung Cancer · 2019 · Derived
    PubMed: PMID 30429032 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  25. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.
    Da Gama Duarte J, Parakh S, Andrews MC, et al. · Front Immunol · 2019 · Derived
    PubMed: PMID 29552014 · NCT01838200 · Melanoma
  26. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP, Mahoney MR, Van Tine BA, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 29370992 · NCT02500797 · Sarcoma
  27. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
    Cottrell TR, Thompson ED, Forde PM, et al. · Ann Oncol · 2019 · Derived
    PubMed: PMID 29982279 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  28. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
    Carlino MS, Long GV, Schadendorf D, et al. · Eur J Cancer · 2019 · Derived
    PubMed: PMID 30096704 · NCT01866319 · Melanoma
  29. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    Callahan MK, Kluger H, Postow MA, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29040030 · NCT01024231 · Melanoma
  30. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.
    Barker CA, Salama AK · J Natl Compr Canc Netw · 2019 · Derived
    PubMed: PMID 29784747 · NCT02224781 · Melanoma
  31. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
    Atkins MB, Hodi FS, Thompson JA, et al. · Clin Cancer Res · 2019 · Derived
    PubMed: PMID 29358500 · NCT02089685 · Melanoma
  32. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J, Wells D, Hiatt JB, et al. · J Immunother Cancer · 2019 · Derived
    PubMed: PMID 30170630 · NCT02488759 (CheckMate358)
  33. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
    Amin A, Plimack ER, Ernstoff MS, et al. · J Immunother Cancer · 2019 · Derived
    PubMed: PMID 30348216 · NCT01472081 · Carcinoma, Renal Cell
  34. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
    Tetzlaff MT, Messina JL, Stein JE, et al. · Ann Oncol · 2019 · Background
    PubMed: PMID 29945191 · NCT06365619 (NeoRelapse) · Melanoma
  35. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
    Rotte A · J Exp Clin Cancer Res · 2019 · Background
    PubMed: PMID 31196207 · NCT04787991 (REVOLUTION)
  36. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H, Sanchez-Vega F, La K, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29337640 · NCT03918252 · Mesothelioma
  37. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies.
    Odegaard JI, Vincent JJ, Mortimer S, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 29691297 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  38. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.
    N Engl J Med · 2019 · Background
    PubMed: PMID 31442371 · NCT06566391 · Melanoma
  39. Immunotherapy and Prevention of Pancreatic Cancer.
    Morrison AH, Byrne KT, Vonderheide RH, et al. · Trends Cancer · 2019 · Background
    PubMed: PMID 29860986 · NCT04787991 (REVOLUTION)
  40. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
    Looi CK, Chung FF, Leong CO, et al. · J Exp Clin Cancer Res · 2019 · Background
    PubMed: PMID 30987642 · NCT04787991 (REVOLUTION)
  41. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
    Leighl NB, Page RD, Raymond VM, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 30988079 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  42. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.
    Le X, Puri S, Negrao MV, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 30228210 · NCT04141644 (Osi+Ipi)
  43. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement.
    Juszczak E, Altman DG, Hopewell S, et al. · JAMA · 2019 · Background
    PubMed: PMID 31012939 · NCT04787991 (REVOLUTION)
  44. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
    Huang AC, Orlowski RJ, Xu X, et al. · Nat Med · 2019 · Background
    PubMed: PMID 30804515 · NCT04013854 · Melanoma
  45. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
    Hellmann MD, Nathanson T, Rizvi H, et al. · Cancer Cell · 2019 · Background
    PubMed: PMID 29657128 · NCT03918252 · Mesothelioma
  46. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
    Goldberg SB, Narayan A, Kole AJ, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 29330207 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  47. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    Golan T, Hammel P, Reni M, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31157963 · NCT04787991 (REVOLUTION)
  48. Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
    Formenti SC, Rudqvist NP, Golden E, et al. · Nat Med · 2019 · Background
    PubMed: PMID 30397353 · NCT07482059
  49. The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.
    Danilova L, Anagnostou V, Caushi JX, et al. · Cancer Immunol Res · 2019 · Background
    PubMed: PMID 29895573 · NCT03918252 · Mesothelioma
  50. Molecular subtypes of pancreatic cancer.
    Collisson EA, Bailey P, Chang DK, et al. · Nat Rev Gastroenterol Hepatol · 2019 · Background
    PubMed: PMID 30718832 · NCT04787991 (REVOLUTION)
  51. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
    Chesney J, Puzanov I, Collichio F, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 28981385 · NCT01740297 · Melanoma
  52. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F, Ferlay J, Soerjomataram I, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 30207593 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  53. Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review.
    Branchoux S, Bellera C, Italiano A, et al. · Crit Rev Oncol Hematol · 2019 · Background
    PubMed: PMID 31014514 · NCT03963518 (SURROGATE-ICI) · Neoplasms
  54. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Blank CU, Rozeman EA, Fanchi LF, et al. · Nat Med · 2019 · Background
    PubMed: PMID 30297911 · NCT06365619 (NeoRelapse) · Melanoma
  55. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
    Bex A, Mulders P, Jewett M, et al. · JAMA Oncol · 2019 · Background
    PubMed: PMID 30543350 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  56. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN, Prieto PA, Tetzlaff MT, et al. · Lancet Oncol · 2019 · Background
    PubMed: PMID 29361468 · NCT06365619 (NeoRelapse) · Melanoma
  57. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
    Ahrens M, Scheich S, Hartmann A, et al. · Oncol Res Treat · 2019 · Background
    PubMed: PMID 30799404 · NCT03075423 · Carcinoma, Renal Cell

2018 (29 papers)

  1. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.
    Tobin RP, Jordan KR, Robinson WA, et al. · Int Immunopharmacol · 2018 · Trial result
    PubMed: PMID 30121453 · NCT02403778 · Melanoma
  2. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J, Ribas A, Long GV, et al. · Lancet · 2018 · Trial result
    PubMed: PMID 28822576 · NCT01866319 · Melanoma
  3. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Hanna GJ, Adkins DR, Zolkind P, et al. · Oral Oncol · 2018 · Trial result
    PubMed: PMID 28939078 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  4. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
    Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. · J Hepatol · 2018 · Trial result
    PubMed: PMID 27816492 · NCT07075120 · Carcinoma, Hepatocellular
  5. Oncolytic Virotherapy by HSV.
    Watanabe D, Goshima F · Adv Exp Med Biol · 2018 · Derived
    PubMed: PMID 29896663 · NCT02272855 · Melanoma
  6. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
    Tawbi HA, Forsyth PA, Algazi A, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 30134131 · NCT02320058 (CheckMate204) · Melanoma
  7. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.
    Reilley MJ, Bailey A, Subbiah V, et al. · J Immunother Cancer · 2018 · Derived
    PubMed: PMID 28428884 · NCT01738139 · Melanoma
  8. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.
    Ranjan S, Quezado M, Garren N, et al. · BMC Cancer · 2018 · Derived
    PubMed: PMID 29490632 · NCT02311920 · Gliosarcoma
  9. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ, Tannir NM, McDermott DF, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29562145 · NCT02231749 · Carcinoma, Renal Cell
  10. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
    Keung EZ, Lazar AJ, Torres KE, et al. · BMC Cancer · 2018 · Derived
    PubMed: PMID 30249211 · NCT03307616 · Histiocytoma, Malignant Fibrous
  11. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
    Jamal R, Lapointe R, Cocolakis E, et al. · J Immunother Cancer · 2018 · Derived
    PubMed: PMID 29157311 · NCT01676649 · Melanoma
  12. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
    Hellmann MD, Ciuleanu TE, Pluzanski A, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29658845 · NCT02477826 (CheckMate 227) · Carcinoma, Non-Small-Cell Lung
  13. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
    Haag GM, Zoernig I, Hassel JC, et al. · Eur J Cancer · 2018 · Derived
    PubMed: PMID 29306769 · NCT01216696 (CTLA4 NY-ESO-1) · Melanoma
  14. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    Forde PM, Chaft JE, Smith KN, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29658848 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  15. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB, Sangro B, Yau T, et al. · Lancet · 2018 · Derived
    PubMed: PMID 28434648 · NCT01658878 (CheckMate040) · Carcinoma, Hepatocellular
  16. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
    Thapa B, Salcedo A, Lin X, et al. · J Thorac Oncol · 2018 · Background
    PubMed: PMID 28257959 · NCT03918252 · Mesothelioma
  17. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC, Ohe Y, Vansteenkiste J, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29151359 · NCT04141644 (Osi+Ipi)
  18. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L, Luft A, Vicente D, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 30280635 · NCT04141644 (Osi+Ipi)
  19. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS, Righi L, Koeppen H, et al. · J Thorac Oncol · 2018 · Background
    PubMed: PMID 29079455 · NCT03918252 · Mesothelioma
  20. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
    Méjean A, Ravaud A, Thezenas S, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29860937 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  21. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
    Le DT, Durham JN, Smith KN, et al. · Science · 2018 · Background
    PubMed: PMID 28596308 · NCT03832621 (MAYA) · Colorectal Neoplasms
  22. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
    Gopalakrishnan V, Spencer CN, Nezi L, et al. · Science · 2018 · Background
    PubMed: PMID 29097493 · NCT03651271
  23. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29658856 · NCT04141644 (Osi+Ipi)
  24. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
    Feldmeyer L, Hudgens CW, Ray-Lyons G, et al. · Clin Cancer Res · 2018 · Background
    PubMed: PMID 27166398 · NCT03651271
  25. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
    Eggermont AMM, Blank CU, Mandala M, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29658430 · NCT04013854 · Melanoma
  26. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
    Duhen T, Duhen R, Montler R, et al. · Nat Commun · 2018 · Background
    PubMed: PMID 30006565 · NCT06365619 (NeoRelapse) · Melanoma
  27. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.
    D'Angelo SP, Shoushtari AN, Keohan ML, et al. · Clin Cancer Res · 2018 · Background
    PubMed: PMID 28007774 · NCT04141644 (Osi+Ipi)
  28. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
    Balachandran VP, Łuksza M, Zhao JN, et al. · Nature · 2018 · Background
    PubMed: PMID 29132146 · NCT04787991 (REVOLUTION)
  29. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
    Adamska A, Domenichini A, Falasca M, et al. · Int J Mol Sci · 2018 · Background
    PubMed: PMID 28640192 · NCT04787991 (REVOLUTION)

2017 (59 papers)

  1. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
    Shimizu T, Seto T, Hirai F, et al. · Invest New Drugs · 2017 · Trial result
    PubMed: PMID 27000274 · NCT01840579 · Carcinoma, Non-Small-Cell Lung
  2. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY, Burtness B, Mehra R, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27247226 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  3. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV, Atkinson V, Cebon JS, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 28729151 · NCT02089685 · Melanoma
  4. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ, Gadgeel SM, Borghaei H, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27745820 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  5. A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.
    Hiniker SM, Reddy SA, Maecker HT, et al. · Int J Radiat Oncol Biol Phys · 2017 · Trial result
    PubMed: PMID 27681753 · NCT01449279 · Melanoma
  6. A theoretical framework for determining cerebral vascular function and heterogeneity from dynamic susceptibility contrast MRI.
    Digernes I, Bjørnerud A, Vatnehol SAS, et al. · J Cereb Blood Flow Metab · 2017 · Trial result
    PubMed: PMID 28273722 · NCT03458455 (TREATMENT) · Brain Neoplasms
  7. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
    Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28889792 · NCT01844505 · Melanoma
  8. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.
    Williams NL, Wuthrick EJ, Kim H, et al. · Int J Radiat Oncol Biol Phys · 2017 · Derived
    PubMed: PMID 28816150 · NCT01703507 · Melanoma
  9. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
    Weber JS, Gibney G, Sullivan RJ, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27269740 · NCT01783938 · Melanoma
  10. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
    Weber J, Mandala M, Del Vecchio M, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28891423 · NCT02388906 (CheckMate 238) · Melanoma
  11. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
    Sharma P, Callahan MK, Bono P, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27733243 · NCT01928394
  12. Health-related quality of life results from the phase III CheckMate 067 study.
    Schadendorf D, Larkin J, Wolchok J, et al. · Eur J Cancer · 2017 · Derived
    PubMed: PMID 28651159 · NCT01844505 · Melanoma
  13. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M, Luft A, Szczesna A, et al. · J Clin Oncol · 2017 · Derived
    PubMed: PMID 27458307 · NCT01450761 · Small Cell Lung Carcinoma
  14. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM, Robert C, Richtig E, et al. · Eur J Cancer · 2017 · Derived
    PubMed: PMID 28987768 · NCT01866319 · Melanoma
  15. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
    Overman MJ, McDermott R, Leach JL, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28734759 · NCT02060188 (CheckMate142)
  16. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
    Morris VK, Salem ME, Nimeiri H, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28223062 · NCT02314169 · Anus Neoplasms
  17. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
    Long GV, Weber JS, Larkin J, et al. · JAMA Oncol · 2017 · Derived
    PubMed: PMID 28662232 · NCT01844505 · Melanoma
  18. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
    Lesokhin AM, Ansell SM, Armand P, et al. · J Clin Oncol · 2017 · Derived
    PubMed: PMID 27269947 · NCT01592370 · Multiple Myeloma
  19. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS, Chesney J, Pavlick AC, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27622997 · NCT01927419 (CheckMate 069) · Melanoma
  20. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.
    Geoerger B, Bergeron C, Gore L, et al. · Eur J Cancer · 2017 · Derived
    PubMed: PMID 29100190 · NCT01696045 · Melanoma
  21. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
    Coens C, Suciu S, Chiarion-Sileni V, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28162999 · NCT00636168
  22. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
    Chapuis AG, Roberts IM, Thompson JA, et al. · J Clin Oncol · 2017 · Derived
    PubMed: PMID 27269940 · NCT00871481 · Melanoma
  23. Thyroid cancer.
    Cabanillas ME, McFadden DG, Durante C, et al. · Lancet · 2017 · Derived
    PubMed: PMID 27240885 · NCT02239900 · Neoplasm Metastasis
  24. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
    Ascierto PA, Del Vecchio M, Robert C, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28359784 · NCT01515189 · Melanoma
  25. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
    Antonia SJ, López-Martin JA, Bendell J, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27269741 · NCT01928394
  26. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
    Yang JC, Ahn MJ, Kim DW, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28221867 · NCT04141644 (Osi+Ipi)
  27. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y, Medeiros LJ, Young KH, et al. · Blood Rev · 2017 · Background
    PubMed: PMID 26699946 · NCT02681302 (CPIT001) · Multiple Myeloma
  28. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC, Levine JH, Cogdill AP, et al. · Cell · 2017 · Background
    PubMed: PMID 28803728 · NCT04141644 (Osi+Ipi)
  29. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
    Thompson ED, Zahurak M, Murphy A, et al. · Gut · 2017 · Background
    PubMed: PMID 26801886 · NCT03651271
  30. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    Symmans WF, Wei C, Gould R, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28135148 · NCT06365619 (NeoRelapse) · Melanoma
  31. Microbiota: a key orchestrator of cancer therapy.
    Roy S, Trinchieri G · Nat Rev Cancer · 2017 · Background
    PubMed: PMID 28303904 · NCT03651271
  32. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA, Hellmann MD, Brahmer JR, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27354481 · NCT01454102 · Carcinoma, Non-Small-Cell Lung
  33. Immunotherapy for Lung Cancer.
    Reinmuth N, Reck M · Oncol Res Treat · 2017 · Background
    PubMed: PMID 27259861 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  34. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
    Puzanov I, Milhem MM, Minor D, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27298410 · NCT01740297 · Melanoma
  35. Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
    Pietrantonio F, de Braud F, Milione M, et al. · Target Oncol · 2017 · Background
    PubMed: PMID 26538496 · NCT03832621 (MAYA) · Colorectal Neoplasms
  36. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    Mok TS, Wu Y-L, Ahn M-J, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 27959700 · NCT04141644 (Osi+Ipi)
  37. Malignant Mesothelioma Mortality - United States, 1999-2015.
    Mazurek JM, Syamlal G, Wood JM, et al. · MMWR Morb Mortal Wkly Rep · 2017 · Background
    PubMed: PMID 28253224 · NCT03918252 · Mesothelioma
  38. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV, Hauschild A, Santinami M, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28891408 · NCT06365619 (NeoRelapse) · Melanoma
  39. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
    Liu J, Blake SJ, Yong MC, et al. · Cancer Discov · 2017 · Background
    PubMed: PMID 27663893 · NCT03918252 · Mesothelioma
  40. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
    Lemery S, Keegan P, Pazdur R, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 29020592 · NCT04787991 (REVOLUTION)
  41. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
    Lee CK, Man J, Lord S, et al. · J Thorac Oncol · 2017 · Background
    PubMed: PMID 27765535 · NCT04141644 (Osi+Ipi)
  42. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
    Horn L, Spigel DR, Vokes EE, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 29023213 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  43. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Hellmann MD, Rizvi NA, Goldman JW, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27932067 · NCT03918252 · Mesothelioma
  44. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
    Hammers HJ, Plimack ER, Infante JR, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28678668 · NCT06566391 · Melanoma
  45. Converting Cold into Hot Tumors by Combining Immunotherapies.
    Haanen JBAG · Cell · 2017 · Background
    PubMed: PMID 28886376 · NCT03651271
  46. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    Govindan R, Szczesna A, Ahn MJ, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28854067 · NCT04141644 (Osi+Ipi)
  47. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Goss G, Tsai CM, Shepherd FA, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27751847 · NCT04141644 (Osi+Ipi)
  48. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
    Gordon EM, Sankhala KK, Chawla N, et al. · Adv Ther · 2017 · Background
    PubMed: PMID 27234989 · NCT03138161 · Sarcoma
  49. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Gettinger S, Rizvi NA, Chow LQ, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27354485 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  50. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
    Gao J, Ward JF, Pettaway CA, et al. · Nat Med · 2017 · Background
    PubMed: PMID 28346412 · NCT03651271
  51. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R, Hoeller C, Gruter IP, et al. · Cancer Immunol Immunother · 2017 · Background
    PubMed: PMID 28238174 · NCT01740297 · Melanoma
  52. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL, Roh W, Reuben A, et al. · Cancer Discov · 2017 · Background
    PubMed: PMID 27301722 · NCT03651271
  53. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
    Carbone DP, Reck M, Paz-Ares L, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28636851 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  54. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    Calegari MA, Inno A, Monterisi S, et al. · Br J Cancer · 2017 · Background
    PubMed: PMID 28427088 · NCT03832621 (MAYA) · Colorectal Neoplasms
  55. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
    Bouffet E, Larouche V, Campbell BB, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27001570 · NCT03233152 (GlitIpNi) · Glioblastoma
  56. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C, Kühnemuth B, Duewell P, et al. · Cancer Lett · 2017 · Background
    PubMed: PMID 26968250 · NCT04787991 (REVOLUTION)
  57. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
    Ayers M, Lunceford J, Nebozhyn M, et al. · J Clin Invest · 2017 · Background
    PubMed: PMID 28650338 · NCT03651271
  58. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ, Villegas A, Daniel D, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28885881 · NCT04141644 (Osi+Ipi)
  59. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
    Alley EW, Lopez J, Santoro A, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 28291584 · NCT03918252 · Mesothelioma

2016 (41 papers)

  1. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    Ferris RL, Blumenschein G, Fayette J, et al. · N Engl J Med · 2016 · Trial result
    PubMed: PMID 27718784 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  2. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
    Zimmer L, Eigentler TK, Kiecker F, et al. · J Transl Med · 2016 · Derived
    PubMed: PMID 26541511 · NCT01355120 (DeCOG) · Uveal Melanoma
  3. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
    Yamazaki N, Uhara H, Fukushima S, et al. · Cancer Chemother Pharmacol · 2016 · Derived
    PubMed: PMID 26407818 · NCT01681212 · Melanoma
  4. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
    Yamazaki N, Kiyohara Y, Uhara H, et al. · Cancer Chemother Pharmacol · 2016 · Derived
    PubMed: PMID 26410424 · NCT01990859 · Melanoma
  5. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: [email protected]; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
    Trump D · Urol Oncol · 2016 · Derived
    PubMed: PMID 25907621 · NCT00861614 · Prostatic Neoplasms
  6. Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation.
    Nguyen AT, Elia M, Materin MA, et al. · Cornea · 2016 · Derived
    PubMed: PMID 26771550 · NCT01024231 · Melanoma
  7. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
    Middleton G, Crack LR, Popat S, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26410619 · NCT02154490
  8. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
    Johnson DB, Friedman DL, Berry E, et al. · Cancer Immunol Res · 2016 · Derived
    PubMed: PMID 25649350 · NCT00623766 · Melanoma
  9. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.
    Horinouchi H, Yamamoto N, Fujiwara Y, et al. · Invest New Drugs · 2016 · Derived
    PubMed: PMID 25924991 · NCT01165216 · Carcinoma, Non-Small-Cell Lung
  10. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27717298 · NCT00636168
  11. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
    Di Giacomo AM, Ascierto PA, Queirolo P, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25538176 · NCT01654692 (NIBIT-M1) · Melanoma
  12. Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
    Davids MS, Kim HT, Bachireddy P, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27410923 · NCT01822509 · Multiple Myeloma
  13. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
    Amin A, Lawson DH, Salama AK, et al. · J Immunother Cancer · 2016 · Derived
    PubMed: PMID 27532019 · NCT01673854 · Melanoma
  14. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, et al. · Lancet · 2016 · Background
    PubMed: PMID 26719230 · NCT03918252 · Mesothelioma
  15. Role of intestinal microbiota in transplantation outcomes.
    Taur Y, Jenq RR, Ubeda C, et al. · Best Pract Res Clin Haematol · 2016 · Background
    PubMed: PMID 26590773 · NCT02681302 (CPIT001) · Multiple Myeloma
  16. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.
    Śledzińska A, Menger L, Bergerhoff K, et al. · Mol Oncol · 2016 · Background
    PubMed: PMID 26578451 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  17. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE, Hoffman-Censits J, Powles T, et al. · Lancet · 2016 · Background
    PubMed: PMID 26952546 · NCT03832621 (MAYA) · Colorectal Neoplasms
  18. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.
    Rezvani AR, Kanate AS, Efron B, et al. · Bone Marrow Transplant · 2016 · Background
    PubMed: PMID 26146806 · NCT02681302 (CPIT001) · Multiple Myeloma
  19. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    Reck M, Rodríguez-Abreu D, Robinson AG, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27718847 · NCT04250246 (NIBIT-ML1) · Melanoma
  20. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
    Preusser M, Lim M, Hafler DA, et al. · Nat Rev Neurol · 2016 · Background
    PubMed: PMID 26260659 · NCT03233152 (GlitIpNi) · Glioblastoma
  21. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
    Motzer RJ, Rini BI, McDermott DF, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 25452452 · NCT03233152 (GlitIpNi) · Glioblastoma
  22. Safety of Infusing Ipilimumab Over 30 Minutes.
    Momtaz P, Park V, Panageas KS, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26124475 · NCT03651271
  23. Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?
    Mehta A, Oklu R, Sheth RA, et al. · Gastroenterol Res Pract · 2016 · Background
    PubMed: PMID 27051417 · NCT04429321 · Carcinoma, Renal Cell
  24. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
    Massi D, Brusa D, Merelli B, et al. · Ann Oncol · 2016 · Background
    PubMed: PMID 26037795 · NCT02681302 (CPIT001) · Multiple Myeloma
  25. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy.
    Maio M, Covre A, Fratta E, et al. · Clin Cancer Res · 2016 · Background
    PubMed: PMID 26374074 · NCT04250246 (NIBIT-ML1) · Melanoma
  26. Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers.
    Maby P, Galon J, Latouche JB, et al. · Oncoimmunology · 2016 · Background
    PubMed: PMID 27467916 · NCT03651271
  27. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
    Kruglyak KM, Lin E, Ong FS, et al. · Adv Exp Med Biol · 2016 · Background
    PubMed: PMID 26703802 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  28. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
    Johnson DB, Estrada MV, Salgado R, et al. · Nat Commun · 2016 · Background
    PubMed: PMID 26822383 · NCT03651271
  29. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Herbst RS, Baas P, Kim DW, et al. · Lancet · 2016 · Background
    PubMed: PMID 26712084 · NCT03651271
  30. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.
    Hegde PS, Karanikas V, Evers S, et al. · Clin Cancer Res · 2016 · Background
    PubMed: PMID 27084740 · NCT03651271
  31. The immune mechanisms of abscopal effect in radiation therapy.
    Grass GD, Krishna N, Kim S, et al. · Curr Probl Cancer · 2016 · Background
    PubMed: PMID 26612692 · NCT07482059
  32. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?
    Gerstner ER, Emblem KE, Sorensen GA, et al. · Cancer J · 2016 · Background
    PubMed: PMID 26222087 · NCT03458455 (TREATMENT) · Brain Neoplasms
  33. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L, Spira A, Ballinger M, et al. · Lancet · 2016 · Background
    PubMed: PMID 26970723 · NCT03832621 (MAYA) · Colorectal Neoplasms
  34. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
    Demetri GD, von Mehren M, Jones RL, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26371143 · NCT03138161 · Sarcoma
  35. Role of Local Radiation Therapy in Cancer Immunotherapy.
    Demaria S, Golden EB, Formenti SC, et al. · JAMA Oncol · 2016 · Background
    PubMed: PMID 26270858 · NCT05088889 · Pancreatic Neoplasms
  36. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
    Cross DA, Ashton SE, Ghiorghiu S, et al. · Cancer Discov · 2016 · Background
    PubMed: PMID 24893891 · NCT04141644 (Osi+Ipi)
  37. New immunotherapies targeting the PD-1 pathway.
    Chinai JM, Janakiram M, Chen F, et al. · Trends Pharmacol Sci · 2016 · Background
    PubMed: PMID 26162965 · NCT02681302 (CPIT001) · Multiple Myeloma
  38. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
    Barault L, Amatu A, Bleeker FE, et al. · Ann Oncol · 2016 · Background
    PubMed: PMID 26113646 · NCT03832621 (MAYA) · Colorectal Neoplasms
  39. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
    Armstrong AJ, Halabi S, Eisen T, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26794930 · NCT03075423 · Carcinoma, Renal Cell
  40. Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.
    Ang YL, Lim JS, Soo RA, et al. · Onco Targets Ther · 2016 · Background
    PubMed: PMID 27313464 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  41. Clock-like mutational processes in human somatic cells.
    Alexandrov LB, Jones PH, Wedge DC, et al. · Nat Genet · 2016 · Background
    PubMed: PMID 26551669 · NCT03832621 (MAYA) · Colorectal Neoplasms

2015 (41 papers)

  1. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
    Tan DS, Bedard PL, Kuruvilla J, et al. · Cancer Discov · 2015 · Trial result
    PubMed: PMID 24743138 · NCT04850755
  2. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C, Schachter J, Long GV, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 25891173 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  3. Nivolumab in previously untreated melanoma without BRAF mutation.
    Robert C, Long GV, Brady B, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 25399552 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J, Reckamp KL, Baas P, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 26028407 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  5. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
    Zimmer L, Vaubel J, Mohr P, et al. · PLoS One · 2015 · Derived
    PubMed: PMID 25761109 · NCT01355120 (DeCOG) · Uveal Melanoma
  6. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.
    Tarhini AA, Zahoor H, Lin Y, et al. · J Immunother Cancer · 2015 · Derived
    PubMed: PMID 26380086 · NCT00972933 · Melanoma
  7. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
    Schadendorf D, Hodi FS, Robert C, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25667295 · NCT00261365
  8. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
    Postow MA, Chesney J, Pavlick AC, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 25891304 · NCT01927419 (CheckMate 069) · Melanoma
  9. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
    Maio M, Grob JJ, Aamdal S, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25713437 · NCT00324155 · Melanoma
  10. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.
    Lebbé C, Weber JS, Maio M, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 25210016 · NCT00162123 · Melanoma
  11. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
    Larkin J, Chiarion-Sileni V, Gonzalez R, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 26027431 · NCT01844505 · Melanoma
  12. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.
    Kitano S, Postow MA, Ziegler CG, et al. · Cancer Immunol Res · 2015 · Derived
    PubMed: PMID 24844912 · NCT00495066 · Melanoma
  13. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. · Lancet Oncol · 2015 · Derived
    PubMed: PMID 25840693 · NCT00636168
  14. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM, Lesokhin AM, Borrello I, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 25482239 · NCT01592370 · Multiple Myeloma
  15. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.
    Xu F, Xu L, Wang Q, et al. · Int J Clin Exp Med · 2015 · Background
    PubMed: PMID 26628942 · NCT02681302 (CPIT001) · Multiple Myeloma
  16. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS, D'Angelo SP, Minor D, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25795410 · NCT03651271
  17. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
    Vétizou M, Pitt JM, Daillère R, et al. · Science · 2015 · Background
    PubMed: PMID 26541610 · NCT03918252 · Mesothelioma
  18. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.
    Vera-Badillo FE, Templeton AJ, Duran I, et al. · Eur Urol · 2015 · Background
    PubMed: PMID 24882670 · NCT03075423 · Carcinoma, Renal Cell
  19. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C, Rech AJ, Maity A, et al. · Nature · 2015 · Background
    PubMed: PMID 25754329 · NCT07482059
  20. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Tumeh PC, Harview CL, Yearley JH, et al. · Nature · 2015 · Background
    PubMed: PMID 25428505 · NCT03651271
  21. Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
    Temraz S, Mukherji D, Shamseddine A, et al. · World J Gastroenterol · 2015 · Background
    PubMed: PMID 24616571 · NCT03832621 (MAYA) · Colorectal Neoplasms
  22. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
    Sivan A, Corrales L, Hubert N, et al. · Science · 2015 · Background
    PubMed: PMID 26541606 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  23. Epigenetic drugs as immunomodulators for combination therapies in solid tumors.
    Sigalotti L, Fratta E, Coral S, et al. · Pharmacol Ther · 2015 · Background
    PubMed: PMID 24384533 · NCT04250246 (NIBIT-ML1) · Melanoma
  24. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA, Mazières J, Planchard D, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25704439 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  25. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
    Rizvi NA, Hellmann MD, Snyder A, et al. · Science · 2015 · Background
    PubMed: PMID 25765070 · NCT03918252 · Mesothelioma
  26. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
    Ribas A, Puzanov I, Dummer R, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 26115796 · NCT03832621 (MAYA) · Colorectal Neoplasms
  27. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
    Pietrantonio F, Perrone F, de Braud F, et al. · Ann Oncol · 2015 · Background
    PubMed: PMID 24379162 · NCT03832621 (MAYA) · Colorectal Neoplasms
  28. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
    Motzer RJ, Escudier B, McDermott DF, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26406148 · NCT03075423 · Carcinoma, Renal Cell
  29. Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
    Mayer RJ, Van Cutsem E, Falcone A, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 25970050 · NCT03832621 (MAYA) · Colorectal Neoplasms
  30. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.
    Mansfield AS, Roden AC, Peikert T, et al. · J Thorac Oncol · 2015 · Background
    PubMed: PMID 24926549 · NCT03918252 · Mesothelioma
  31. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
    Lo PC, Dahlberg SE, Nishino M, et al. · Cancer · 2015 · Background
    PubMed: PMID 25876525 · NCT04141644 (Osi+Ipi)
  32. Response assessment criteria for brain metastases: proposal from the RANO group.
    Lin NU, Lee EQ, Aoyama H, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 26065612 · NCT03458455 (TREATMENT) · Brain Neoplasms
  33. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    Le DT, Uram JN, Wang H, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26028255 · NCT03832621 (MAYA) · Colorectal Neoplasms
  34. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
    Larkin J, Hodi FS, Wolchok JD, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26398076 · NCT03233152 (GlitIpNi) · Glioblastoma
  35. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
    Kvistborg P, Philips D, Kelderman S, et al. · Sci Transl Med · 2015 · Background
    PubMed: PMID 25232180 · NCT03651271
  36. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA, Yang JC, Kim DW, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 25923549 · NCT04141644 (Osi+Ipi)
  37. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
    Donato ML, Siegel DS, Vesole DH, et al. · Biol Blood Marrow Transplant · 2015 · Background
    PubMed: PMID 24792872 · NCT02681302 (CPIT001) · Multiple Myeloma
  38. Epigenetics meets immune checkpoints.
    Covre A, Coral S, Di Giacomo AM, et al. · Semin Oncol · 2015 · Background
    PubMed: PMID 25965370 · NCT02608437 (NIBIT-M4) · Melanoma
  39. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
    Conlon KC, Lugli E, Welles HC, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25403209 · NCT03388632
  40. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H, Paz-Ares L, Horn L, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26412456 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  41. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.
    Bekaii-Saab T, Wu C · Crit Rev Oncol Hematol · 2015 · Background
    PubMed: PMID 24534706 · NCT03832621 (MAYA) · Colorectal Neoplasms

2014 (22 papers)

  1. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
    Xu Y, Zhang M, Ramos CA, et al. · Blood · 2014 · Derived
    PubMed: PMID 24782509 · NCT00586391 (CRETI-NH) · Neoplasms
  2. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M, Voit C · Crit Rev Oncol Hematol · 2014 · Derived
    PubMed: PMID 23415641 · NCT01400451 · Melanoma
  3. Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids.
    Ludlow SP, Pasikhova Y · Melanoma Res · 2014 · Derived
    PubMed: PMID 24025700 · NCT01400451 · Melanoma
  4. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
    Kwon ED, Drake CG, Scher HI, et al. · Lancet Oncol · 2014 · Derived
    PubMed: PMID 24831977 · NCT00861614 · Prostatic Neoplasms
  5. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
    Iwama S, De Remigis A, Callahan MK, et al. · Sci Transl Med · 2014 · Derived
    PubMed: PMID 24695685 · NCT00495066 · Melanoma
  6. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
    Hodi FS, Lee S, McDermott DF, et al. · JAMA · 2014 · Derived
    PubMed: PMID 25369488 · NCT01134614 · Melanoma
  7. Novel tyrosine kinase inhibitors for renal cell carcinoma.
    Dorff TB, Pal SK, Quinn DI, et al. · Expert Rev Clin Pharmacol · 2014 · Derived
    PubMed: PMID 24308791 · NCT01472081 · Carcinoma, Renal Cell
  8. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer.
    de Liaño AG, Reig O, Mellado B, et al. · Br J Cancer · 2014 · Derived
    PubMed: PMID 24722180 · NCT01057810 · Prostatic Neoplasms
  9. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
    Ackerman A, Klein O, McDermott DF, et al. · Cancer · 2014 · Derived
    PubMed: PMID 24577748 · NCT01400451 · Melanoma
  10. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
    Topalian SL, Sznol M, McDermott DF, et al. · J Clin Oncol · 2014 · Background
    PubMed: PMID 24590637 · NCT03233152 (GlitIpNi) · Glioblastoma
  11. Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity?
    Tejpar S, Piessevaux H · Asia Pac J Clin Oncol · 2014 · Background
    PubMed: PMID 24512508 · NCT03832621 (MAYA) · Colorectal Neoplasms
  12. How to select the optimal treatment for first line metastatic colorectal cancer.
    Stein A, Bokemeyer C · World J Gastroenterol · 2014 · Background
    PubMed: PMID 24574764 · NCT03832621 (MAYA) · Colorectal Neoplasms
  13. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).
    McDermott D, Haanen J, Chen TT, et al. · Ann Oncol · 2014 · Background
    PubMed: PMID 23942774 · NCT04141644 (Osi+Ipi)
  14. Health related quality of life in colorectal cancer patients: state of the art.
    Marventano S, Forjaz M, Grosso G, et al. · BMC Surg · 2014 · Background
    PubMed: PMID 24267735 · NCT03832621 (MAYA) · Colorectal Neoplasms
  15. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
    Marabelle A, Kohrt H, Levy R, et al. · Clin Cancer Res · 2014 · Background
    PubMed: PMID 23965900 · NCT03233152 (GlitIpNi) · Glioblastoma
  16. Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression.
    Laoui D, Van Overmeire E, De Baetselier P, et al. · Front Immunol · 2014 · Background
    PubMed: PMID 25339957 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  17. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
    Goldstein J, Tran B, Ensor J, et al. · Ann Oncol · 2014 · Background
    PubMed: PMID 24585723 · NCT03832621 (MAYA) · Colorectal Neoplasms
  18. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
    Fritzell S, Sandén E, Eberstål S, et al. · Cancer Immunol Immunother · 2014 · Background
    PubMed: PMID 23775421 · NCT03832621 (MAYA) · Colorectal Neoplasms
  19. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.
    Fransen MF, van der Sluis TC, Ossendorp F, et al. · Clin Cancer Res · 2014 · Background
    PubMed: PMID 23788581 · NCT03233152 (GlitIpNi) · Glioblastoma
  20. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.
    Feng Y, Roy A, Masson E, et al. · Clin Cancer Res · 2014 · Background
    PubMed: PMID 23741070 · NCT07482059
  21. Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.
    Emblem KE, Farrar CT, Gerstner ER, et al. · Nat Rev Clin Oncol · 2014 · Background
    PubMed: PMID 25113840 · NCT03458455 (TREATMENT) · Brain Neoplasms
  22. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
    Armand P, Nagler A, Weller EA, et al. · J Clin Oncol · 2014 · Background
    PubMed: PMID 24127452 · NCT02681302 (CPIT001) · Multiple Myeloma

2013 (21 papers)

  1. A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.
    Maki RG, Jungbluth AA, Gnjatic S, et al. · Sarcoma · 2013 · Trial result
    PubMed: PMID 23554566 · NCT00140855 · Sarcoma
  2. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
    Le DT, Lutz E, Uram JN, et al. · J Immunother · 2013 · Trial result
    PubMed: PMID 23924790 · NCT00836407 · Pancreatic Neoplasms
  3. Nivolumab plus ipilimumab in advanced melanoma.
    Wolchok JD, Kluger H, Callahan MK, et al. · N Engl J Med · 2013 · Derived
    PubMed: PMID 23724867 · NCT01024231 · Melanoma
  4. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
    Von Hoff DD, Ervin T, Arena FP, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 24131140 · NCT04787991 (REVOLUTION)
  5. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.
    Viaud S, Saccheri F, Mignot G, et al. · Science · 2013 · Background
    PubMed: PMID 24264990 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  6. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
    Schmoll HJ, Van Cutsem E, Stein A, et al. · Ann Oncol · 2013 · Background
    PubMed: PMID 23012255 · NCT03832621 (MAYA) · Colorectal Neoplasms
  7. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
    Reck M, Bondarenko I, Luft A, et al. · Ann Oncol · 2013 · Background
    PubMed: PMID 22858559 · NCT04141644 (Osi+Ipi)
  8. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?
    Pennock GK, Waterfield W, Wolchok JD, et al. · Am J Clin Oncol · 2013 · Background
    PubMed: PMID 21336089 · NCT03832621 (MAYA) · Colorectal Neoplasms
  9. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
    Oettle H, Neuhaus P, Hochhaus A, et al. · JAMA · 2013 · Background
    PubMed: PMID 24104372 · NCT04787991 (REVOLUTION)
  10. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M, Di Giacomo AM, Robert C, et al. · Curr Opin Oncol · 2013 · Background
    PubMed: PMID 23299197 · NCT02608437 (NIBIT-M4) · Melanoma
  11. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.
    Lipson EJ, Sharfman WH, Drake CG, et al. · Clin Cancer Res · 2013 · Background
    PubMed: PMID 23169436 · NCT03832621 (MAYA) · Colorectal Neoplasms
  12. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
    Lin NU, Wefel JS, Lee EQ, et al. · Lancet Oncol · 2013 · Background
    PubMed: PMID 23993385 · NCT03458455 (TREATMENT) · Brain Neoplasms
  13. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
    Lin NU, Lee EQ, Aoyama H, et al. · Lancet Oncol · 2013 · Background
    PubMed: PMID 23993384 · NCT03458455 (TREATMENT) · Brain Neoplasms
  14. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
    Lee CK, Brown C, Gralla RJ, et al. · J Natl Cancer Inst · 2013 · Background
    PubMed: PMID 23594426 · NCT04141644 (Osi+Ipi)
  15. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.
    Iida N, Dzutsev A, Stewart CA, et al. · Science · 2013 · Background
    PubMed: PMID 24264989 · NCT02681302 (CPIT001) · Multiple Myeloma
  16. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
    Hochhauser D, Glynne-Jones R, Potter V, et al. · Mol Cancer Ther · 2013 · Background
    PubMed: PMID 23443801 · NCT03832621 (MAYA) · Colorectal Neoplasms
  17. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
    Hervieu A, Rébé C, Végran F, et al. · J Invest Dermatol · 2013 · Background
    PubMed: PMID 22951720 · NCT03832621 (MAYA) · Colorectal Neoplasms
  18. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A, Van Cutsem E, Sobrero A, et al. · Lancet · 2013 · Background
    PubMed: PMID 23177514 · NCT03832621 (MAYA) · Colorectal Neoplasms
  19. Combining radiotherapy and cancer immunotherapy: a paradigm shift.
    Formenti SC, Demaria S · J Natl Cancer Inst · 2013 · Background
    PubMed: PMID 23291374 · NCT05088889 · Pancreatic Neoplasms
  20. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy.
    Emblem KE, Mouridsen K, Bjornerud A, et al. · Nat Med · 2013 · Background
    PubMed: PMID 23955713 · NCT03458455 (TREATMENT) · Brain Neoplasms
  21. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
    Amatu A, Sartore-Bianchi A, Moutinho C, et al. · Clin Cancer Res · 2013 · Background
    PubMed: PMID 23422094 · NCT03832621 (MAYA) · Colorectal Neoplasms

2012 (22 papers)

  1. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
    Cho YA, Yoon HJ, Lee JI, et al. · Oral Oncol · 2012 · Trial result
    PubMed: PMID 21911310 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  2. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ, Versluis J, van den Berg HP, et al. · Lancet Oncol · 2012 · Derived
    PubMed: PMID 22326922 · NCT01510288 · Prostatic Neoplasms
  3. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
    Margolin K, Ernstoff MS, Hamid O, et al. · Lancet Oncol · 2012 · Derived
    PubMed: PMID 22456429 · NCT00623766 · Melanoma
  4. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
    Hamid O, Schmidt H, Nissan A, et al. · J Transl Med · 2012 · Derived
    PubMed: PMID 22123319 · NCT00261365
  5. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    Di Giacomo AM, Ascierto PA, Pilla L, et al. · Lancet Oncol · 2012 · Derived
    PubMed: PMID 22894884 · NCT01654692 (NIBIT-M1) · Melanoma
  6. Novel therapies for metastatic castrate-resistant prostate cancer.
    Dayyani F, Gallick GE, Logothetis CJ, et al. · J Natl Cancer Inst · 2012 · Derived
    PubMed: PMID 21917607 · NCT00861614 · Prostatic Neoplasms
  7. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
    Woo SR, Turnis ME, Goldberg MV, et al. · Cancer Res · 2012 · Background
    PubMed: PMID 22186141 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  8. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    Topalian SL, Hodi FS, Brahmer JR, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22658127 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  9. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
    Taube JM, Anders RA, Young GD, et al. · Sci Transl Med · 2012 · Background
    PubMed: PMID 22461641 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  10. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.
    Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22124104 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  11. Tumor immunotherapy directed at PD-1.
    Ribas A · N Engl J Med · 2012 · Background
    PubMed: PMID 22658126 · NCT04141644 (Osi+Ipi)
  12. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.
    Postow MA, Harding J, Wolchok JD, et al. · Cancer J · 2012 · Background
    PubMed: PMID 22453017 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  13. Immunologic correlates of the abscopal effect in a patient with melanoma.
    Postow MA, Callahan MK, Barker CA, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22397654 · NCT04141644 (Osi+Ipi)
  14. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.
    Park IJ, You YN, Agarwal A, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22493423 · NCT06365619 (NeoRelapse) · Melanoma
  15. The blockade of immune checkpoints in cancer immunotherapy.
    Pardoll DM · Nat Rev Cancer · 2012 · Background
    PubMed: PMID 22437870 · NCT04787991 (REVOLUTION)
  16. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
    Lynch TJ, Bondarenko I, Luft A, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22547592 · NCT04141644 (Osi+Ipi)
  17. Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain metastases.
    Lo SS, Clarke JW, Grecula JC, et al. · Med Oncol · 2012 · Background
    PubMed: PMID 20814764 · NCT01703507 · Melanoma
  18. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
    Lipson EJ, Drake CG · Clin Cancer Res · 2012 · Background
    PubMed: PMID 21900389 · NCT03388632
  19. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
    Kumar SK, Lee JH, Lahuerta JJ, et al. · Leukemia · 2012 · Background
    PubMed: PMID 21799510 · NCT02681302 (CPIT001) · Multiple Myeloma
  20. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.
    Joseph RW, Sullivan RJ, Harrell R, et al. · J Immunother · 2012 · Background
    PubMed: PMID 22130161 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  21. Comprehensive molecular characterization of human colon and rectal cancer.
    Cancer Genome Atlas Network · Nature · 2012 · Background
    PubMed: PMID 22810696 · NCT03832621 (MAYA) · Colorectal Neoplasms
  22. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    Brahmer JR, Tykodi SS, Chow LQ, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22658128 · NCT03832621 (MAYA) · Colorectal Neoplasms

2011 (18 papers)

  1. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
    Royal RE, Levy C, Turner K, et al. · J Immunother · 2011 · Trial result
    PubMed: PMID 20842054 · NCT00112580 · Pancreatic Neoplasms
  2. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.
    Sarnaik AA, Yu B, Yu D, et al. · Clin Cancer Res · 2011 · Derived
    PubMed: PMID 21106722 · NCT00084656 · Melanoma
  3. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
    Robert C, Thomas L, Bondarenko I, et al. · N Engl J Med · 2011 · Derived
    PubMed: PMID 21639810 · NCT00324155 · Melanoma
  4. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
    Yu P, Steel JC, Zhang M, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 20924130 · NCT02681302 (CPIT001) · Multiple Myeloma
  5. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
    Treasure T, Lang-Lazdunski L, Waller D, et al. · Lancet Oncol · 2011 · Background
    PubMed: PMID 21723781 · NCT03918252 · Mesothelioma
  6. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.
    Tosolini M, Kirilovsky A, Mlecnik B, et al. · Cancer Res · 2011 · Background
    PubMed: PMID 21303976 · NCT03832621 (MAYA) · Colorectal Neoplasms
  7. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis.
    Timmermann B, Kerick M, Roehr C, et al. · PLoS One · 2011 · Background
    PubMed: PMID 21203531 · NCT03832621 (MAYA) · Colorectal Neoplasms
  8. CTLA-4 blockade: therapeutic potential in cancer treatments.
    Tarhini AA, Iqbal F · Onco Targets Ther · 2011 · Background
    PubMed: PMID 20616954 · NCT01703507 · Melanoma
  9. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.
    Shima K, Morikawa T, Baba Y, et al. · Cancer Causes Control · 2011 · Background
    PubMed: PMID 21140203 · NCT03832621 (MAYA) · Colorectal Neoplasms
  10. Active immunotherapy induces antibody responses that target tumor angiogenesis.
    Schoenfeld J, Jinushi M, Nakazaki Y, et al. · Cancer Res · 2011 · Background
    PubMed: PMID 21159637 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  11. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
    Schneider T, Kimpfler S, Warth A, et al. · J Thorac Oncol · 2011 · Background
    PubMed: PMID 21258248 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  12. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T, Blank C, Chowdhury S, et al. · Eur Urol · 2011 · Background
    PubMed: PMID 21612860 · NCT07233668 (IVE in mRCC) · Carcinoma, Renal Cell
  13. Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis.
    Meyners T, Heisterkamp C, Kueter JD, et al. · BMC Cancer · 2011 · Background
    PubMed: PMID 20977700 · NCT01703507 · Melanoma
  14. CD38 and chronic lymphocytic leukemia: a decade later.
    Malavasi F, Deaglio S, Damle R, et al. · Blood · 2011 · Background
    PubMed: PMID 21765022 · NCT03832621 (MAYA) · Colorectal Neoplasms
  15. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis.
    Ju HX, An B, Okamoto Y, et al. · Am J Pathol · 2011 · Background
    PubMed: PMID 21406167 · NCT03832621 (MAYA) · Colorectal Neoplasms
  16. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
    Fu T, He Q, Sharma P, et al. · Cancer Res · 2011 · Background
    PubMed: PMID 21708958 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  17. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T, Desseigne F, Ychou M, et al. · N Engl J Med · 2011 · Background
    PubMed: PMID 21561347 · NCT04787991 (REVOLUTION)
  18. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer.
    Bremnes RM, Al-Shibli K, Donnem T, et al. · J Thorac Oncol · 2011 · Background
    PubMed: PMID 21173711 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung

2010 (29 papers)

  1. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
    Wolchok JD, Neyns B, Linette G, et al. · Lancet Oncol · 2010 · Derived
    PubMed: PMID 20004617 · NCT00289640 · Melanoma
  2. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer.
    Zhang Y, Huang S, Gong D, et al. · Cell Mol Immunol · 2010 · Background
    PubMed: PMID 20514052 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  3. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
    Wolchok JD, Hoos A, O'Day S, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 19934295 · NCT03651271
  4. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J · Semin Oncol · 2010 · Background
    PubMed: PMID 21074057 · NCT02681302 (CPIT001) · Multiple Myeloma
  5. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.
    Vaisitti T, Aydin S, Rossi D, et al. · Leukemia · 2010 · Background
    PubMed: PMID 20220774 · NCT03832621 (MAYA) · Colorectal Neoplasms
  6. Modern multidisciplinary management of brain metastases.
    Thomas SS, Dunbar EM · Curr Oncol Rep · 2010 · Background
    PubMed: PMID 20425606 · NCT01703507 · Melanoma
  7. ACR Appropriateness Criteria: single brain metastasis.
    Suh JH, Videtic GM, Aref AM, et al. · Curr Probl Cancer · 2010 · Background
    PubMed: PMID 20541055 · NCT01703507 · Melanoma
  8. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
    Shimizu K, Nakata M, Hirami Y, et al. · J Thorac Oncol · 2010 · Background
    PubMed: PMID 20234320 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  9. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
    Shah GD, Socci ND, Gold JS, et al. · Ann Oncol · 2010 · Background
    PubMed: PMID 20080829 · NCT06566391 · Melanoma
  10. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.
    Schartz NE, Farges C, Madelaine I, et al. · Melanoma Res · 2010 · Background
    PubMed: PMID 20216240 · NCT01703507 · Melanoma
  11. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.
    NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. · Lancet · 2010 · Background
    PubMed: PMID 20338627 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  12. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
    Mitsudomi T, Morita S, Yatabe Y, et al. · Lancet Oncol · 2010 · Background
    PubMed: PMID 20022809 · NCT04141644 (Osi+Ipi)
  13. Regulation of CD4+ T-cell contraction during pathogen challenge.
    McKinstry KK, Strutt TM, Swain SL, et al. · Immunol Rev · 2010 · Background
    PubMed: PMID 20636812 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  14. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M, Inoue A, Kobayashi K, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20573926 · NCT04141644 (Osi+Ipi)
  15. Circadian timing in cancer treatments.
    Lévi F, Okyar A, Dulong S, et al. · Annu Rev Pharmacol Toxicol · 2010 · Background
    PubMed: PMID 20055686 · NCT07338981
  16. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
    Ku GY, Yuan J, Page DB, et al. · Cancer · 2010 · Background
    PubMed: PMID 20143434 · NCT04141644 (Osi+Ipi)
  17. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW, Higano CS, Shore ND, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20818862 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  18. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
    Kaehler KC, Piel S, Livingstone E, et al. · Semin Oncol · 2010 · Background
    PubMed: PMID 21074064 · NCT01703507 · Melanoma
  19. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A, Ibrahim R, Korman A, et al. · Semin Oncol · 2010 · Background
    PubMed: PMID 21074069 · NCT03832621 (MAYA) · Colorectal Neoplasms
  20. Improved endpoints for cancer immunotherapy trials.
    Hoos A, Eggermont AM, Janetzki S, et al. · J Natl Cancer Inst · 2010 · Background
    PubMed: PMID 20826737 · NCT01363206 (GIPI) · Melanoma
  21. Improved survival with ipilimumab in patients with metastatic melanoma.
    Hodi FS, O'Day SJ, McDermott DF, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20525992 · NCT01703507 · Melanoma
  22. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
    Gisselbrecht C, Glass B, Mounier N, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20660832 · NCT02681302 (CPIT001) · Multiple Myeloma
  23. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
    Di Giacomo AM, Biagioli M, Maio M, et al. · Semin Oncol · 2010 · Background
    PubMed: PMID 21074065 · NCT03832621 (MAYA) · Colorectal Neoplasms
  24. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
    Currie AJ, Prosser A, McDonnell A, et al. · J Immunol · 2010 · Background
    PubMed: PMID 20007574 · NCT03918252 · Mesothelioma
  25. Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis.
    Clarke JW, Register S, McGregor JM, et al. · Am J Clin Oncol · 2010 · Background
    PubMed: PMID 19652578 · NCT01703507 · Melanoma
  26. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
    Carthon BC, Wolchok JD, Yuan J, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 20460488 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  27. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
    Butts CA, Ding K, Seymour L, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 19933915 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  28. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
    Brahmer JR, Drake CG, Wollner I, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20516446 · NCT03918252 · Mesothelioma
  29. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
    Ansell SM, Hurvitz SA, Koenig PA, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 19808874 · NCT02681302 (CPIT001) · Multiple Myeloma

2009 (21 papers)

  1. Targeted therapies in squamous cell carcinoma of the head and neck.
    Gold KA, Lee HY, Kim ES, et al. · Cancer · 2009 · Trial result
    PubMed: PMID 19156911 · NCT03700905 (IMSTAR-HN) · Head and Neck Neoplasms
  2. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM, Danielli R, Guidoboni M, et al. · Cancer Immunol Immunother · 2009 · Derived
    PubMed: PMID 19139884 · NCT00289627 · Melanoma
  3. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
    Bashey A, Medina B, Corringham S, et al. · Blood · 2009 · Derived
    PubMed: PMID 18974373 · NCT00060372 · Neoplasms
  4. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
    Yip S, Miao J, Cahill DP, et al. · Clin Cancer Res · 2009 · Background
    PubMed: PMID 19584161 · NCT03832621 (MAYA) · Colorectal Neoplasms
  5. Phase I/II study of ipilimumab for patients with metastatic melanoma.
    Weber JS, O'Day S, Urba W, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19018089 · NCT01703507 · Melanoma
  6. Malignant pleural mesothelioma.
    Tsao AS, Wistuba I, Roth JA, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19255316 · NCT03918252 · Mesothelioma
  7. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses.
    Sabel MS · Cryobiology · 2009 · Background
    PubMed: PMID 19007768 · NCT04429321 · Carcinoma, Renal Cell
  8. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.
    Sabatino M, Kim-Schulze S, Panelli MC, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19364969 · NCT03918252 · Mesothelioma
  9. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
    Robert C, Ghiringhelli F · Oncologist · 2009 · Background
    PubMed: PMID 19648604 · NCT01703507 · Melanoma
  10. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma.
    Powell JW, Chung CT, Shah HR, et al. · J Neurosurg · 2009 · Background
    PubMed: PMID 19123898 · NCT01703507 · Melanoma
  11. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.
    Pilones KA, Kawashima N, Yang AM, et al. · Clin Cancer Res · 2009 · Background
    PubMed: PMID 19147765 · NCT01703507 · Melanoma
  12. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
    Pagès F, Kirilovsky A, Mlecnik B, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19858404 · NCT03832621 (MAYA) · Colorectal Neoplasms
  13. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    Mok TS, Wu YL, Thongprasert S, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19692680 · NCT04141644 (Osi+Ipi)
  14. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
    Krug LM, Pass HI, Rusch VW, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19364962 · NCT03918252 · Mesothelioma
  15. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
    Koopman M, Kortman GA, Mekenkamp L, et al. · Br J Cancer · 2009 · Background
    PubMed: PMID 19165197 · NCT03832621 (MAYA) · Colorectal Neoplasms
  16. American College of Radiology appropriateness criteria on multiple brain metastases.
    Expert Panel on Radiation Oncology-Brain Metastases, Videtic GM, Gaspar LE, et al. · Int J Radiat Oncol Biol Phys · 2009 · Background
    PubMed: PMID 19857783 · NCT01703507 · Melanoma
  17. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
    PubMed: PMID 19097774 · NCT01703507 · Melanoma
  18. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
    de Perrot M, Feld R, Cho BC, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19224855 · NCT03918252 · Mesothelioma
  19. A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision.
    Davey P, Hoegler D, Ennis M, et al. · Radiother Oncol · 2009 · Background
    PubMed: PMID 18555546 · NCT01703507 · Melanoma
  20. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
    Chen H, Liakou CI, Kamat A, et al. · Proc Natl Acad Sci U S A · 2009 · Background
    PubMed: PMID 19202079 · NCT03918252 · Mesothelioma
  21. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.
    Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration · J Clin Oncol · 2009 · Background
    PubMed: PMID 19001332 · NCT05492123 · Uterine Cervical Neoplasms

2008 (21 papers)

  1. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
    Kavanagh B, O'Brien S, Lee D, et al. · Blood · 2008 · Derived
    PubMed: PMID 18523152 · NCT00064129 · Prostatic Neoplasms
  2. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
    Wong RM, Scotland RR, Lau RL, et al. · Int Immunol · 2008 · Background
    PubMed: PMID 17898045 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  3. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J · Oncologist · 2008 · Background
    PubMed: PMID 17673617 · NCT04141644 (Osi+Ipi)
  4. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM, Herndon JE, Maddaus MA, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18809614 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  5. Epitope landscape in breast and colorectal cancer.
    Segal NH, Parsons DW, Peggs KS, et al. · Cancer Res · 2008 · Background
    PubMed: PMID 18245491 · NCT03832621 (MAYA) · Colorectal Neoplasms
  6. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A, Trojan A, Burnand B, et al. · Lung Cancer · 2008 · Background
    PubMed: PMID 17720276 · NCT05715229 (G360-IIT) · Carcinoma, Non-Small-Cell Lung
  7. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
    Pignon JP, Tribodet H, Scagliotti GV, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18506026 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  8. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ, Hamid O, Urba WJ, et al. · Cancer · 2008 · Background
    PubMed: PMID 18000991 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  9. Gamma knife radiosurgery for malignant melanoma brain metastases.
    Mathieu D, Kondziolka D, Cooper PB, et al. · Clin Neurosurg · 2008 · Background
    PubMed: PMID 18504926 · NCT01703507 · Melanoma
  10. Detection of mutations in EGFR in circulating lung-cancer cells.
    Maheswaran S, Sequist LV, Nagrath S, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18596266 · NCT04141644 (Osi+Ipi)
  11. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
    Liakou CI, Kamat A, Tang DN, et al. · Proc Natl Acad Sci U S A · 2008 · Background
    PubMed: PMID 18818309 · NCT03918252 · Mesothelioma
  12. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
    Korn EL, Liu PY, Lee SJ, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18235113 · NCT01703507 · Melanoma
  13. PD-1 and its ligands in tolerance and immunity.
    Keir ME, Butte MJ, Freeman GJ, et al. · Annu Rev Immunol · 2008 · Background
    PubMed: PMID 18173375 · NCT02681302 (CPIT001) · Multiple Myeloma
  14. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.
    Ishikawa N, Takano A, Yasui W, et al. · Cancer Res · 2008 · Background
    PubMed: PMID 18089789 · NCT03784040 (da VINci) · Stomach Neoplasms
  15. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
    Hodi FS, Oble DA, Drappatz J, et al. · Nat Clin Pract Oncol · 2008 · Background
    PubMed: PMID 18665147 · NCT01703507 · Melanoma
  16. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
    Hodi FS, Butler M, Oble DA, et al. · Proc Natl Acad Sci U S A · 2008 · Background
    PubMed: PMID 18287062 · NCT01715077 · Melanoma
  17. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
    Fong L, Small EJ · J Clin Oncol · 2008 · Background
    PubMed: PMID 18838703 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  18. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
    Downey SG, Klapper JA, Smith FO, et al. · Clin Cancer Res · 2008 · Background
    PubMed: PMID 17982122 · NCT00357461 · Melanoma
  19. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.
    Azuma T, Yao S, Zhu G, et al. · Blood · 2008 · Background
    PubMed: PMID 18223165 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  20. Current neurosurgical management of brain metastases.
    Andrews DW · Semin Oncol · 2008 · Background
    PubMed: PMID 18396195 · NCT01703507 · Melanoma
  21. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
    Al-Shibli KI, Donnem T, Al-Saad S, et al. · Clin Cancer Res · 2008 · Background
    PubMed: PMID 18698040 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung

2007 (8 papers)

  1. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H, Oki Y, Garcia-Manero G, et al. · Blood · 2007 · Trial result
    PubMed: PMID 16882708 · NCT02608437 (NIBIT-M4) · Melanoma
  2. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
    Weder W, Stahel RA, Bernhard J, et al. · Ann Oncol · 2007 · Background
    PubMed: PMID 17429100 · NCT03918252 · Mesothelioma
  3. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.
    Sharpe AH, Wherry EJ, Ahmed R, et al. · Nat Immunol · 2007 · Background
    PubMed: PMID 17304234 · NCT03832621 (MAYA) · Colorectal Neoplasms
  4. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    Oettle H, Post S, Neuhaus P, et al. · JAMA · 2007 · Background
    PubMed: PMID 17227978 · NCT04787991 (REVOLUTION)
  5. Merkel cell carcinoma: more deaths but still no pathway to blame.
    Lemos B, Nghiem P · J Invest Dermatol · 2007 · Background
    PubMed: PMID 17700621 · NCT01913691 · Carcinoma, Merkel Cell
  6. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.
    Gilligan D, Nicolson M, Smith I, et al. · Lancet · 2007 · Background
    PubMed: PMID 17544497 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  7. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases.
    DiLuna ML, King JT, Knisely JP, et al. · Cancer · 2007 · Background
    PubMed: PMID 17133440 · NCT01703507 · Melanoma
  8. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer.
    Burdett S, Stewart LA, Rydzewska L, et al. · J Thorac Oncol · 2007 · Background
    PubMed: PMID 17409927 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung

2006 (21 papers)

  1. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV, Phan GQ, Attia P, et al. · Ann Surg Oncol · 2006 · Trial result
    PubMed: PMID 16283570 · NCT00058279 · Melanoma
  2. Cancer despite immunosurveillance: immunoselection and immunosubversion.
    Zitvogel L, Tesniere A, Kroemer G, et al. · Nat Rev Immunol · 2006 · Background
    PubMed: PMID 16977338 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  3. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
    Wagner AD, Grothe W, Haerting J, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16782930 · NCT03784040 (da VINci) · Stomach Neoplasms
  4. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma.
    Tsushima F, Tanaka K, Otsuki N, et al. · Oral Oncol · 2006 · Background
    PubMed: PMID 16271509 · NCT03918252 · Mesothelioma
  5. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
    Thompson RH, Kuntz SM, Leibovich BC, et al. · Cancer Res · 2006 · Background
    PubMed: PMID 16585157 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  6. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
    Thompson RH, Gillett MD, Cheville JC, et al. · Cancer · 2006 · Background
    PubMed: PMID 16208700 · NCT03918252 · Mesothelioma
  7. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
    Peggs KS, Quezada SA, Korman AJ, et al. · Curr Opin Immunol · 2006 · Background
    PubMed: PMID 16464564 · NCT01703507 · Melanoma
  8. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
    Moschos SJ, Edington HD, Land SR, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16809739 · NCT01703507 · Melanoma
  9. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
    Morse MA · Curr Opin Mol Ther · 2006 · Background
    PubMed: PMID 16370382 · NCT01703507 · Melanoma
  10. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
    Martino R, Iacobelli S, Brand R, et al. · Blood · 2006 · Background
    PubMed: PMID 16597592 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  11. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397).
    Manon R, O'Neill A, Knisely J, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16314647 · NCT01703507 · Melanoma
  12. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
    Maker AV, Attia P, Rosenberg SA, et al. · J Immunol · 2006 · Background
    PubMed: PMID 16301685 · NCT00032045 · Melanoma
  13. Whole-brain radiotherapy in the management of brain metastasis.
    Khuntia D, Brown P, Li J, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16525185 · NCT01703507 · Melanoma
  14. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
    Jaber SH, Cowen EW, Haworth LR, et al. · Arch Dermatol · 2006 · Background
    PubMed: PMID 16490844 · NCT01703507 · Melanoma
  15. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    Giacchetti S, Bjarnason G, Garufi C, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16877722 · NCT07338981
  16. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Galon J, Costes A, Sanchez-Cabo F, et al. · Science · 2006 · Background
    PubMed: PMID 17008531 · NCT03832621 (MAYA) · Colorectal Neoplasms
  17. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
    Douillard JY, Rosell R, De Lena M, et al. · Lancet Oncol · 2006 · Background
    PubMed: PMID 16945766 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  18. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.
    den Brok MH, Sutmuller RP, Nierkens S, et al. · Br J Cancer · 2006 · Background
    PubMed: PMID 16953240 · NCT04429321 · Carcinoma, Renal Cell
  19. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY, Millward M, Pehamberger H, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16966688 · NCT01703507 · Melanoma
  20. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.
    Aoyama H, Shirato H, Tago M, et al. · JAMA · 2006 · Background
    PubMed: PMID 16757720 · NCT01703507 · Melanoma
  21. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
    Andreadis C, Schuster SJ, Chong EA, et al. · Bone Marrow Transplant · 2006 · Background
    PubMed: PMID 16205727 · NCT02681302 (CPIT001) · Multiple Myeloma

2005 (15 papers)

  1. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
    Attia P, Phan GQ, Maker AV, et al. · J Clin Oncol · 2005 · Trial result
    PubMed: PMID 16087944 · NCT00032045 · Melanoma
  2. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Zou W · Nat Rev Cancer · 2005 · Background
    PubMed: PMID 15776005 · NCT01445379 · Sarcoma
  3. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.
    Wang J, Yoshida T, Nakaki F, et al. · Proc Natl Acad Sci U S A · 2005 · Background
    PubMed: PMID 16087865 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  4. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.
    Thompson RH, Webster WS, Cheville JC, et al. · Urology · 2005 · Background
    PubMed: PMID 16194701 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  5. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
    Thompson RH, Gillett MD, Cheville JC, et al. · Proc Natl Acad Sci U S A · 2005 · Background
    PubMed: PMID 15569934 · NCT03918252 · Mesothelioma
  6. Dietary intake estimates in the National Health Interview Survey, 2000: methodology, results, and interpretation.
    Thompson FE, Midthune D, Subar AF, et al. · J Am Diet Assoc · 2005 · Background
    PubMed: PMID 15746822 · NCT04787991 (REVOLUTION)
  7. Performance of a short tool to assess dietary intakes of fruits and vegetables, percentage energy from fat and fibre.
    Thompson FE, Midthune D, Subar AF, et al. · Public Health Nutr · 2005 · Background
    PubMed: PMID 15548349 · NCT04787991 (REVOLUTION)
  8. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
    Robinson MR, Chan CC, Yang JC, et al. · J Immunother · 2005 · Background
    PubMed: PMID 15534492 · NCT01703507 · Melanoma
  9. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.
    Ohigashi Y, Sho M, Yamada Y, et al. · Clin Cancer Res · 2005 · Background
    PubMed: PMID 15837746 · NCT03918252 · Mesothelioma
  10. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.
    Mehta MP, Tsao MN, Whelan TJ, et al. · Int J Radiat Oncol Biol Phys · 2005 · Background
    PubMed: PMID 16111570 · NCT01703507 · Melanoma
  11. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
    Konishi J, Yamazaki K, Azuma M, et al. · Clin Cancer Res · 2005 · Background
    PubMed: PMID 15297412 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  12. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
    Iwai Y, Terawaki S, Honjo T, et al. · Int Immunol · 2005 · Background
    PubMed: PMID 15611321 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  13. Merkel cell carcinoma: changing incidence trends.
    Hodgson NC · J Surg Oncol · 2005 · Background
    PubMed: PMID 15611998 · NCT01913691 · Carcinoma, Merkel Cell
  14. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
    Hirano F, Kaneko K, Tamura H, et al. · Cancer Res · 2005 · Background
    PubMed: PMID 15705911 · NCT03918252 · Mesothelioma
  15. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.
    Berger AC, Farma J, Scott WJ, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15781882 · NCT06365619 (NeoRelapse) · Melanoma

2004 (22 papers)

  1. Structural and functional analysis of the costimulatory receptor programmed death-1.
    Zhang X, Schwartz JC, Guo X, et al. · Immunity · 2004 · Background
    PubMed: PMID 15030777 · NCT03918252 · Mesothelioma
  2. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
    Waller D, Peake MD, Stephens RJ, et al. · Eur J Cardiothorac Surg · 2004 · Background
    PubMed: PMID 15200998 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  3. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
    Su YB, Sohn S, Krown SE, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 14726505 · NCT03832621 (MAYA) · Colorectal Neoplasms
  4. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.
    Sheppard KA, Fitz LJ, Lee JM, et al. · FEBS Lett · 2004 · Background
    PubMed: PMID 15358536 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  5. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice.
    Okazaki T, Tanaka Y, Nishio R, et al. · Nat Med · 2004 · Background
    PubMed: PMID 14595408 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  6. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
    Neoptolemos JP, Stocken DD, Friess H, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15028824 · NCT04787991 (REVOLUTION)
  7. Natural T cell immunity against cancer.
    Nagorsen D, Scheibenbogen C, Marincola FM, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 14555498 · NCT01703507 · Melanoma
  8. CpG oligodeoxynucleotide enhances tumor response to radiation.
    Milas L, Mason KA, Ariga H, et al. · Cancer Res · 2004 · Background
    PubMed: PMID 15289307 · NCT05088889 · Pancreatic Neoplasms
  9. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    Lynch TJ, Bell DW, Sordella R, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15118073 · NCT04141644 (Osi+Ipi)
  10. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.
    Esteller M, Herman JG · Oncogene · 2004 · Background
    PubMed: PMID 14712205 · NCT03832621 (MAYA) · Colorectal Neoplasms
  11. The three Es of cancer immunoediting.
    Dunn GP, Old LJ, Schreiber RD, et al. · Annu Rev Immunol · 2004 · Background
    PubMed: PMID 15032581 · NCT01445379 · Sarcoma
  12. B7-H1 pathway and its role in the evasion of tumor immunity.
    Dong H, Chen L · J Mol Med (Berl) · 2004 · Background
    PubMed: PMID 12721664 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  13. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.
    Diaconescu R, Flowers CR, Storer B, et al. · Blood · 2004 · Background
    PubMed: PMID 15150081 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  14. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
    de Lima M, Anagnostopoulos A, Munsell M, et al. · Blood · 2004 · Background
    PubMed: PMID 15090449 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  15. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.
    Chen L · Nat Rev Immunol · 2004 · Background
    PubMed: PMID 15122199 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  16. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.
    Chemnitz JM, Parry RV, Nichols KE, et al. · J Immunol · 2004 · Background
    PubMed: PMID 15240681 · NCT03918252 · Mesothelioma
  17. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
    Blank C, Brown I, Peterson AC, et al. · Cancer Res · 2004 · Background
    PubMed: PMID 14871849 · NCT03918252 · Mesothelioma
  18. The treatment of brain metastases in melanoma patients.
    Bafaloukos D, Gogas H · Cancer Treat Rev · 2004 · Background
    PubMed: PMID 15325032 · NCT01703507 · Melanoma
  19. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF, Aamdal S, Grob JJ, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 15020614 · NCT01654692 (NIBIT-M1) · Melanoma
  20. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
    Arriagada R, Bergman B, Dunant A, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 14736927 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  21. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
    Andrews DW, Scott CB, Sperduto PW, et al. · Lancet · 2004 · Background
    PubMed: PMID 15158627 · NCT01703507 · Melanoma
  22. Epidemiology of primary Merkel cell carcinoma in the United States.
    Agelli M, Clegg LX · J Am Acad Dermatol · 2004 · Background
    PubMed: PMID 14576661 · NCT01913691 · Carcinoma, Merkel Cell

2003 (10 papers)

  1. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Phan GQ, Yang JC, Sherry RM, et al. · Proc Natl Acad Sci U S A · 2003 · Trial result
    PubMed: PMID 12826605 · NCT00032045 · Melanoma
  2. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. · J Clin Oncol · 2003 · Background
    PubMed: PMID 12860938 · NCT03918252 · Mesothelioma
  3. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
    Strome SE, Dong H, Tamura H, et al. · Cancer Res · 2003 · Background
    PubMed: PMID 14559843 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  4. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.
    Sheehan JP, Sun MH, Kondziolka D, et al. · J Neurosurg · 2003 · Background
    PubMed: PMID 12593621 · NCT01703507 · Melanoma
  5. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
    Scagliotti GV, Fossati R, Torri V, et al. · J Natl Cancer Inst · 2003 · Background
    PubMed: PMID 14519751 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  6. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis.
    Salama AD, Chitnis T, Imitola J, et al. · J Exp Med · 2003 · Background
    PubMed: PMID 12847138 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  7. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases.
    Patchell RA, Regine WF · Technol Cancer Res Treat · 2003 · Background
    PubMed: PMID 12680791 · NCT01703507 · Melanoma
  8. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Hodi FS, Mihm MC, Soiffer RJ, et al. · Proc Natl Acad Sci U S A · 2003 · Background
    PubMed: PMID 12682289 · NCT01715077 · Melanoma
  9. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.
    Fukuda T, Hackman RC, Guthrie KA, et al. · Blood · 2003 · Background
    PubMed: PMID 12855568 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  10. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.
    Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. · J Immunol · 2003 · Background
    PubMed: PMID 12874215 · NCT03918252 · Mesothelioma

2002 (7 papers)

  1. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.
    Woo EY, Yeh H, Chu CS, et al. · J Immunol · 2002 · Background
    PubMed: PMID 11970966 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  2. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors.
    Oberg A, Samii S, Stenling R, et al. · Int J Colorectal Dis · 2002 · Background
    PubMed: PMID 12018450 · NCT03832621 (MAYA) · Colorectal Neoplasms
  3. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
    Iwai Y, Ishida M, Tanaka Y, et al. · Proc Natl Acad Sci U S A · 2002 · Background
    PubMed: PMID 12218188 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  4. Cancer immunoediting: from immunosurveillance to tumor escape.
    Dunn GP, Bruce AT, Ikeda H, et al. · Nat Immunol · 2002 · Background
    PubMed: PMID 12407406 · NCT03918252 · Mesothelioma
  5. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
    Dong H, Strome SE, Salomao DR, et al. · Nat Med · 2002 · Background
    PubMed: PMID 12091876 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  6. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.
    Depierre A, Milleron B, Moro-Sibilot D, et al. · J Clin Oncol · 2002 · Background
    PubMed: PMID 11773176 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  7. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
    Carter L, Fouser LA, Jussif J, et al. · Eur J Immunol · 2002 · Background
    PubMed: PMID 11857337 · NCT03918252 · Mesothelioma

2001 (12 papers)

  1. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.
    Williams CD, Harrison CN, Lister TA, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11157024 · NCT02681302 (CPIT001) · Multiple Myeloma
  2. High number of tumour-infiltrating lymphocytes is associated with apoptosis in non-small cell lung carcinoma.
    Törmänen-Näpänkangas U, Soini Y, Pääkkö P, et al. · APMIS · 2001 · Background
    PubMed: PMID 11552950 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  3. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.
    Street SE, Cretney E, Smyth MJ, et al. · Blood · 2001 · Background
    PubMed: PMID 11133760 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  4. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma.
    Smyrk TC, Watson P, Kaul K, et al. · Cancer · 2001 · Background
    PubMed: PMID 11413533 · NCT03832621 (MAYA) · Colorectal Neoplasms
  5. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
    Shankaran V, Ikeda H, Bruce AT, et al. · Nature · 2001 · Background
    PubMed: PMID 11323675 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  6. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
    Phan GQ, Attia P, Steinberg SM, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11481353 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  7. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
    Nishimura H, Okazaki T, Tanaka Y, et al. · Science · 2001 · Background
    PubMed: PMID 11209085 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  8. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.
    Nishimura H, Honjo T · Trends Immunol · 2001 · Background
    PubMed: PMID 11323285 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  9. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
    Latchman Y, Wood CR, Chernova T, et al. · Nat Immunol · 2001 · Background
    PubMed: PMID 11224527 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  10. A systematic overview of chemotherapy effects in gastric cancer.
    Janunger KG, Hafström L, Nygren P, et al. · Acta Oncol · 2001 · Background
    PubMed: PMID 11441938 · NCT03784040 (da VINci) · Stomach Neoplasms
  11. Human CD38: a (r)evolutionary story of enzymes and receptors.
    Deaglio S, Mehta K, Malavasi F, et al. · Leuk Res · 2001 · Background
    PubMed: PMID 11137554 · NCT03832621 (MAYA) · Colorectal Neoplasms
  12. Carcinogen-specific induction of genetic instability.
    Bardelli A, Cahill DP, Lederer G, et al. · Proc Natl Acad Sci U S A · 2001 · Background
    PubMed: PMID 11296254 · NCT03832621 (MAYA) · Colorectal Neoplasms

2000 (10 papers)

  1. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma.
    Zielinski H, Szmigielski S, Petrovich Z, et al. · Am J Clin Oncol · 2000 · Background
    PubMed: PMID 10683065 · NCT04429321 · Carcinoma, Renal Cell
  2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. · J Natl Cancer Inst · 2000 · Background
    PubMed: PMID 10655437 · NCT00140855 · Sarcoma
  3. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.
    Spitler LE, Grossbard ML, Ernstoff MS, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10764421 · NCT01363206 (GIPI) · Melanoma
  4. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.
    Shaw E, Scott C, Souhami L, et al. · Int J Radiat Oncol Biol Phys · 2000 · Background
    PubMed: PMID 10802351 · NCT01703507 · Melanoma
  5. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
    Read S, Malmström V, Powrie F, et al. · J Exp Med · 2000 · Background
    PubMed: PMID 10899916 · NCT01703507 · Melanoma
  6. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
    Middleton MR, Lorigan P, Owen J, et al. · Br J Cancer · 2000 · Background
    PubMed: PMID 10735499 · NCT01703507 · Melanoma
  7. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
    Freeman GJ, Long AJ, Iwai Y, et al. · J Exp Med · 2000 · Background
    PubMed: PMID 11015443 · NCT03918252 · Mesothelioma
  8. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.
    Esteller M, Toyota M, Sanchez-Cespedes M, et al. · Cancer Res · 2000 · Background
    PubMed: PMID 10811111 · NCT03832621 (MAYA) · Colorectal Neoplasms
  9. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
    Cheson BD, Horning SJ, Coiffier B, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10561185 · NCT02254772 · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
    Chapman PB, Einhorn LH, Meyers ML, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10561349 · NCT01703507 · Melanoma

1999 (3 papers)

  1. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A, Hurwitz AA, Allison JP, et al. · J Exp Med · 1999 · Background
    PubMed: PMID 10430624 · NCT01703507 · Melanoma
  2. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
    Nishimura H, Nose M, Hiai H, et al. · Immunity · 1999 · Background
    PubMed: PMID 10485649 · NCT02846376 (CPIT-002) · GATA2 Deficiency
  3. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States.
    Linet MS, Ries LA, Smith MA, et al. · J Natl Cancer Inst · 1999 · Background
    PubMed: PMID 10379968 · NCT01445379 · Sarcoma

1998 (4 papers)

  1. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.
    Sampson JH, Carter JH, Friedman AH, et al. · J Neurosurg · 1998 · Background
    PubMed: PMID 9420067 · NCT01703507 · Melanoma
  2. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases.
    Pirzkall A, Debus J, Lohr F, et al. · J Clin Oncol · 1998 · Background
    PubMed: PMID 9817276 · NCT01703507 · Melanoma
  3. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.
    Patchell RA, Tibbs PA, Regine WF, et al. · JAMA · 1998 · Background
    PubMed: PMID 9809728 · NCT01703507 · Melanoma
  4. Value of radiation theray in the management of intracranial metastases.
    CHU FC, HILARIS BB · Cancer · 1998 · Background
    PubMed: PMID 13693470 · NCT01703507 · Melanoma

1997 (2 papers)

  1. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
    Murray KJ, Scott C, Greenberg HM, et al. · Int J Radiat Oncol Biol Phys · 1997 · Background
    PubMed: PMID 9336134 · NCT01703507 · Melanoma
  2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
    Burris HA, Moore MJ, Andersen J, et al. · J Clin Oncol · 1997 · Background
    PubMed: PMID 9196156 · NCT04787991 (REVOLUTION)

1996 (5 papers)

  1. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.
    Mihm MC, Clemente CG, Cascinelli N, et al. · Lab Invest · 1996 · Background
    PubMed: PMID 8569196 · NCT01703507 · Melanoma
  2. CD28/B7 system of T cell costimulation.
    Lenschow DJ, Walunas TL, Bluestone JA, et al. · Annu Rev Immunol · 1996 · Background
    PubMed: PMID 8717514 · NCT01715077 · Melanoma
  3. Enhancement of antitumor immunity by CTLA-4 blockade.
    Leach DR, Krummel MF, Allison JP, et al. · Science · 1996 · Background
    PubMed: PMID 8596936 · NCT03918252 · Mesothelioma
  4. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.
    Håkansson A, Gustafsson B, Krysander L, et al. · Br J Cancer · 1996 · Background
    PubMed: PMID 8845294 · NCT01703507 · Melanoma
  5. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
    Clemente CG, Mihm MC, Bufalino R, et al. · Cancer · 1996 · Background
    PubMed: PMID 8608507 · NCT01715077 · Melanoma

1995 (4 papers)

  1. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.
    Thall PF, Simon RM, Estey EH, et al. · Stat Med · 1995 · Background
    PubMed: PMID 7746977 · NCT03651271
  2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T, Guglielmi C, Hagenbeek A, et al. · N Engl J Med · 1995 · Background
    PubMed: PMID 7477169 · NCT02681302 (CPIT001) · Multiple Myeloma
  3. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
    Krummel MF, Allison JP · J Exp Med · 1995 · Background
    PubMed: PMID 7543139 · NCT03918252 · Mesothelioma
  4. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A, Wanek LA, Morton DL, et al. · J Am Coll Surg · 1995 · Background
    PubMed: PMID 7670677 · NCT01703507 · Melanoma

1994 (1 paper)

  1. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase.
    Chatani M, Matayoshi Y, Masaki N, et al. · Strahlenther Onkol · 1994 · Background
    PubMed: PMID 8160096 · NCT01703507 · Melanoma

1993 (4 papers)

  1. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
    Tao MH, Levy R · Nature · 1993 · Background
    PubMed: PMID 8469286 · NCT03918252 · Mesothelioma
  2. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.
    Schwartz RH · Cell · 1993 · Background
    PubMed: PMID 1335362 · NCT01715077 · Melanoma
  3. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases.
    Haie-Meder C, Pellae-Cosset B, Laplanche A, et al. · Radiother Oncol · 1993 · Background
    PubMed: PMID 7681997 · NCT01703507 · Melanoma
  4. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
    Chen L, Ashe S, Brady WA, et al. · Cell · 1993 · Background
    PubMed: PMID 1335364 · NCT01715077 · Melanoma

1992 (1 paper)

  1. Relevance of environmental alkylating agents to repair protein O6-alkylguanine-DNA alkyltransferase: determination of individual and collective repair capacities of O6-methylguanine.
    Oesch F, Klein S · Cancer Res · 1992 · Background
    PubMed: PMID 1532345 · NCT03832621 (MAYA) · Colorectal Neoplasms

1990 (1 paper)

  1. A randomized trial of surgery in the treatment of single metastases to the brain.
    Patchell RA, Tibbs PA, Walsh JW, et al. · N Engl J Med · 1990 · Background
    PubMed: PMID 2405271 · NCT01703507 · Melanoma

1989 (1 paper)

  1. Optimal two-stage designs for phase II clinical trials.
    Simon R · Control Clin Trials · 1989 · Background
    PubMed: PMID 2702835 · NCT04787991 (REVOLUTION)

1988 (1 paper)

  1. Surgery of metastatic renal cell carcinoma and use of renal infarction.
    Swanson DA, Wallace S · Semin Surg Oncol · 1988 · Background
    PubMed: PMID 3293153 · NCT04429321 · Carcinoma, Renal Cell

1987 (1 paper)

  1. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    West WH, Tauer KW, Yannelli JR, et al. · N Engl J Med · 1987 · Background
    PubMed: PMID 3493433 · NCT03918252 · Mesothelioma

1983 (3 papers)

  1. Evaluation of human lymphoblastoid interferon in advanced malignant melanoma.
    Retsas S, Priestman TJ, Newton KA, et al. · Cancer · 1983 · Background
    PubMed: PMID 6821816 · NCT02259621 (NA_00092076) · Carcinoma, Non-Small-Cell Lung
  2. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
    Oken MM, Creech RH, Tormey DC, et al. · Am J Clin Oncol · 1983 · Background
    PubMed: PMID 7165009 · NCT04787991 (REVOLUTION)
  3. Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders.
    Martin S, Baldock SC, Ghoneim AT, et al. · J Clin Pathol · 1983 · Background
    PubMed: PMID 6311878 · NCT02846376 (CPIT-002) · GATA2 Deficiency

1982 (2 papers)

  1. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group.
    Kurtz JM, Gelber R, Brady LW, et al. · Int J Radiat Oncol Biol Phys · 1982 · Background
    PubMed: PMID 6171553 · NCT01703507 · Melanoma
  2. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.
    Borgelt B, Gelber R, Larson M, et al. · Int J Radiat Oncol Biol Phys · 1982 · Background
    PubMed: PMID 6174490 · NCT01703507 · Melanoma

1978 (1 paper)

  1. Radiation therapy of cerebral metastases: a randomized prospective clinical trial.
    Harwood AR, Simson WJ · Int J Radiat Oncol Biol Phys · 1978 · Background
    PubMed: PMID 74375 · NCT01703507 · Melanoma

1976 (1 paper)

  1. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
    Butchart EG, Ashcroft T, Barnsley WC, et al. · Thorax · 1976 · Background
    PubMed: PMID 1257933 · NCT03918252 · Mesothelioma

1968 (1 paper)

  1. Improvement in quality of survival following whole-brain irradiation for brain metastasis.
    Order SE, Hellman S, Von Essen CF, et al. · Radiology · 1968 · Background
    PubMed: PMID 4172540 · NCT01703507 · Melanoma

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).